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Colorectal cancer (CRC) is the third most lethal cancer worldwide, caused by both 
genetic and environmental exposures, with underlying mechanisms that dovetail genetic, 
epigenetic, metabolomic, and gut microbiome influences. Adenomatous polyposis coli 
(Apc) is a tumor suppressor and a negative regulator of Wnt/b-catenin signaling, found 
mutated in over 70% of CRC cases. The current dissertation used two rodent models, one 
genetic and one environmental, in the context of cancer prevention to study the etiology 
of CRC and provide preclinical mechanistic insights. The environmental model 
incorporated a cooked meat derived mutagen, 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine (PhIP), to mediate multi-organ carcinogenesis in the rat. The study focused on 
microRNA (miRNA) profiling in the PhIP model. miRNAs are stable negative regulators 
of gene targets, and play important roles in cancer and pluripotency. Rat tumor profiles 
and human pan-cancer datasets defined a miRNA signature of PhIP-induced multi-organ 
tumorigenesis. The miR-21high/miR-126low/miR-29clow/miR-215low/miR-145low signature 
was associated with poor survival and reduced Klf4 levels, being predictive of possible 
environmental exposure and paradigm-shifting from ‘genotoxic’ to epigenetic regulation 
of dietary heterocyclic amines. A genetic angle was provided by the Apc-mutant polyposis 
in rat colon (Pirc) model, which harbors a large number of polyps in the colon, and 
recapitulates human familial adenomatous polyposis (FAP). The second study employed 
sequencing technology for mRNA, miRNA and 16S rRNA to assess the crosstalk between 




reduced tumor outcomes significantly in the Pirc model, and reversed host genetic effects 
on microbiota. mRNA and miRNA analyses revealed the importance of an inflammatory 
response in Pirc tumorigenesis, and implicated specific miRNA-mRNA associations, such 
as miR-145/Serpine1 and miR-34a/Klf4. The third study utilized untargeted metabolomics 
to investigate metabolic changes in the Pirc model along with the prevention effects of 
dietary spinach. The preliminary results indicated purine and lipid metabolism are 
important for tumorigenesis and prevention of colorectal cancer. Current technologies are 
providing new insights at the molecular level, incorporating ‘big data’ with genetic and 
phenotypic read-outs, to identify underlying leads associated with a designed dietary 
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CHAPTER I  
INTRODUCTION 
 
Introduction and background of colorectal cancer (CRC) 
The burden of CRC is a leading issue worldwide and has been associated with 
countries with a high human development index. The estimated incidence rates in males, 
carrying a greater risk than female, varies from <2 per 100,000 people in sub-Saharan 
Africa to over 60 per 100,000 people in central Europe.1 Although incidence and mortality 
rates of CRC in the US are gradually declining, the overall prevalence is estimated to 
increase from 1,216,000 in 2010 to 1,517,000 in 2020.  Medical expenditure for CRC is 
the second highest in cancer care, only behind female breast cancer. With a cost of $14.14 
billion in 2010, the national cost of CRC care could reach $20 billion in 2020.2 In the 
mission of fostering fundamental discoveries in disease etiology to improving clinical 
prognosis, the US National Institute of Health funded various priority areas, including 
CRC for $270 million in 2017.3 Healthcare systems and the research community have 
made substantial efforts towards lowering the disease burden, but there are still great needs 
to be met for improved understanding of a complex malignancy, using advanced 
technologies and multidisciplinary collaborations. Notably, Welch and Robertson used 
incidence and mortality rates among the US population, 50 years of age or older, between 
1975-2012, to demonstrate that the decline in CRC attributes to 1) improved therapies to 
reduce mortality, 2) early detection to avoid advanced disease, and 3) risk management, 
such as through diet/lifestyle changes and anticancer therapeutics, such as nonsteroidal 
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anti-inflammatory drugs (NSAIDs).4 Therefore, addressing the needs in CRC has the 
potential for significant impact on the economic and health burden of the population.5 
Multiple risk factors are associated with the incidence of CRC, beyond geographic 
variations. Some of these are generally considered to be non-modifiable, such as age, 
gender, and hereditary factors. Other risk factors involve environmental and lifestyle 
aspects that an individual can modify to reduce or increase the potential for CRC.6 In 
general, men have 30% higher incidence rates of CRC than women, but lifetime risks are 
similar between genders (1 in 22 in men and 1 in 24 in women) due to longer life 
expectancy of women.7 Diagnosis of CRC increases after the age of 40, and the incidence 
rate peaks between the ages of 60-79.8 Notably, the incidence rate of those younger than 
40 years old has been increasing in the past two decades. A substantial proportion of 
patients have a family history of CRC, and about 5% of those carry an inherited genetic 
abnormality. Familial CRC includes Lynch syndrome and Familial adenomatous 
polyposis (FAP). Lynch syndrome is at 50% risk of CRC between age 40-70 and also 
inherits higher risk for other cancers, both endometrial and gastrointestinal.9 FAP has early 
onset of polyposis at the age of 10-12, and almost 100% at risk for CRC by age 40.10,11 In 
addition, people who have other medical history, such as inflammatory bowel disease and 
type 2 diabetes, are more likely to develop CRC at a younger age.12 It could be because 
the diseases share similar risk factors, or one disease subsequently became a risk factor 
for another. Environmental factors and lifestyle, including physical activities, diet, 
nutrition, smoking, and alcohol consumption, play important roles in CRC etiology.13 
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Thus, modifying and managing risk provides an avenue to prevent a major proportion of 
human malignancies due to CRC.  
Symptoms of CRC vary among patients depending on size and location of the 
tumor. Symptoms include changing bowel habits, blood in the stool, persistent abdominal 
discomfort, fatigue, and weight loss, but many patients experience no symptoms in early 
stages. Screening tools have been established for early detection of CRC. According to 
the American Cancer Society Guideline for Colorectal Cancer Screening14, either an 
annual stool-based test or a visual examination (endoscopy) every five years is 
recommended for people at risk, starting with screening at age 45. Currently, National 
Colorectal Cancer Roundtable (NCCRT) is seeking to reach an 80% colorectal screening 
rate for adults 50 and older by 2018, to lower the mortality burden of CRC in the US.6 
Diagnostic tests of CRC include blood tests related to complete blood count, liver 
enzymes, and tumor markers. Diagnostic colonoscopy and proctoscopy can provide 
biopsy samples for genetic testing, regarding mutations and genomic instability for further 
disease management. Additional imaging examinations can detect advance of metastasis. 
Tumor-node-metastasis (TNM) system defined by the American Joint Committee on 
Cancer is widely used for cancer staging in the clinic.  The TNM system emphasizes 
invasiveness and spread of the tumor from stage 0 to stage IV, corresponding to the earliest 
intra-mucosal carcinoma (cancer-in-situ) to metastases in distant organs or peritoneum.15  
The majority of CRC cases are ‘sporadic’, potentially tied to diet/lifestyle or 
environmental factors. Other cases arise from familial risk factors and inheritance, 
including hereditary nonpolyposis colon cancer (HNPCC/Lynch syndrome) and FAP (Fig. 
 
4 
I-1). The defective DNA mismatch repair (MMR) genes in HNPCC and the inactivation 
of APC gene in FAP are highly penetrant, inherited traits leading to lifetime risk of CRC 
between 50% to 100%.16 The underlying dysregulations are also observed in sporadic 
cases, indicating the essential genetic drivers of CRC.17,18 Depending on the genomic 
instability, CRC is categorized to microsatellite instability (MSI) and chromosomal 
instability (CIN). MSI is caused by the defective DNA mismatch repair machinery leading 
to hypermutations in nucleotide repeat sequences, occurring in ~15% of CRC cases. The 
MMR defects can be caused by germline mutation or somatic gene epigenetic silencing of 
MLH1, MSH2, and MSH6. On the other hand, CIN contributes to the other ~85% of cases 
involving point mutations and/or chromosomal rearrangements.  These changes activate 
oncogenes, such as KRAS, BRAF, PTEN, and PIK3CA, or inactivate tumor suppressor 
genes, such as APC, CTNNB1, TP53, SMAD4 and TGFBR2, via loss of heterozygosity or 
epigenetic silencing (an extension of the Knudson two-hit rule). According to the multi-
stage carcinogenesis model by Fearon and Vogelstein in 199019, early APC mutation was 
associated with aberrant hyperplasia, KRAS mutation caused clonal expansion, and 
subsequent loss of suppressor genes (e.g. TP53) leads to later stage adenocarcinoma.   The 
specific sequence and timing of these events has been open to debate, and adjusted on a 





Figure I-1 Model of colon cancer risk susceptibility. 
Colorectal cancer (CRC) cases are mainly divided into sporadic and familial/genetically 
inherited, which corresponds to high to low prevalence with relatively low to high lifetime 





The heterogeneous nature of CRC has been recognized from anatomical sites, 
morphological phenotypes, and additional genetic and epigenetic changes beyond the 
relatively simple linear tumorigenesis steps originally conceived (Fig. I-2). Epigenetic 
regulators are emerging as key players in CRC, modulating gene expression, protein 
expression and biological functions.20 The CpG island methylator phenotype (CIMP) 
subtype described by Feinberg and Vogelstein in 198321 showed overall depletion of DNA 



























methylation specific promoter regions was found to silence critical tumor suppressors.22 
Cytosine hydroxymethylation (5hmC) was also globally reduced in colon tumors and 
resisted to cancerous hypermethylation in the promoter region.23 microRNAs (miRNA) 
are small negative regulators of protein expression, stably detected in various tissues, 
including tumors and body fluids. Dysregulation of miR-21, miR-34a, and let-7 are 
associated with cell proliferation, Wnt pathway activation, and inflammation during CRC 
development24. Long-noncoding RNAs (LncRNAs), on the other hand, act as a signal, 
guide, sequester or scaffold for proteins.  For example, CCAT1-L and HOTAIR are 
oncogenic LncRNAs in CRC.25 CCAT1-L positively regulates MYC expression by 
incorporating CTCF binding26, and HOTAIR participates in CRC progression through 




Figure I-2 Multistep sequences of colorectal adenoma-carcinoma development.  
The APC mutation is believed the first step transforming normal colorectal epithelium to 
adenoma, and it takes years with accumulated genetic and epigenetic events to develop 
colorectal carcinoma. Figure is adapted from Oncol Lett. 2018; 16: 9-1828. 
MMR gene inactivation and/or 



























Classification of CRC provides mechanistic categories for investigating causation, 
pathogenesis, therapeutics and prevention. Jass proposed more than a decade ago29 five 
subgroups according to the molecular, clinical, and morphological features. Molecular 
features included MSI, CIMP, and genetic alterations in APC, KRAS, BRAF, and TP53.  
Clinical and morphological features, such as mucin secretion, differentiation status, 
invasive tumor budding, and lymphocytic infiltration, were correlated to the molecular 
features, implicating the underlying mechanisms. About the same time, the consensus 
coding sequences and the genomic landscapes of 11 human breast and 11 colorectal 
cancers were revealed.30,31 The studies had more than 250,000 PCR primer pairs for 
protein coding exon amplification followed by Sanger sequencing. The results identified 
299 and 131 validated mutations according to two cohorts. The somatic mutations are 
related to cellular adhesion and motility, signal transduction and transcriptional regulation, 
providing opportunities for further research on etiology, biomarker development, as well 
as personalized medicine. Oncogenic mutations and genomic rearrangements were 
identified by Next generation sequencing (NGS) around 201132, and The Cancer Genome 
Atlas (TCGA) Network performed a comprehensive characterization of somatic 
alternations in colorectal carcinoma in 2012.33 The analyses included exome sequence, 
DNA copy number, promoter methylation, and messenger RNA and microRNA 
expression profiles, and a subset with whole genome sequencing. The report mainly 
focused on hypermutation of mismatch-repair genes, POLE silencing, high-frequent 
mutations including APC, TP53, SMAD4, PI3KCA, KRAS, novel mutations in ARID1A, 
SOX9, and FAM123B, copy number alternations and chromosomal translocations. The 
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proteomic analyses of 95 TCGA colorectal tumor specimens were performed by the 
Clinical Proteomic Tumour Analysis Consortium (CPTAC).34 CPTAC identified 124,823 
distinct peptides which assemble 7,526 protein groups corresponding to 7,211 genes by 
liquid chromatography–tandem mass spectrometry (LC-MS/MS)-based shotgun 
proteomic analyses. The analyses detected 796 single amino acid variants, including 152 
unreported variants, and 544 accrued in 3 databases (TCGA, COSMIC and dbSNP), plus 
a strong copy number alteration and amplification of transcription factor protein HNF4A. 
The proteome proposed A-E subtypes in which type C was associated with epithelial-to-
mesenchymal transition markers and leading to poor outcome. Although positive 
correlation of mRNA to protein was observed, poor prediction of mRNA abundances and 
variants to protein indicated the biological function of gene products is much more 
dynamics and further quantification of all biological stages are needed.35,36 Soon after 
multiple efforts toward colorectal classification, Guinney et al. consolidated four 
consensus molecular subtypes (CMS1-4) from 17 gene expression microarray and TCGA 
RNA sequencing data sets.37 CMS1(14%) is characterized by MSI and immune activation. 
CMS2(37%) is representing the classic colorectal carcinogenesis with upregulation of Wnt 
pathway and c-Myc targets. CMS3(13%) displayed metabolism adaptation and KRAS 
activating mutations. CMS4(23%) carries epithelial-mesenchymal transition (EMT), 
TGF-b signaling, stroma remodeling and invasive features. Mixed (13%) or non-
consensus reflects the potentials of phenotype transition or intra-tumor heterogeneity. The 
consensus subtypes were also compared to copy number, DNA methylation, proteome, 
miRNA profile, and clinicopathological parameters and the study found the worse overall 
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survival in CMS4 patients which was consistent with the previous report by Calon et al., 
emphasizing the importance of stroma cells and microenvironment in CRC etiology38.  
Three primary treatments for CRC are surgery, chemotherapy, and radiation. 
Surgery is useful to remove minimally invasive lesions and also to remove affected colon 
and lymph node when cancer invasion occurs to the colon wall. Chemotherapy reduces 
the risk of cancer spread, and radiation therapy helps to shrink large tumors before surgery. 
Major chemotherapy regimens for CRC incorporate 5-fluorouracil and capecitabine for 
inhibition of thymidylate synthase39, and oxaliplatin and irinotecan to prevent DNA 
replication and synthesis.40,41 Additionally, several target therapies have been developed 
for treating advanced cases. For example, antiangiogenic agents are currently used for 
metastatic CRC. Bevacizumab (Avastin), Ziv-aflibercept (Zaltrap), and Ramucirumab 
(Cyramza) are antibodies to target VEGF ligands, and Regorafenib (Stivarga) is a receptor 
tyrosine kinase inhibitor.42 Patients with wild-type RAS (both KRAS and NRAS) benefit 
from anti-EGFR (epidermal growth factor receptor) drugs, such as Cetuximab (Erbitux) 
and Panitumumab (Vectibix), to block the growth and proliferation of cancer cells. 
Immunotherapies, such as pembrolizumab (Keytruda) and nivolumab (Opdivo)43–45, are 
indicated to re-activate the immune system to attack cancer cells for MSI-High or defected 
MMR patients.  
Because it takes several years to develop, and many of the factors are modifiable, 
there are numerous clinical trials targeting CRC with therapeutic drugs and dietary 
components for general and high-risk populations.46,47 According to Clinicaltrials.gov, 
many of the active trials use NSAIDs, such as cyclooxygenase (COX) inhibitors and 
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aspirin, to evaluate efficacy, while dietary agents like omega-3 fatty acids, folic acid, 
vitamins, antioxidants, and probiotic bacteria also are undergoing clinical evaluation.  
Multiple rodent models have been established to study CRC in rats and mice, from 
genetic and carcinogen-induced perspectives. Genetic models emphasize Apc mutation, 
including ApcMin/+ mice and polyposis in rat colon (Pirc) (Fig. I-3).48 Chemical 
carcinogenesis models are characterized by early mutation events in DNA.49 
Methylazoxymethanol, 1,2-dimethylhydrazine (DMH) and azoxymethane (AOM) cause 
G to A transition. Heterocyclic amines (HCAs), such as 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) and 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), 
leads to G to T transversion or G deletion. Additionally, inflammatory agents, such as 
dextran sodium sulfate (DSS) or 2,4,6-trinitrobenzene sulfonic acid50, strongly promote 
colorectal carcinogenesis in rodents in conjunction with genetic or carcinogen-induced 
drivers.51,52 Two such models were selected for use in this dissertation, namely, the 
PhIP/high-fat diet and Pirc models.  The PhIP/high-fat diet model was designated as 
‘environmental’ and the Pirc model as ‘genetic’. Compared to ApcMin/+ mice, Pirc has a 
prevalent colon tumor yield, plus some polyps in the duodenum, and more closely mimics 
human FAP.5348 The Pirc model also has a longer life span, suitable for intervention 
studies. An added feature of the dissertation project is the application of a murine 
colonoscopy procedure to monitor disease progression, tumor suppression, and resection 





Figure I-3 APC protein and mutations that correlate with disease severity. 
Protein domains of the protein are indicated in colored bars, and the lower color bar 
indicates the correlation of protein truncation sites to tumor multiplicity in human patients. 
Top arrows indicate orthologous mutation sites of rodent model of CRC. FAP, familial 
adenomatous polyposis; Min, multiple intestinal neoplasia; Pirc, polyposis in rat colon. 













































The main focus of the dissertation is to understand the molecule profiles of tumors 
in both environmental (PhIP/high-fat diet) and genetic (Pirc) models of CRC, and to 
clarify the key drivers of tumor suppression by dietary spinach. The dissertation research 
utilizes real-time quantitative reverse transcription PCR (RT-PCR), human TCGA 
database mining, RNA sequencing, small RNA sequencing, 16S rRNA sequencing, and 
untargeted metabolomics. The study in PhIP-treated rats concentrated on pre-selected 
miRNAs and archival tumor tissue samples, whereas the Pirc experiments were conducted 
by candidate, during the course of the research, incorporating unbiased profiling/omic 
technologies. Both studies used male rats, which are more susceptible to tumor formation 
than female, and group numbers that were based on published or in-house data and the 
expected tumor outcomes. Analysis of efficacy (prevention) considered multiple 
variables, such as genetic background, dietary intervention, duration of intervention, and 
tissue types, but housing and littermate factors were not included as variables.  As detailed 
in the individual chapters that follow, molecular profiling identified potential new leads 




CHAPTER II  
MICRORNAS AND ENVIRONMENTAL EXPOSURE IN VIVO: CARCINOGENS 
AND PREVENTIVE AGENTS IN ANIMAL MODELS AND HUMAN SUBJECTS 
 
Overview 
MicroRNA (miRNAs) are stable short oligonucleotides found in various tissues 
and body fluids, and are functional negative regulators of multiple mRNA targets. 
Although cell-based assays have demonstrated the underlying mechanisms of 
(de)regulation in cancer etiology, including the impact of diet and environmental agents, 
few investigations have corroborated the implicated molecular phenotypes in preclinical 
models or in human subjects.  Reports have accrued in the literature on miRNA changes 
from environmental chemical exposures, and on miRNAs as potential mediators of the 
anti-cancer effects of dietary interventions. We review the evidence in vivo on the use of 
miRNAs, or miRNAs ‘signatures’, as biomarkers of environmental carcinogenesis and 
prevention. The scope of work encompasses mycotoxins, endocrine disruptors, foodborne 
mutagens/carcinogens, and heavy metals among agents commonly associated with cancer 
and chronic disease, as well as preventive agents such as curcumin and polyphenols from 
dietary intakes, beverages, and whole foods. Many of the affected miRNAs are related to 
deregulated disease mechanisms or anti-inflammatory properties, implicating a role for 
miRNAs in prevention outcomes by dietary agents.  However, cause-and-effect remain 
open to debate in the vast majority of such reports.  Due to the variety of target tissues and 
different criteria for determining exposures, there is limited consistency among the 
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miRNAs prioritized and the dietary exposures in animal and human studies.  Future work 
assessing potential tissue-specific miRNA ‘signatures’ altered during disease progression, 
and the dynamic changes in miRNAs with specific environmental/dietary exposures, 
should be conducted in a more concerted manner, assisted by omics and bioinformatics-
based approaches. This should advance the field by prioritizing biomarkers for further 




Environmental exposure can be viewed, broadly, as a mixture of detrimental and 
beneficial influences that have significant impacts on human health.57 Detrimental 
exposures typically encompass airborne mutagens, pesticides, endocrine disruptors, food 
borne carcinogens, heavy metals, and other contaminants in food or water. These hazards 
have been implicated in metabolic disorders, reproductive system abnormalities, 
degenerative diseases, and cancers58–60. Conversely, dietary intake of fruits, vegetables, 
and other plant-based foods (‘botanicals’) offer the promise of protection against disease 
development through their constituent nutrients, vitamins, fiber, phytochemicals, and 
other bioactive components.61–63 Here, we focus on dietary exposure as an important 
‘environmental’ influence on human lifespan.  In 1981, Doll and Peto64 estimated that 
35% of cancer incidence could be attributed to diet.  Alternatively, in 2016, Blot and Taron 
proposed a dietary contribution of 20%65, while Song and Giovannucci emphasized that 
the effect of early life malnutrition on later cancer risk may require a closer examination.66  
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Diet and nutrition also contribute to risks of other major chronic conditions, including 
obesity, diabetes, and cardiovascular diseases.67 Therefore, numerous studies have 
attempted to investigate the impacts of our living environment through dietary exposure.  
It is now well accepted that most common human diseases involve interactions, or 
‘crosstalk’, between genes and environment.68 Starting from four decades ago,  studies in 
environmental health focused mainly on aspects of genotoxicity and mutagenicity, leading 
to a genetic perspective in risk assessment.69,70 Emerging evidence in epigenetic research 
suggests that environmental influences exert consequences beyond gene mutations, 
chromosome aberrations, and DNA damage responses.71,72 Epigenetic regulations are 
essential processes in physiological development, and also participate in pathological 
progression.73 Importantly, the epigenetic mechanisms are potentially reversible, unlike 
the genetic changes affecting DNA sequence. Cancer and other pathologies involve 
deregulation of histone modifications, DNA methylation states, and non-coding RNAs 
with key roles in gene regulation and homeostasis. MicroRNAs (miRNAs), a class of 
small non-coding RNAs, are post-transcriptional regulators that were first identified 
through developmental studies using the nematode C. elegans in 199374. Thousands of 
mammalian miRNAs have now been identified,  where they are estimated to regulate 30% 
to 60% of coding genes.75,76 Although many miRNAs are conserved in terms of their 
sequences and central mechanisms across phylogeny, their expression and regulation are 
highly context- and tissue-specific. During the past 15 years, the roles of mammalian 
miRNAs have been reported in development, proliferation, apoptosis, differentiation, 
pluripotency, oncology, and other pathophysiological conditions.  Notably, miRNAs are 
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gaining attention as potential early biomarkers in epidemiological studies and clinical 
applications for the following reasons: (i) miRNA profiling can distinguish normal and 
pathological lesions; (ii) miRNAs can classify different cancer subtypes; (iii) miRNAs 
provide diagnostic and prognostic insights77; (iv) miRNAs are relatively stable molecules; 
and (v) miRNAs can be detected in fresh tissues, blood, body fluid,78 and archived 
formalin-fixed paraffin-embedded (FFPE) tissues.79 
In previous reviews on the topic, the primary focus was on miRNA biogenesis and 
results from cell-based assays, seeking to elucidate molecular mechanisms of miRNA’s, 
sometimes under the influence of environmental80,81 or nutritional/dietary agents.82,83 
Here, we highlight findings from preclinical models and from human subjects, in which 
miRNA changes were examined in the context of exposures to dietary carcinogens or 
preventive agents. 
 
MicroRNA biogenesis and decay 
MiRNAs are a class of small, non-coding RNAs that act as post-transcriptional 
negative regulators of coding gene expression. MiRNA was first described in C. elegans 
as lin-4 RNA, a negative regulator of lin-14 protein translation during temporal post-
embryonic development.74 Subsequently, thousands of miRNAs have been identified in 
metazoans and plants, and their sequences and the conserved functional mechanisms of 
gene regulation have emerged.84 There are 439 mature miRNAs in C. elegans, 2,654 
miRNAs in H. sapiens, 1,978 in M. musculus, and 764 in R. norvegicus (March 12, 2018, 
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www.mirbase.org). During the past two decades, we have learned the significance of 
miRNAs in cellular processes, embryonic development, and disease progression.  
The canonical biogenesis of miRNAs (Fig. II-1) is initiated from the transcription 
of independent genes or introns of coding genes by RNA polymerase II (Pol II) in the 
nucleus, where the primary microRNA (pri-miRNA) transcript can be an independent unit 
or a part of its host gene.85 The pri-miRNAs contain a characteristic hairpin structure that 
is cleaved by Microprocessor complex to yield the precursor miRNA (pre-miRNA),86,87 
The Microprocessor complex consists of double-stranded binding protein DGCR8, 
double-stranded RNase III enzyme DROSHA, and other cofactors.88 Methylation of N6-
adenosine (m6A) of pri-miRNA, a post-transcriptional modification, was found to be 
recognized by DGCR8 and promotes DROSHA recruitment.89 A ribonucleoprotein, 
HNRNPA2B1, was also found to bind to the methylated mark and facilitated pri-miRNA 
processing.90 The cleaved pre-miRNA is then exported to the cytoplasm by exportin 5 
(XPO5) protein91–93 and further processed by RNase III enzyme Dicer94 and 
transactivation-responsive RNA binding protein TARBP2.95 One strand of the mature 
miRNA duplex, with 2 nucleotide 3’overhangs, gets degraded and one is loaded to 
Argonaute (AGO) protein to assemble the miRNA-induced silencing complex 
(miRISC).96 In addition to the canonical pathway, Drosha-independent,97 Dicer-
independent,98 and terminal uridylyl transferase (TUTase)-dependent pathways99 also 
contribute to miRNA maturation. The asymmetric miRISC complex undergoes RNA 
cleavage or translational repression of its target RNA, depending on the pairing 
complementarity.100 MiRNAs can target coding sequence, 3’UTR, and 5’UTR with 
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bulged or mismatched seed interactions and specific non-seed base pairing.101–103 
Interestingly, the m6A marks on RNA were detected across coding and non-coding RNA 
regions by m6A specific methylated RNA immunoprecipitation (MeRIP)-seq, and the 
marks were enriched near stop codons and 3’UTR of coding genes. The study also showed 
an inverse correlation between  m6A marks  and miRNA-binding sites within 3’ UTRs, 
suggesting an epigenetic regulation involving miRNA targeting events.104 Deadenylation, 
decapping, and exonucleolytic decay of the target RNA are commonly required to achieve 
gene silencing.105 The miRNA impact on target gene output was further established 
through stable isotope labeling with amino acids (SILAC) in cell culture experiments by 
Selbach et al.106 and Baek et al.107 Thousands of genes were suppressed by a single 
miRNA alteration.  However, miRNA repression of gene expression is often complex. 
One mRNA transcript can be targeted by multiple miRNAs,108 and miRNA can also up-
regulate protein translation109. The field has evolved rapidly, and we are still a long way 






Figure II-1 miRNA biogenesis pathways and epigenetic modifications in mammals. 
A, Canonical pathway of miRNA biogenesis through DROSHA and DICER dependent 
pathway. Three examples of alternative miRNA biogenesis pathways are marked in 
orange and the post-transcriptional methylation of RNAs were marked in purple including 
facilitating pri-miRNA processing and epigenetic modifications on stop codon and 3’UTR 
of targeted coding RNA. B, Mirtron as an example of Drosha and DGCR8-independent 
pathway by generating pre-miRNA through slicing and lariat debranching from coding or 
non-coding RNA. C, For Group II miRNAs (let-7 family), TUTases incorporate mono-
uridylation of pre-miRNA to generate 1-nt 3’ overhang (TUT4 and TUT7 utilized UTP, 
while TENT2 could use UTP, GTP, or ATP) for further Dicer processing. D, Ago2 protein 









Defective microRNA biogenesis in cancer 
Cancer is the second-leading cause of death in the US.110 The first cancer-related 
miRNAs were identified in the majority of B cell chronic lymphocytic leukemia patients 
that were located on a minimally deleted region of 13q14, carrying two non-coding RNAs. 
Loss of miR-15 and miR-16111,112 were inversely correlated with the increased anti-
apoptotic BCL2 gene expressison113. Through a comprehensive analysis of 334 tumor 
samples across 11 tumor types, Lu et al. demonstrated significant changes of miRNAs in 
human and murine cancer, which in part reflected loss of ‘suppressor’ miRNAs and poor 
differentiation in malignant cells.77 To test the causality of the global effects of miRNAs 
in cancer, Kumar et al. demonstrated that disruption of miRNA processing proteins, 
including DGCR8, DROSHA and DICER1, increased oncoprotein expression in a mouse 
lung adenocarcinoma cell line. Conditional knockout of Dicer1 promoted in vivo tumor 
burden in a Kras mutated mouse lung cancer model.114 Loss of Dicer1 induced tumor 
development and reduced survival rates. Further investigation suggested that Dicer1 is a 
haplosufficient tumor suppressor, linked to severe tumor development and worsened 
survival rates in heterozygous than homozygous conditioned mice.115 Diverse gene 
mutations of miRNA biogenesis proteins and dysregulation of the biogenesis pathways in 
human cancer were identified.116,117  
Although some human cancer-cell-based experiments and analyses in silico 
indicated that environmental toxins might affect miRNA biogenesis proteins, the current 
literature remains unclear on the subject118,119. Moreover, very few rodent preclinical 
studies have demonstrated a clear and unambiguous link between environmental exposure 
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and dysregulation of miRNA biogenesis pathways.  One example is the altered expression 
of Dicer1 and Drosha, suppressed significantly by Orchratoxin A (OTA) in a dose-
dependent manner in the kidney of rats120. A second example would be chronic dichloro-
diphenyl-trichloroethane (DDT) exposure in female rats leading to a reduction in Dicer1 
expression in uterine tissues121.  
 
miRNAs as biomarkers 
Microarray and sequencing technologies coupled with computational analysis 
have identified recurrent miRNA targets across various cancer types. The miR-106 family 
modulates TGFBP2, as identified in a study of 540 solid tumors,122 and statistical analysis 
of over 3000 tumors from The Cancer Genome Atlas (TCGA) database,123 which indicated 
the critical role of TGF-b signaling in the progression of various types of cancer. MiRNAs 
are altered across all types of cancer, and the profiles can be characterized by their tissue-
specific dysregulation.77,124  
Multiple studies have explored the potential of miRNA profiles as biomarkers for 
diagnosis and prognosis. MiR-155 was found to be elevated in lung cancer tissues 
compared to adjacent normal tissue, and was correlated with poor survival, using 
multivariate analysis in an adenocarcinoma and squamous cell carcinoma cohort.125 In a 
study investigating colorectal cancer using two cohorts, one in the US with 84 patients 
and another in Hong Kong with 113 patients, high miR-21 expression was determined to 
be associated with advanced stage, poor prognosis, and poor therapeutic outcome after 
adjuvant chemotherapy.126  
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MiRNAs also can be detected in serum and plasma, which offers noninvasive 
biomarker assessment. The miRNAs in serum and plasma from healthy subjects were first 
characterized and the profile was compared to serum miRNA from patients with non-small 
cell lung carcinoma (NSCLC), colorectal cancer, ovarian cancer, and type 2 diabetes. 
Based on the analysis, the induction of miR-25 and miR-223 was verified in serum of 
NSCLC127. Resnick et al. also identified miRs-21, 92 and 93 overexpression in serum 
samples of ovarian cancer patients.128 Later, Weber et al. demonstrated the successful 
detection of miRNAs in 12 human body fluids, which gave rise to the new era of biomarker 
discovery of health and disease.78 For example, plasma miR-122 was identified as a liver 
injury biomarker, which correlated with liver disease alanine aminotransferase (ALT) 
elevation but not with muscle injury ALT level129. One of the specific sources of miRNA 
in plasma is circulating plasma macrovesicles (PMVs). Badrnya et al. identified 
decreasing PMV numbers and miR-233 level but significantly upregulated miR-29b in 20 
young, apparently healthy smokers. 130 
 
Dietary carcinogens and miRNA 
Major human carcinogenic influences include cigarette smoking, environmental/ 
dietary factors, and inflammation/infection.64,131 Some of these agents possess genotoxic 
activity, and others induce tumor promoting effects such as DNA damage response,132 
oxidative stress, and inflammation.133,134 Recent studies have contributed an additional 
layer of knowledge regarding how these carcinogens affect miRNA profiles and their 
involvement in cancer and other diseases. Five categorized agents are addressed in the 
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discussion. These include naturally-occurring mutagen, endocrine disruption chemicals, 
foodborne carcinogens, heavy metal contaminates, and alcohol consumption. Table II-1 
presents a summary of dietary carcinogens involved in miRNA modulation in animal 
models or human subjects.  
 
Mycotoxins (aflatoxins and ochratoxins). Mycotoxins are toxic secondary metabolites 
produced by fungi. Hundreds of mycotoxins have been identified, but only a few regularly 
contaminate food. Aflatoxin and ochratoxin contaminations are often found in cereals, 
nuts, flours, vine fruit, coffee and cocoa.135 miR-429 is one member of the miR-200 
family, which can regulate transcription factor ZEB. miR-429 was identified in a cohort 
that included 138 pathology-diagnosed hepatocellular carcinoma (HCC) subjects. miR-
429 upregulation was associated with larger tumor size, poor survival rate, and higher 
aflatoxin(AF)-DNA adducts in tumor tissues.136 In a F344 rat dosing experiment, 200 
µg/kg aflatoxin B1(AFB1) exposure perturbed the expression of 36 miRNAs in liver 
tissue, while increased miR-429 was identified among 10 validated miRNAs. The serum 
miRNA profile was rather different in the same study, but it nevertheless shared the 
upregulation of miR-34a and miR-181 by AFB1 in both serum and liver tissue137. Liu et 
al. suggested a joint effect of high miR-24 and high AFB1-DNA adducts in tumor samples 
on disease outcome of HCC.138 Small RNA sequencing of rat liver tissue after a three-day 
exposure to 1.5mg/kg AFB1 revealed changes in the miRNA profile, seed sequence, and 
potential novel miRNA expression. miR-34a was validated in the study as being 
upregulated as an oncogenic miRNA after AFB1 exposure.139 While AF primarily causes 
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liver toxicity, ochratoxin A (OTA) prominently causes nephrotoxicity. Heme oxygenase-
1(HO-1) was reported participating in OTA-induced toxicity in mouse kidney. Wild-type 
and HO-1 knockout mice were tested with OTA exposure140. NQO1 and NRF2 proteins 
were significantly decreased by OTA in HO-1 knockout mice, while NQO1 was also 
reduced by OTA in wild-type mice. On the other hand, the dysregulation of increasing 
p53-dependent miR-34a and pro-fibrotic/anti-apoptotic miR-21, and decreasing anti-
fibrotic/tumor suppressive miR-29b in HO-1 knockout mouse can be further exacerbated 
by OTA, suggesting a role of OTA antioxidant pathways through miRNA modulation. 
Similarly, in a 26-week OTA exposure of F344 rats, Nrf2 reduction and Keap1 induction 
were observed in kidney, which indicated the involvement of oxidative stress and 
detoxification pathways.120 In the latter study, miRNA biogenesis genes Drosha and 
Dicer1 were downregulated, and further led to the suppression of most miRNAs. The 
study illustrated the deleterious effect of OTA on miRNA maturation, which may be a 
novel mechanism of OTA toxicity. 
 
Endocrine disruption chemicals (BPA and DDT). Endocrine disruption chemicals 
(EDCs) originate from both natural and man-made sources. EDCs can interfere with 
diverse pathways in the endocrine system, reproductive system, neurological and 
immunological development of humans and wildlife. Common substances in our 
environment include solvent byproducts, pesticides, and plasticizers such as dioxin, 
dichlorodiphenyltrichloroethane and bisphenol A. Dichloro-diphenyl-trichloroethane 
(DDT) and bisphenol A (BPA) are found in ground water, vegetables grown under 
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contaminated soil, and meat coming from the top of the food chain. In the placental tissue 
of pregnant women, miR-146a was overexpressed and significantly correlated with 
placental BPA level.141 In a Northern Swedish population, a blood leucocyte miRNA 
signature, including 193a-3p, miR-152, miR-31-5p, and miR-34a-5p, was positively 
associated with persistent organic pollutants (POPs) levels, which were calculated from 
measurements of polychlorinated biphenyls (PCBs), hexachlorobenzene (HCB) and DDT 
metabolites in serum. The study suggested that the miRNA signature crosstalks with 
oncogenes, such as MYC, CCND1, BCL2, and VEGFA, and further implied a connection 
between miRNAs and human cancer142 through p53 and Wnt pathways.  
          In addition to the exposure of EDCs observed in the reproductive system and blood, 
research has also demonstrated the toxic effects in local organs. In a male Wistar rat oral 
gavage study, BPA induced miR-122 expression through activation of JNK, ERK1/2, 
MAPK, and Akt pathways. The induced miR-122 was further predicted to interfere lipid 
metabolism and liver homeostasis.143 BPA also has been demonstrated to influence miR-
338 through different upstream regulators, Gpr30 and Glp1r, in mouse pancreatic islets 
following short-term and long-term exposures, respectively. By targeting the Pdx1 gene, 
the dysregulated miR-338 interrupted the compensation of glucose-stimulated insulin 
secretion and ATP production.144 On the other hand, in liver tissues, intraperitoneally (i.p.) 
administered DDT to female Wistar rats increased Cyp2b1 gene and protein expression as 
well as CYP substrates after 72-hour exposure. Reductions of miR-21, 221, 222, and 429, 
were predicted to target Cyp2b1 gene, which also were observed in DDT-treated liver 
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tissues. The results suggested the involvement of miRNAs in DDT-induced CYP enzymes 
in liver.145  
 
Foodborne mutagens (PAH and HCA). Polycyclic aromatic hydrocarbons (PAHs) and 
heterocyclic amines (HCAs) are chemicals found in high-temperature cooked meat146. The 
metabolites of PAHs and HCAs can form DNA-adducts which contribute to their 
mutagenic activity and DNA damage responses.147,148 Several epidemiologic studies have 
illustrated that meat consumption and cooking methods are associated with increased risks 
of cancers149,150. PAHs also may be airborne pollutants. By measuring urinary 
monohydroxy-PAHs and plasma benzo[a]pyrene (BaP)-albumin adduct in coke plant 
workers, Deng et el. demonstrated an inverse association between the increasing plasma 
albumin adducts and decreasing miR-24-3p, miR-27a-3p, miR-142-5p, and miR-28-5p 
levels. On the contrary, miR-150-5p was increased and positively associated with urinary 
monohydroxy-PAHs.151 BaP is one of the most widely studied PAHs and can bind to aryl 
hydrocarbon receptors (AhR) to trigger downstream gene regulation152,153. A systematic 
evaluation of BaP-DNA adducts, gene expression, and miRNA profile were conducted in 
BaP-treated mice. BaP–DNA adduct was detected in the stomach, spleen, lung, liver, and 
colon, which indicated a systematic toxic effect. The gene profile indicated a tissue-
specific response which demonstrated that only Ccng1, Cyp1a1 and Hspa8 were 
consistently upregulated in BaP-targeted organs. Notably, the miRNA profile was 
modestly changed in the study,154 and appears to be consistent with another short-term 
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exposure study in male mice which indicated a lack of change in miRNA through BaP 
exposure in rodent models155.  
         2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is one of the most 
common HCAs.  Rat oral gavage studies indicated a 13-miRNA signature in PhIP-induced 
rat colon tumors. Let-7 miRNA downregulation and the upregulation of its target genes, 
including c-Myc and Lin28, were identified.156 A follow-up study which focused on the 
other target organs of PhIP-induced tumorigenesis in the rat identified a five miRNA ‘PhIP 
signature’ involving miR-21, miR-126, miR-29c, miR-215, and miR-145, associated with 
reduced Klf4 levels in PhIP-induced tumors and correlated with a subgroup of human 
cancer patients.157 Assigning this subgroup as potential HCA consumers was not feasible. 
 
Heavy metals (As and Hg). Arsenic is a natural element but is highly toxic in its inorganic 
form. Contamination of groundwater by arsenic poses risks for irrigation, food 
preparation, and drinking water. Exposure to inorganic arsenic increases risk of skin 
cancer, bladder cancer, lung cancer, metabolic syndrome, cardiovascular disease and 
defective fetus development. When sodium arsenite was added in drinking water to male 
Sprague Dawley rats, 26 miRNAs were differently expressed in liver tissue158. The activity 
of hepatic glutamate-cysteine ligase (GCL) was increased by low doses but decreased by 
high doses of sodium arsenite exposure. Interestingly, the gene expression of Gclc and 
Gclm, the subunits of GCL, were affected in the same manner. miR-25 was identified as 
a conserved miRNA, which regulates Gclc and Gclm in rats and humans, and is 
responsible for arsenic-induced toxicity in the liver. In a cohort in Mexico which consisted 
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of 200 pregnant women, twelve miRNAs were upregulated in cord blood of newborns and 
were associated with in utero arsenic exposure by detecting maternal urine arsenic level. 
The miRNAs were predicted to regulate immune response in blood cells suggesting the 
miRNAs were prenatal exposure responders.159 In a fetal growth focused birth cohort of 
1,141 cases in Bangladesh, Rahman et al. identified the increasing miR-1290 in the 
placenta was significantly associated with preterm birth, lower birthweight, and high cord 
blood arsenic exposure in the 466 mother-infant pairs.160  
          Mercury is another natural element that possesses toxicity through vapor exposure, 
mercury-containing products, and food source contamination. For example, mercury-
containing dental material, plants grown in contaminated soil, and accumulated toxins in 
the food chain, particularly in seafood, enter the body through unintentional or dietary 
exposure. Mercury can cause cardiomyopathy, bowel immune response, renal disease, and 
neurotoxicity.161 Plasma miR-92a-3p and miR-486-5p are upregulated in mercury exposed 
workers, and the two miRNAs can suppress the expression of Klf4 and Cezanne to further 
sustain NFkB pathway activation.162 In utero exposure of environmental pollutants in the 
US population was linked to let-7 miRNA family downregulation, and was negatively 
correlated with the increasing mercury and lead exposure levels in placenta tissue.163  
 
Alcohol. Alcohol consumption is associated with steatosis, hepatitis, fibrosis, and 
cirrhosis, which contribute to mortality in western countries164. miR-122 has been reported 
to be a highly abundant miRNA in mature hepatocytes and was inversely correlated with 
the prognosis of hepatocellular cancer (HCC). Liver miR-122 was suppressed in alcoholic 
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liver disease (ALD) patients and in an ALD mouse model.165 Loss of miR-122 expression 
was mechanistically due to activation of the transcriptional repressor Grainyhead like 
transcription factor 2 (GRHL2) via an alternative splicing event induced by ethanol 
exposure. The suppression of miR-122 led to hepatic steatosis and inflammation through 
HIFa.  In serum samples, however, miR-122 was elevated, implying miR-122 released 
from injured liver tissue from an investigation of recreational alcohol consumption.166 A 
follow up-study from the same group used unbiased small RNA sequencing and analysis 
of serum miRNAs.  By comparing small RNA sequencing profiles between 48-hours 
before drinking and 3-5 hours post-drinking in 16 healthy participants, the study found 
that a fifth of the total detected miRNAs, including miR-122, were upregulated, and only 
miR-185-5p was downregulated.167 Additionally, a non-human primate study illustrated 
that chronic alcohol consumption disrupted the homeostasis of peripheral blood and 
colonic immunity. The results suggested the reduced expression of transcription factors, 
such as Stat3 and Arnt, and growth factors, such as Vegf, Hgf, and G-csf, may be due to 
the dysregulation of miR-181-5p and miR-221-3p.168 
 
Chemopreventive agents and miRNA 
Dietary patterns, macronutrients, and phytochemicals have been reported to affect 
cancer risk.169 Although the benefits of natural agents are not limited to cancer prevention, 
the majority of bioactive components in the food have been historically studied in the 
context of cancer. Phytochemicals are non-nutrient plant-derived chemicals which possess 
anti-oxidation, anti-inflammation, and anti-proliferation capabilities against neoplasia 
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stages.170–172 The miRNA regulation in vivo by phytochemicals, including curcumin, 
resveratrol, polyphenols, and cruciferous vegetable-derived compounds, other 
macronutrients and whole food are discussed and listed in Table II-2.  
 
Curcumin. Curcumin and other curcuminoid analogs, such as demethoxycurcumin and 
bisdemethoxycurcumin, are polyphenolic compounds found in turmeric spice (Curcuma 
longa). Although low bioavailability of curcumin has been reported,173,174 curcumin has 
been demonstrated to contain anti-inflammatory, anti-oxidation, anti-microbial, and anti-
cancer properties in numerous reports.175,176 In 2012, Bao et al. indicated that 
diflourinated-curcumin, a curcumin analog, restored the expression of let-7, miR-26a, and 
miR-101, which are commonly lost in pancreatic cancer, and inhibited pancreatic tumor 
growth in cell-based assays and in a xenografted mouse model through intragastric 
treatment. The inhibition effects also involved downregulation of histone 
methyltransferase Ezh2 and other factors, such as Notch-1, Cd44, Epcam, and Nanog.177 
Since inflammation is a critical mediator for cancer progression178, a study combined 
curcumin and another anti-inflammatory agent, 3 acetyl-11-keto-β-boswellic acid 
(AKBA), to combat colorectal cancer tumor growth in a HCT116-cell-derived xenograft 
mouse model. The intraperitoneal treatments of the two agents worked together to 
suppress the tumor growth in mice. Induction of miR-34a and the reduction of targets such 
as MYC, CDK6 and CCNE1, and the repression of miR-27a with the increasing FBXW7 
were observed in tumor growth inhibition179. A more recent study demonstrated the 
systemic effects of curcumin in the lipopolysaccharide (LPS)-induced sepsis mouse 
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model. Pretreatment with curcumin via oral gavage ameliorated LPS damage in the liver 
and kidney, with reduced serum biomarkers, including AST and BUN, decreased cytokine 
IL-6 and TNF-a level, and improved histology. Curcumin also inhibited the elevation of 
miR-155 through the PI3K/Akt pathway in LPS-induced liver and kidney inflammation.180 
miR-155 was one of the first identified miRNAs in B cell lymphoma and was derived from 
BIC RNA induced by avian leukosis virus.181 miR-155 was also proven to perform a 
multifunctional role in cell-specific inflammatory responses. Together, the literature 
suggests that curcumin could modulate inflammatory conditions through miR-155. 
Moreover, curcumin also showed a protective effect in renal podocytes against fructose-
induced metabolic syndrome, proteinuria, and insulin resistance in rats.182 The 
upregulation of miR-206 and downregulation of protein tyrosine phosphatase 1B (PTP1B) 
by curcumin, with consequentially improved insulin signaling, suggested curcumin can be 
a potential dietary intervention to combat diabetes, metabolic syndrome, and fructose-
associated podocyte injury involved in defective insulin signaling. 
 
Resveratrol and stilbene. Resveratrol and its glucoside are bioactive stilbenoids derived 
from plants such as grape skin, grape seeds, mulberry183, pistachio and peanut.184 In a 
previous report on tumor inhibition by resveratrol in Transgenic Adenocarcinoma Mouse 
Prostate (TRAMP) mouse model through reducing IGF-1 and ERK1/2 signaling,185 Seth 
et al. extended the mechanistic study from signaling to miRNA alterations.186 Oral 
administration of resveratrol reduced tumor growth and metastasis of aggressive PC-3M-
MM2 cells in immune compromised mouse models. Resveratrol reduced Akt signaling 
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resulting in reduced miR-21 and elevated PDCD4 expression. The study also explored 
resveratrol protective effects on other prostate cancer cell lines, and the results indicated 
tumor suppression by resveratrol can be either miR-21 dependent or independent. Another 
prostate cancer study tested the effects of resveratrol and its analog, pterostilbene, on 
xenografted prostate cancer tumor growth. The results indicated that pterostilbene could 
restore the loss of PTEN expression in DU145 and 22Rv1 human prostate cancer cells 
through suppressing miR-17, miR-20a and miR-106b.187  
       Additionally, anti-inflammatory miRNAs, miR-101b and miR-455, were upregulated 
by resveratrol in intestinal tissues after dextran sodium sulfate-induced colitis-associated 
tumorigenesis in ApcMin/+ mouse. Functionally, resveratrol mitigated intestinal epithelial 
proliferation, pro-inflammatory cytokines such as IL-6 and TNF-a, and modulated 
immune cell infiltration to lymph nodes.188 Resveratrol also demonstrated an anti-
inflammatory response through downregulation of RELA, a NF-kB subunit, resulting in 
reduced miR-221 transcriptionally. TRK-fused gene (TFG), a tumor suppressor, was 
identified as a miR-221 target. Peritoneal administered resveratrol suppressed xenografted 
melanoma via repression of RELA and miR-221 and the de-repression of TFG.189  
       A one-year supplementation of grape extract with enriched resveratrol was performed 
in type 2 diabetes patients. Downregulation of cytokine expression such as CCL3, IL-1b, 
and TNF-a, and modulation of miR-181b, miR-155, miR-34a and miR-30c2 were 
observed in peripheral blood mononuclear cells (PBMCs), which indicated an immune 




Other polyphenols such as EGCG, quercetin, genistein, and anthocyanin. 
Epigallocatechin-3-gallate (EGCG) is a highly abundant tea catechin with anti-cancer 
potency. It can scavenge reactive oxygen species (ROS) to modulate gene expression and 
signaling.191 The effects of EGCG on miRNA and mRNA expression were evaluated by 
microarrays in a tobacco carcinogen-induced mouse lung adenoma. The results indicated 
a modest upregulation of 21 miRNAs and gene networks associated with IGFBP5 and 
AKT/MAPK regulation.192 miR-210 was one of the elevated tumor suppressor miRNA by 
EGCG in mouse lung, and was investigated in lung carcinogenesis via cell-based 
assays,193 indicating the role of mi-210 was consistent in both in vitro and in vivo 
conditions.   
     Quercetin is a flavonoid found in several fruits and vegetables such as apples, plums, 
peppers, and onions. Quercetin has anti-inflammatory and proapoptotic properties. 
Epidemiological studies have used paraffin-embedded lung cancer tissues and quercetin-
rich food frequency questionnaires to 264 lung cancer patients to assess the miRNA level 
and quercetin exposure. The study identified 33 miRNAs associated with quercetin 
exposure. The tumor suppressor let-7 family and pro-apoptotic miR-26 were significantly 
higher in the frequent quercetin consumption group.194  
       Pomegranate contains other types of polyphenols, such as ellagitannins and 
anthocyanins, which are precursors of anti-oxidative ellagic acids and phenolic acids. 
Pomegranate extracts showed anti-tumor activities through downregulation of PI3K/AKT 
and NF-kB pathways in lung cancer cells.195,196 Banerjee et al. later demonstrated the anti-
cancer effect on reducing aberrant crypt foci (ACF) by pomegranate polyphenol in 
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azoxymethane (AOM), a colon carcinogen, treated rat model. Drinking pomegranate juice 
increased miR-126 and reduced Vcam1 and Pik3ca expression and further suppress 
PI3K/AKT and NF-kB pathway activation in an AOM-treated rat colon.197  
 
Cruciferous vegetables. Cruciferous vegetables have four cross-shaped petals, and the 
common edible cruciferous vegetable are cabbage, broccoli, Brussels sprouts and mustard 
greens. They have been determined to be associated with reduced colorectal cancer risk.198 
Particularly, glucosinolate precursors and isothiocyanates (ITC), such as sulforaphane, 
and indole-3-carbinol (I3C) and its dimeric analog 3,3’-diindolylmethane (DIM), have 
been reported to possess substantial chemoprevention potential199,200 through modulating 
liver metabolism enzymes, anti-oxidation machinery involving in nuclear factor E2-factor 
related factor (Nrf2) pathway, and histone deacetylase (HDAC) inhibition.201 Izzotti et al. 
used oral administration of chemopreventive agents, including phenethyl isothiocyanate 
(PEITC) and I3C, and evaluated early carcinogenesis changes from environmental 
cigarette smoke (ECS) exposure. The study first identified 25 miRNAs modulated by 
chemopreventive agents in rat lung, while the combination of PEITC and I3C showed the 
most protective effect on normalizing miRNA changes, including let-7 family, miR-30 
family, miR-34 family and miR-99b.202 Another study used i.p. injected vinyl carbamate 
(VC) to induce lung tumors in A/J mice to assess the miRNA regulation by dietary 
administered I3C. Although the study did not reveal tumor prevention, I3C reduced 5 VC-
induced miRNAs in lung tumors. The induction of miR-21 targets, Pten, Pdcd4, and Reck 
by VS were observed while miR-21 was downregulated by I3C treatment. The effect of 
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I3C was also recapitulated in A549 lung cancer cell lines.203 More recently, Wang et al. 
demonstrated I3C suppressed HCC cell-based assays and xenografted tumors with 
intraperitoneal I3C administration. The result indicated that I3C inhibited miR-21 
activated PTEN/Akt pathway both in vitro and in vivo.204 
 
Macronutrients and whole foods. n-3 polyunsaturated fatty acids (PUFA), but not n-6 
PUFA, and dietary fiber possess chemopreventive efficacy against colon cancer 
development. This work demonstrated in a series of studies using fish oil and dietary fiber 
miRNA changes in AOM-induced rat colon tumors.205–207 Fish oil reduced the colon tumor 
incidence regardless of the combination with dietary fibers, cellulose or pectin, and 
selectively modulated let-7d, miR-15b, miR-107, miR-191 and miR-324- 5p in the rat 
colon. The second study focused on the upregulation of miR-26b and miR-203 after fish 
oil and pectin combination. An inverse correlation of the miRNAs and the reduced target 
genes Ptk2b, Pde4b, and Tcf4, supported the chemopreventive outcomes. The most recent 
report indicated that miR-26b and miR-203 regulation was specifically in the Lgr5hi stem 
cell population from mouse colon.  
The whole food approach is also an emerging topic in cancer prevention 
research208,209 due to its multi-targeting effects. Parasramka et al. demonstrated that 
dietary spinach inhibited PhIP-induced rat tumorigenesis across various organs, and 
normalized the miRNA alterations in PhIP-induced colon tumors. The protection included 
de-repression of several let-7 family members and the association of reduced pluripotency 
targets such as Myc, Lin28, and Hmga2.156 Jeyabalan et al. demonstrated the 
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chemopreventive and therapeutic effects of dietary blueberries in female ACI rats with 
17β-estradiol (E2) induced breast cancer.210 Dietary blueberries were supplied in the 
beginning of the study for evaluating preventive effects while therapeutic effect was 
supplied with blueberry after the appearance of the first palpable tumor. In the end of the 
25-week study, 5% blueberry and had both preventive and therapeutic outcomes, with 
downregulation of Cyp1a1 and Esr1 gene expression. Among four estrogen specific 
miRNAs, significant down-regulation of miR-18a and miR-34c in the therapeutic mode 
of mammary tissues were observed.  
 
Conclusion and future perspectives 
MiRNAs are critical gene regulators in physiological and pathological processes, 
as well as being implicated in environmental exposures. This review summarized the 
impact of in vivo dietary exposures on miRNA biogenesis, and miRNA profiling with 
selected agents that exert detrimental or beneficial effects on human health. The literature 
provides evidence of miRNAs responding to external exposures, in locally affected organs 
or in body fluids.  In addition, the influence of dietary components on miRNAs provides 
deeper insight into novel disease prevention mechanisms via nutritional intervention. 
Our living environment is complex and dynamic, which exacerbates the difficulty 
of discerning the contributions of individual exposures. In addition, it remains unknown 
whether miRNAs are exposure-specific or disease-specific read-outs. Ideally, monitoring 
environmental exposure through biomarkers should enable the early detection of exposure 
for intervention before disease progression Developing miRNAs as biomarkers of 
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environmental exposure presents several challenges. First, few comprehensive and cross 
validated studies have been published on body fluids and disease sites in relation to dietary 
toxin exposure. Therefore, specificity and reproducibility are difficult to assess. Notably, 
few consistent results are found in the literature. For example, in a rodent aflatoxin 
exposure model, miR-429 was elevated by aflatoxin exposure and miR-429 was correlated 
with AF-adduct in human liver tumors. However, other cases appeared to be either non-
specific to various exposures or study-specific findings. For instance, let-7, a tumor 
suppressor across various cancers211, was upregulated by quercetin194, curcumin177 and 
spinach156 in lung and colonic tumors indicating its non-specific roles in multiple cancer 
types in response to dietary exposure. Thus, detecting let-7 level may not be sufficient to 
reflect a specific disease or environmental exposure.  
Study-specific results may be due to the complexity of content-dependent miRNA 
regulation. miRNAs in different sample types could have distinct meanings. For example, 
miR-122 was downregulated in the liver tissue of alcohol treated mice, but was elevated 
in human serum after recreational alcohol consumption. Therefore, one must be careful in 
interpretations across studies and cognizant of their reproducibility and widespread 
significance. Secondly, there are technical issues involved in assessing miRNAs. The 
biomarker source (e.g. tissue, tumor, or a particular biofluid) that serves as the miRNA 
starting-material varies depending upon particular research interests. Interestingly, Haider 
et al. analyzed 104 publicly available studies focusing on miRNA profiling in non-
neoplastic diseases and identified significant methodology issues, including sample 
preparation, lysis of hematologic cells, and data normalization, in serum, plasma and 
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PBMC-based miRNA biomarker research212. The study also demonstrated a high 
inconsistency of results across the literature, in which non-disease-specific miRNA 
biomarkers were identified, such as in the case of organ injuries. For example, miR-122 
was associated with liver injuries regardless of damage types, including viral infection and 
drug-induced toxicity. miR-370 was only identified in two independent studies of 
coronary artery disease and was not found in other included reports.  
While the research investment regarding miRNAs as biomarkers is increasing, the 
studies to date suggest that a careful sample acquisition and interpretation are necessary 
to facilitate clinical biomarker development. Specificity and reproducibility issues in 
miRNAs as biomarkers have also been recognized in the cancer field.213 Although 
circulating cell-free miRNAs were reported since 2008127,214,215, a profound effect on 
miRNA profiles from platelets during plasma processing was addressed by Cheng et al.216 
For miRNA biomarker development across multi-institutional operation and validation, 
the necessities of protocol optimization and quality control (including data normalization) 
are substantial challenges to overcome.  
Second, whether the miRNA changes truly reflect a specific environmental 
exposure remains unclear in the current literature, since the timing of environmental 
exposure and disease progression could be overlapped. Many studies in this review 
included either case-control human studies or xenograft mouse models for toxin exposure 
and testing health-promoting agents. There are apparent demands for longitudinal 
exposure studies with miRNA profiling and disease prevalence analysis in human 
subjects. On the other hand, rodent models with comparable human etiology are more 
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suitable to justify in vivo study for functional dissection217,218. Exposure studies in rodents 
also require consideration of the delivery method, the dose, and the duration to be relevant 
to human conditions. Testing prevention in various rodent backgrounds, mimicking wider 
human exposure scenarios, might provide more insights and allow knowledge go be 
translated from rodent models to  medicine.219,220 Collectively, the limitations in miRNAs 
as biomarkers could be tackled through in-depth study designs which are targeted towards 
a specific purpose, such as exposure-driven or disease mechanism-driven designs, with 
proper sample acquisition and standardized processing in a relevant longitudinal setting.  
Third, dietary impacts on miRNAs involves layers of new knowledge. Recent 
reports have indicated that diet-derived miRNAs may affect human health through 
exosome uptake221,222. Gut microbiota also has been proven to play a role in bioactive 
compound releasing,223,224 cross-talking with miRNA modulation,225,226 and even 
interaction with environmental exposure.227 Relative to toxin exposure measurement for 
risk management, dietary or phytochemical intervention for health promotion presents 
other difficulties in the clinic, such as long-term compliance and the single molecule 
mindset.208 Moreover, the need for relevant end point measurements benefiting patients’ 
health must be further developed and evaluated.228 In summary, achieving dietary 
intervention of miRNAs or the combination with other aspects would require further 
interdisciplinary efforts.  
Although dietary intervention and phytochemicals are proposed to be effective in 
combating cancer through miRNA modulation83,229, careful evaluation is necessary. The 
the bioavailability of active compounds is one of the barriers to transfer the cell-based 
 
40 
successes to human cases. Various methods can improve the delivery,230–232 such as 
derived analogues, conjugation, nanoparticle, and liposome. Also, it is challenging to 
determine whether a single phytochemical or a mixture, either of enriched components or 
whole food, would be a superior strategy. Phytochemicals possess multiple functions in 
addition to modulating miRNAs, including preventing genotoxicity, regulating immune 
response, and reducing proliferation. Ricciardiello et al.,208 Hussain et al.,209 and Potter233 
have all proposed a potential for whole food intervention for cancer prevention. However, 
without a direct comparison, their decisive benefits from one or the other remain open to 
debate.  
Understanding the modulation of miRNA profiles through environmental 
exposure in circulation or in at-risk organs provides future directions for monitoring and 
disease prevention. Utilizing dietary components for disease intervention remains 
optimistic, due to modulation of miRNAs, which further regulates multiple targets and 
exerts other anti-cancer properties. The current review summarizes evidence of miRNA 
alterations from detrimental and beneficial environmental exposures linked to human 
health. Future investigations with longitudinal cohorts and with standardized processes 
and procedures will offer enhanced solutions for disease prevention strategies centered on 




Table II-1 miRNA modulation by dietary carcinogens. 
Abbreviation:  
AF, aflatoxin; BaP, Benzo[a]pyrene; BPA, bisphenol A; DRC-ICP-MS, dynamic reaction 
cell inductively coupled plasma mass spectrometer; ELISA, enzyme-linked 
immunosorbent assay; GC-MS, Gas chromatography–mass spectrometry; HCC, 
hepatocellular carcinoma; HG-AAS, hydride generation-atomic absorption spectrometry; 
Hg, mercury; OTA, ochratoxin A; PAHs, polycyclic aromatic hydrocarbons; Pb, lead; 
PBMC, peripheral blood mononuclear cell; PhIP, 2-amino-1-methyl-6-phenylimidazo 
[4,5-b] pyridine; POPs, persistent organic pollutants (POPs) level was calculated 6 
polychlorinated biphenyls (PCBs), 1 hexachlorobenzene (HCB) and 












• 138 HCC 
patients
• Liver tumor 
tissue
AFB1 DNA adduct, 
ELISA RT-PCR
miR-429⇑(Zeb) Huang et al.136
AF • Male rats• Liver and serum
• 200 µg/kg/d AFB1
• 4 weeks
• oral gavage
• Small RNA 
sequencing
• RT-PCR
Liver: miR-434⇑, miR-411⇑, miR-
221⇑, miR-127⇑, miR-205⇑, miR-
429⇑, miR-34a⇑, miR-181c⇑, moir-
200b⇑, miR-541⇑





• 207 HCC cases 







miR-24⇑ Liu et al.138




• Small RNA 
sequencing
• RT-PCR 





• 2.5 mg/kg OTA 




• RT-PCR miR-34a⇑ and miR-21⇑, miR-29b⇓ Loboda et al.140
OTA • Male rats• Kidney
• 0, 70 or 210 µg/kg







And Pan-miRNA⇓ Dai et al.120
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• Small RNA 
sequencing
• RT-PCR
miR-146a⇑ De Felive et al.141
DDT
• 229 lymphoma 
case and 327 
controls







193a-3p⇑, miR-152⇑, miR-31-5p⇑, 
and miR-34a-5p⇑ Krauskopf et al.142
BPA • Male rats• Liver
• 0.5, 5, 50 mg/kg/d
• 30 days
• oral gavage
• RT-PCR miR-122⇑ Vahdati Hassani et 
al.143
BPA • Male mice• Pancreatic islets
• 50, 500 m g/kg/d
• 8-weeks
• oral gavage
• RT-PCR miR-338⇓(Pdx1) Wei et al.144






Liver: miRs-21⇓, 221⇓, 222⇓, and 
429⇓











Uterus: miR-221⇑, and Dicer⇓
Ovaries: miR-222⇓, miR-205⇓, miR-






• 135 exposure 
cases and 256 
controls
• Plasma




by clinical chemistry 
analysis
• Small RNA 
sequencing
• RT-PCR
Urine: miR-24-3p⇓, miR-27a-3p⇓, 
miR-142-5p⇓, miR-28-5p⇓ and miR-
150-5p⇑





• Stomach, spleen, 







miR-290⇑, miR-298⇑, miR-346⇑, and 
miR-351⇑
tissue-specific responses, modest 
changes
Zuo et al.154







Lack of change in miRNA profiling Yauk et al.155
PhIP • Male rats• Colon
• 40 mg/kg/d PhIP 
and 4-weeks HF diet 
cycling 
• 2-weeks for 3 
times









• Male rats 
• Small intestine, 
liver, skin, lung, 
zymbal's gland
• 40 mg/kg/d PhIP
and 4-weeks HF diet 
cycling 




miR-21⇑, miR-126⇓, miR-29⇓, miR-
215⇓, miR-145⇓ Chen et al.157
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Table II-1 Continued 
  







Sodium arsenite • Male rats• Liver
• 0.1, 1, 10, or 100 
mg/L, 60 days
drinking water
• Small RNA 
sequencing 
• RT-PCR 
miR-151⇑, miR-183⇑, miR-25⇑ (Gclc 
and Gclm) Ren et al.158
Total arsenic in 
maternal urine
• 200 pregnant 
women
• Maternal urine 
and cord blood





Cord blood: let-7a⇑, miR-107⇑, miR-
126⇑, miR-16⇑, miR-17*⇑, miR-
195⇑, miR-20a⇑, miR-20b⇑, miR-













placenta: miR-1290⇑ Rahman et al.160
Urine mercury




Plasma: miR-92a-3p⇑ and miR-486-
5p⇑ Ding et al.162








Let-7 family⇓, miR-151-5p⇓, miR-
190b⇓, miR-193b⇓, miR-423-5p⇓, 




• 18 healthy 
subjects
• Blood
• medical lab • RT-PCR miR-122⇑ McCrae et al.166
Alcohol
• 16 modest 
alcohol drinkers
• Blood
• medical lab • Small RNA sequencing




• Blood and colon




PBMC: miR-181-5p⇑ and miR-221-
3p⇑




Table II-2 miRNA modulation by chemopreventive agents. 
Abbreviation:  
AKBA, 3 acetyl-11-keto-β -boswellic acid; AOM, Azoxymethane; DSS, Dextran sulfate 
sodium; ECS, environmental cigarette smoke; EGCG, Epigallocatechin-3-gallate; I3C, 
indol-3-carbinol; LPS, lipopolysaccharide; NNK, tobacco-specific nitrosamine 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone; PBMC, peripheral blood mononuclear 
cell; EITC, phenethyl isothiocyanate; PhIP, 2-amino-1-methyl-6-phenylimidazo [4,5-b] 
pyridine; RT-PCR, real time PCR; SCID, Severe combined immunodeficiency; T2DM, 














• Female SCID mice
• Pancreatic cancer 
xenografted tumor




let-7⇑, miR-26a⇑, and 





• Male nude mice
• Colorectal cancer 
xenografted tumor










CDK6 and CyclinE1) 
miR-27a⇓ (FBXW7) Toden et al.
179
Curcumin
• LPS-induced mice 
sepsis model
• Liver and kidney
• 20mg/kg curcumin 
• 3-day pretreatment 
before LPS injection 
• oral gavage
• RT-PCR miR-155⇓ Tili et al.181
Curcumin • Male rats• Kidney
• 15, 30 and 60 mg/kg
• 6 weeks
• oral gavage
• RT-PCR miR-206⇑ (PTP1B) Ding et al.182
Resveratrol
Resveratrol
• Male SCID mice
• Prostate cancer 
xenografted
• 20 mg/kg
• every other day for 5 
weeks




miR-21⇓ (PDCD4) Sheth et al.186
Pterostilbene
• Male mice
• Prostate cancer 
xenografted tumor
• 50 mg/kg/d





miR-17⇓, miR-20a⇓ and 






















• RT-PCR miR-221⇓ (TFG) Wu et al.189
Grape extract with 
resveratrol 




• 8 mg/d/first 6 month 



























EGCG • NNK treated mice• Lung






dysregulation, miR-210⇑ Zhou et al.192
Quercetin • 264 lung cancer cases• Lung FFPE samples






let-7 family⇑, miR-17 
family⇓, miR-26⇑, and 
miR-146⇑ Lam et al.
194
Pomegranate juice
• AOM-treated male 
rats
• Colon
• pomegranate juice 




• RT-PCR miR-126⇑ (VCAM-1) Banerjee et al.197
Cruciferous vegetable
PEITC and I3C • ECS-treated male rats• Lung
• 500 mg/kg diet 






let-7 family⇑, miR-30 
family⇑, miR-34 
family⇓ and miR-99b⇑ Izzotti et al.
202
I3C • VC-treated mice• Lung

















• I3C at 25 mg/kg, 






221⇓ and miR-222⇓ Wang et al.204
Macronutrient and whole food
Fish oil 
• AOM-treated male 
rats
• Colon
• 11.5 g fish oil/100g






and miR-324- 5p⇑ Davidson et al.
205
Fish oil and pectin
• AOM-treated male 
rats
• Colon
• 11.5 g fish oil/100g •
6 mg pectin/100g




miR-26b⇑ (PDE4B) and 
miR-203⇑ (TCF4) Shah et al.206
Spinach • PhIP-treated male rats• Colon 
• 10% wt/wt freeze-





















34c⇓ Jeyabalan et al.210
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CHAPTER III  
MULTI-OMIC APPROACHES FOR TARGET IDENTIFICATION AND NOVEL 
INTERVENTION FOR COLORECTAL CANCER   
 
Overview 
The burden of colorectal cancer (CRC) demands better understanding of the 
disease etiology and improved intervention strategies. Environmental exposures, genetics, 
and diet/life style factors all contribute to CRC risk. Diet/lifestyle style factors influence 
several areas, including the gut microbiome. There is increasing appreciation of the 
complex interactions that exist between diet, microbiota, bile acids, and host epithelial 
cells in the gut.  Recent advances in sequencing and mass spectrometry-based technologies 
have rapidly expanded the availability of large biological datasets and an appreciation for 
various ‘omics’ approaches, including genomics, epigenomics, transcriptomics, 
proteomics, metabolomics, and microbiomics. Multi-omic approaches hold the promise 
of uncovering exciting and important new scientific directions, from dynamic multivariate 
analyses of large biological datasets, sometimes called ‘Big Data’, integrated with 
established molecular pathways and networks.  This has been characterized as the era of 
hypothesis-generating research, rather than hypothesis-testing, and the ‘one gene/one 
drug’ philosophy applied historically to cancer treatment. We review multi-omic advances 
associated with CRC etiology, focusing on diet/host/microbiome interactions in the gut. 
We highlight challenges in the field linked to emerging interventions for CRC. Lastly, we 




Colorectal cancer (CRC) is the third leading lethal cancer in the US234.  Over many 
years, the accumulation of deregulated genetic and epigenetic factors provides a driver for 
the progressive transformation from normal colonic epithelium to invasive cancer20,235. 
Although ~30% of CRC cases are familial and genetically related, the majority (~70%) 
are described as sporadic.  The latter cases have been linked to environmental exposures, 
including nutritional status and dietary intake patters61,131,236–239, along with physical 
activity240–242.  There growing appreciation for the importance of environmental exposures 
interfacing with microorganisms living in the human gut243–247. The human-gut 
microbiome field has been aided by advances in various key technologies248.  Gut 
dysbiosis is implicated in CRC, colitis-associated cancer, inflammatory bowel disease 
(IBD), and other intestinal disorders/syndromes249–252 253,254. 
The molecular landscapes of CRC have evolved enormously in the past decade 
with improved understanding of the basic mechanisms and clinical applications, yet this 
remains a complex disease requiring new advances on multiple fronts. The refined 
“Hallmarks of Cancer” by Hanahan and Weinberg in 2011255 added two categories, 
‘Energy re-programming’ and ‘Evasion from immunity’, and advanced newer concepts 
related to genomic instability and tumor-promoting inflammation. The recognition of 
signaling networks/circuits and tumor microenvironment further highlight the intrinsic, 
diverse interplay of factors in the neoplastic setting.  Advances in CRC and other human 
malignancies support the important hallmark of  Epigenetics71,256,257, including noncoding 
RNAs, such as microRNAs258 and LncRNAs259. All of these hallmarks interface with the 
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emerging fields of host-microbiota interactions and infectious pathogenesis, emphasizing 
the complex nature of CRC tied to extrinsic factors260.  
Omic technologies hold the promise of identifying critical regulatory molecules in 
biological samples261.  These approaches have prompted a rapid growth of ‘Big Data’ 
investigations in (epi)genomics, transcriptomics, proteomics, and metabolomics for 
various diseases262–264.   Here, we discuss the advances made in understanding CRC, 
linked to single ‘omic’ determinations.  We propose that integrated multi-omic approaches 
are needed to advance the field towards improved intervention and therapeutic strategies 
for CRC, while acknowledging that this is by no means a trivial pursuit. 
 
Advancements in technologies 
DNA sequencing. The fields of genomics and transcriptomics strongly support inherited 
aspects of biological information, regulatory machinery, and functional activities within 
the cell.  Microarrays were used frequently to detect transcripts by hybridization265,266 
before the advancement of DNA sequencing technologies. The sequencing field evolved 
over three generations during the past 40 years267. First-generation sequencing refers to 
Maxam-Gilbert sequencing (chemical sequencing)268 and Sanger chain-termination 
sequencing269 in gel-based systems. The primer guided DNA polymerase reaction of 
Sanger sequencing circumvented several complex methodological steps and extensive 
radiolabeling. Improvements, including the polymerase chain reaction (PCR), 
recombinant DNA technologies, and capillary array electrophoresis, led to automated 
DNA sequencing. By combining sheared DNA segments, cloning into vectors, Sanger 
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sequencing, and assembly of overlapping sequence reads results, de novo ‘shotgun’ 
sequencing generated the first human genome ‘draft’ copy, accomplished by the Human 
Genome Project270,271.  
       The next (second) generation sequencing (NGS) also has been referred to as 
‘massively parallel’ sequencing. Breakthroughs on increasing speed and throughput 
capacity crucially reduced sequencing cost. The principle involved converting the entire 
genome into small fragments and generating DNA reads from annealed adaptors via real 
time image acquisition. Common methods include pyrosequencing (Roche 454), sequence 
by ligation (ABI SOLiD), or sequencing by synthesis (illumine Solexa)272,273. NGS 
generates 50-500 base reads, which are much shorter than traditional Sanger sequencing, 
ranging from 700-1200 bases.  However, in principle, mapped reads from high throughput 
sequencing can provide coverage across the whole genome.  
       Third-generation sequencing involves single molecule sequencing274 by nanopore 
technologies275 to reduce the bias and error from DNA amplification, and to achieve long 
reads within a short time276.  Notably, NGS technology has grown exponentially since 
2010, providing a cost-efficient solution for diverse molecular profiling applications277. 
Applications range from genome (whole genome, exome, or targeted regions), 
transcriptome (mRNA, small and long non-coding RNAs), and epigenome (chromatin 
topology, histone and chromatin modification, transcriptome machinery, and DNA 
modification)278. The sequencing technologies also enable determination of 
microorganisms in particular environments279–281, such as soil, water, or human body sites. 
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The human microbiome is an emerging field based on sequencing technology, used to 
investigate the colonized bacteria influencing human health and disease282.  
 
Analytical mass spectrometry. Mass spectrometry (MS) evolved to understand the mass 
of particles, and has been adopted to study a wide range of molecules in the life sciences283. 
In contrast to DNA sequencing as an alignment-based data assembly, MS-based 
proteomics and metabolomics approaches are often exploratory, due to their complex 
nature and insufficient characterization of biological molecules for comparative and 
database searching. As pioneers of MS-based metabolite detection, Horning developed 
gas chromatography (GC)-MS to examine steroids, drugs, and drug metabolites in human 
urine samples284, whereas Pauling et al. used GC-MS to profile about 250 substances in 
breath and urine vapor285. The successful measurements of human metabolites in the 
1970s to 1980s led to further development of several analytical techniques to achieve high-
resolution/sensitivity, to advance metabolic profiling of human diseases. Many MS and 
nuclear magnetic resonance (NMR)286 configurations seek to achieve low sample 
requirement and high sensitivity, and have been used for both qualitative and quantitative 
studies to discover changes in proteomics287,288 and metabolomics289,290. In general, the 
procedure is initiated from ionization of an individual sample, or series of samples, 
followed by separation techniques such as liquid (LC) or gas chromatography (GC), 
capillary electrophoresis (CE), and ion mobility spectrometry (IMS)291. The chemical 
species then can be sorted according to their mass to charge ratio by various mass selection 
methods, which include time-of-flight (TOF), quadrupole mass filter, ion traps, and 
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Fourier transform ion cyclotron resonance. A scanning instrument produces the mass 
spectrum from the obtained signals for further interpretation, and the final detector records 
the charge or current from the passing ion, or ion hits on a surface with an electron 
multiplier. Coupling MS instruments can increase the sensitivity of detection through 
product-ion scan, precursor-ion scan, neutral-loss scan, and selected reaction 
monitoring292. For proteomics, samples are usually applied with prior gel-based separation 
and enzyme digestion before MS analysis. Analytically, proteins are considered gene 
products consisting of a combination of defined amino acids. Although there is basic 
knowledge accrued of protein composition, interpretation of proteomics remains 
complicated, due to functional aspects such as conformation, interaction, activity, 
subcellular location, and post-translational modifications293,294. Unlike proteins, 
metabolites are not linked directly to genomic information, and are highly dynamic, 
relying on enzymatic reactions for formation, flux and degradation. Metabolomics can be 
briefly divided into targeted and untargeted approaches, emphasizing specific metabolites 
with closely related biochemical properties, such as lipidomics, or global profiling of 
samples295. Modern MS approaches combine imaging technologies and direct ionization 
methods, leading to spatial distribution of targeted metabolites in tissues296,297.  
 
From genetics to omics 
Classification of CRC typically involves genetic and epigenetic aspects, including 
genomic instability and DNA methylation29,298. Mutations of DNA mismatch repair 
machinery results in microsatellite instability (MSI) phenotype with hypermutations. 
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Chromosomal instability (CIN) refers to chromosomal mutation and rearrangement 
leading to activation of oncogenes and inactivation of tumor suppressors. Epigenetic gene 
silencing by DNA hypermethylation is described as CpG island methylator phenotype 
(CIMP)29,298–301.  Coupled to sequencing technology advancement, several milestones 
have been made in the cancer arena that led to the evolution of omic concepts.   
In 2006, Sjöblom et al. used more than 250,000 PCR primers to assess exomes via 
Sanger sequencing30,31. The study validated hundreds of somatic mutations associated 
with cellular adhesion/motility, signal transduction, and transcriptional regulation in 
breast and CRC patients. Beginning in 2008, the cost for whole genome sequencing had 
declined due to advances in NGS, and again in 2012302. In 2012, The Cancer Genome 
Atlas (TCGA) Network reported a subset of whole genome sequencing results, confirming 
known genetic and epigenetic abnormalities, and identifying novel chromosomal 
alternations, gene mutations, and gene silencing after comprehensive characterization of 
genome, epigenome and transcriptome read-outs in CRC33.  After multiple efforts toward 
unified colorectal classification, Guinney et al. consolidated four consensus molecular 
subtypes (CMS1-4)m from 17 gene expression microarray and TCGA RNA sequencing 
datasets37. In 2013, the first epidemiologic study identified decreased microbial 
community diversity and Clostridia, and increased Fusobacterium and Porphyromonas by 
16S rRNA sequencing in human CRC cases compared to health subjects303. 
In parallel, MS-based measurements contributed towards enhanced understanding 
of the proteome and metabolome. In 2009, Chan et al. applied NMR and GC/MS to paried 
normal and tumor samples from CRC patients. The results indicated an increase of 
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hypoxia, glycolysis, lipid metabolism, and immune response in tumors, and the potential 
of using metabolites as biomakers for disease mangement and prognosis304. Around the 
same time, Hirayama et al. utilized CE-TOF to profile metabolome of colon and gastric 
cancer, and uncovered the dysregulation of glycolysis, glutaminolysis, aerobic repiration, 
and nucleotide metabolism305. Two years after the original TCGA study of CRC, the 
Clinical Proteomic Tumour Analysis Consortium performed LC-MS/MS based proteomic 
analysis in CRC specimens. The restuls identified more than a hundred novel amino acid 
variants, and indicated poor protein prediction from mRNA34.  In 2016, a comprehensive 
metabolome was generated for CRC, adjacent normal tissue, and stool using untargeted 
GC-MS/MS and ultra-performance (UP)-LC-MS/MS306.  The results indicated that short 
chain fatty acid metabolism was the most critical dysregulated metabolic pathway, and 
stool metabolome differed from patient tissue samples. Thus, molecular profiling of CRC 
has progressed tredmendously over the last decade.  
Omics provides opportunities to identify new leads based on robust and high 
throughput information, as well as expanding knowledge beyond a central dogma to seek 






Figure III-1 Diet/host/microbe interactions coupled to -omics 
The overview figure presents targets of detection, omic applications, and sample origins 
of colonic compartments. Multi-omic approaches can encompass multiple molecular 





Methods and tools for multivariate and network analysis 
Several key databases and resources are available to facilitate biomedical 
research308,309 (Table III-1). Genome related resources include Ensembl, NCBI (The 
National Center for Biotechnology Information), ENCODE (Encyclopedia of DNA 



























































































































Genomes). Omic database repositories include GEO (Gene expression Ominibus) and 
TCGA. Pathway analysis tools include DAVID (The Database for Annotation, 
Visualization and Integrated Discovery), GO (Gene Ontology Consortium), MSigDB 
(Molecular signature database), and Reactome.  For microbiome and metabolome research 
there are HMP (NIH Human Microbiome Project), HMDB (The Human Metabolome 
Database), PubChem, FooDB (The Food Database), METLIN, ChemSpider, 
WEIZMASS310, and KEGG Compound, plus PeptideAtlas and PRIDE (PRoteomics ID 
Entifications) Archive for proteome work. For global analysis and data visualization, 
resources are available through Bioconductor, Github or Galaxy, and others can be 
accessed by web-based or software-based platforms such as Metaboanalyst, XCMS, IPA, 
MetaCore, IMPALA (Integrated Molecular Pathway Level Analysis), and Cytoscape.  
With increasing high throughput data from omics, bioinformatic tools and systems 
biology are in great demand for data processing, interpretation, and integration. Ge et al. 
pointed out in 2003 the need of systems biology for moving from ‘molecule biology’ to 
‘modular biology’, that combines co-expression, localization, and phenotypic patterns of 
protein functional network311. Joyce and Palsson summed omics integration techniques 
into identifying scaffold, scaffold decomposition, and cellular modeling and analysis, 
involving multiple algorithms and databases in model organisms312. Buescher and 
Driggers reiterated the challenges in omics integration. They included technical and 
statistical caveat of each -omics, biological relationships across multiple -omics, and the 
dynamics in time or conditions313. Overcoming those difficulties would expand our 
knowledge by either co-analyzing or merged analysis of the integrated multi-omics. 
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Learning from bacteria or model organisms such as C. elegans and yeast may provide 
insights to resolve relationships of multi-omic layers311–313. Yugi et al. later proposed five 
trans-omics technologies and three network concepts to pursue trans-omic network 
reconstruction, which could be helpful for multifactorial diseases314. Data heterogeneity, 
pitfalls of the individual analytical tools, and lack of systematic bioinformatics, will need 
further improvements to better dissect biology via multi-omic integration. Towards this 
end, integrating multi-omic experimental data remains challenging.  
 
Multi-omic integration for CRC 
 Using matched colonic tissues to study epigenetic alterations leading to gene 
expression dysregulation revealed molecular subtypes and underlying regulatory networks 
in CRC. Tang et al. identified 72 miRNA-mRNA pairs in CRC tissues compared to 
matched adjacent normal315. Bioinformatic analysis uncovered miRNA-mRNA regulation 
of Wnt signaling, and confirmed the association of Klf4 downregulation and miR-29a 
upregulation. Vishnubalaji316 et al. used microarrays for detecting mRNA and miRNA to 
confirm dysregulation of the Wnt pathway, and identified epigenetic regulators, miR-26a 
and let-7, associated with upregulation of EZH2, an important enzymatic chromatin 
component. Inhibition of EZH2 by pharmacological chemicals and siRNA, or ectopically 
overexpressed pre-miRNA regulators, led to changes in viability of colorectal cell line, 
suggesting anti-cancer roles of miRNA-mRNA regulations on chromatin.  
            Public resources also provide valuable and robust analysis pipelines. Although 
data heterogeneity and subtype heterogeneity were observed, Cantini et al. employed 
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stepwise microRNA master regulator analysis to identify miRNA drivers in TCGA data. 
The analysis found that downregulation of miR-194, miR-200b, miR-203, and miR-429 
was associated with poor prognosis in stem/serrated/mesenchymal subtype, along with 
dysregulation of TNFa signaling through NF-kB, inflammatory response, and 
extracellular matrix remodeling pathway in CRC317.  
 Tumor heterogeneity and tumor microenvironment are associated with disease 
progression and the resistance to therapies318,319. Laser-capture microdissection, flow 
cytometry-assisted cell sorting techniques, and microfluidic systems are increasingly used 
for subpopulation analysis320–322. Human colorectal intratumor heterogeneity was 
elucidated by single-cell transcriptomics, enabling the separation of epithelial, endothelial, 
fibroblast, T cell, Mast cell , B cell and other myeloid cells with their cell type specific 
gene dysregulation323. Compared to bulk transcriptome, the study identified EMT related 
genes that were upregulated specifically in cancer-associated fibroblast (CAFs) subtype, 
and provided better stratification of prognosis, indicating the critical role of CAFs in CRC. 
To further increase omic resolution and investigate the nature of mutational 
diversification, Roerink et al. utilized clonal organoids derived from patient normal and 
neoplastic colorectal epithelial cells324. The study involved whole genome sequencing, 
RNA-seq, methylation chip array, and identified high somatic mutation rates, and 
correlated DNA methylation and gene expression to drugs on CRC primary organoids.  
 Metabolic reprogramming is an evolving but poorly understood hallmark of 
cancer255. Satoh et al. assessed both transcriptome and metabolome data of human CRC 
across different stages, and found early global metabolic reprogramming in adenoma 
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stages, which was independent from mutation status but was associated with c-Myc 
expression325. The investigation discovered the roles of MYC-dependent metabolic gene 
expression, and metabolites associated with purine and pyrimidine metabolism, with 
further validation by rodent and cell-based assays.  
 IBD are considered possible precursors of CRC, and inflammation has been 
implicated in CRC progression and survival326–330. Haberman et al.331 characterized 
transcriptome and microbiome in pediatric Crohn’s disease patients and identified 
increased dual oxidase (DUOX2) correlated with an expansion of Proteobacteria and 
decreased APOA1 in association with Firmicutes, which led to severe mucosal immune 
response by Th1 polarization331. Morgan et al. sought to identify host-microbe interactions 
by transcriptome and microbiome in pouchitis from IBD and familial adenomatous 
polyposis (FAP) patients332. With co-variants in biopsy location, inflammation score, and 
antibiotic use, the interaction between host and microbiome was unexpectedly modest. 
Enriched pathways in Complement cascade and IL-12 pathway were inversely correlated 
to Sutterella, Akkermansia, Bifidobacterial, and Rosebura abundance suggesting host 
transcriptome was not the major regulatory component.  
When using 100 inbred mice strains to assess host genetic and microbe factors in 
response to high-fat, high-sucrose diet, Parks et al. revealed a stain-specific single 
nucleotide polymorphisms (SNPs) effect on genetically determined obesity, regardless of 
diet, and demonstrated a robust microbiome shift by diet with host strain-specific 
plasticity333. To investigate the influence of high-protein diet on gut health, Mu et al. 
employed microbial and host colonic gene expression analyses in rats, and suggested an 
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increased risk of colonic disease by dietary intervention334. The high-protein diet shifted 
microbiome leading to dysbiosis, reduced butyrate levels, and downregulation of genes 
related to oxidative phosphorylation, O-linked glycosylation of mucins, and innate 
immune response.  
It remains open to explore structure and microbial gene expression of microbiota 
in the gut335,336 and how diet can play a part shaping the gut microbiota337,338. David et al. 
showed a replicable short-term microbiome alteration by animal- and plant-based diets in 
human subjects245. The animal-based diet increased bile acids, the expressions of bile salt 
hydrolases and sulphite reductases, and the abundance of Alistipes, Bilophila and 
Bacteroides linking to IBD-prone microbiota. It was reported that the luminal contents 
and mucus layer had distinguishable microbial community339. Mono-colonized bacteria 
also had different transcriptional profiles from the content and mucus, and the defined 
microbiota showed differences in functional metabolism and proliferative adaptation, 
suggesting a specified spatial and functional role of certain bacteria in the host gut.  
To address the diet effect on human microbiome, Desai et al. colonized a 
gnotobiotic mouse model with human microbiome and supplemented fiber-rich, Fiber-
free and prebiotic diets. With 16S-seq profiling of the bacteria community and microbial 
RNA-seq, the results indicated fiber-depleted microbiome promoted mucus-degrading 
bacteria growth, and induced carbohydrate active enzymes to degrade mucus 
polysaccharide. A lack of complex fiber led to reduced barrier function resulting in 
susceptibility to pathogen infection and severe colitis340. To understand the impact of diet 
and obesity on CRC risk, a diet-induced obesity mouse model with transcriptome and 
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methylome analysis was conducted. Li et al.341 identified diet-induced obesity caused 
reprogramming of DNA methylation leading to metabolic gene dysregulation in fatty acid 
metabolism at young age and cancer-prone gene signature.  
 Gut microbiota can co-metabolize with host mammalian cells342–344. Weir et al. 
utilized a case-control study to employ microbiome and metabolome profiling of stool 
samples345. There was no significant difference in bacterial community but reduced 
butyrate-producing species and increased mucin-degrading species were observed. Higher 
levels of acetate, unsaturated fatty acids, amino acids and a conjugated-bile acid were 
detected in stools from CRC patients. The correlation analysis also identified strong 
correlations between certain microbes and metabolites such as glutamine, cholesterol 
derivatives, serine, linoleic acid, and oleic acid.  
Other studies engaged mutli-omics approaches to dissect the interactions in the 
complex gut ecosystem. Aidy et al. used a conventionalization of germfree mouse to 
elucidate the host-microbe dynamics in a time series multi-omic analyses346. The results 
indicated a rapid microbiota adaptation after day 4, reduced succinate and lactate, 
increased acetate, propionate and butyrate throughout the course, induction of genes 
related to glycolysis, amino acid and nucleotide pathways in late time points, and 
increased urine creatinine and formate in early time points. The multi-omic correlation 
models also suggested fructose and mannose metabolism and folate biosynthesis 
connecting the interaction among microbes-host transcript-tissue metabolites.  
To determine the impacts of host genetics and diet on gut microbiome and 
metabolome, stool samples from 30 strains of mouse were investigated by 16S sequencing 
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and GC-MS with integrated SNPs information347. The study demonstrated early 
environmental exposure and host genetic variants as contributing to microbiome structure, 
related to human disease and dietary impacts. The study also suggested that non-dietary 
metabolites were more closely regulated by microbial metabolism. A mono-colonization 
of E. coli commensal strain was indicated to affect lipid metabolism through bile acids 
and inflammation via a genome-scale metabolic model involving 696 differentially altered 
mRNAs, 400 reactions and 704 metabolites348.  
Out microbiome also participates in epigenetic regulation of host gene 
expression349,350. Richards et al. treated primary human colonocytes with suspended 
human microbes and utilized RNA-seq, Assay for transposase-accessible chromatin 
sequencing (ATAC-seq), and 16S rRNA-seq to address the interaction between 
mammalian cells and microbes351. Microbiome taxa was associated with mammalian 
genes related to hemidesmosome and membrane targeting, and acute exposure to microbes 
altered the mammalian chromatin accessibility leading to changes in gene expression. Qin 
et al. 352 showed the microbiota changes prior to host phenotype in a sex-dependent manner 
by high fat diet. The diet intervention led to alterations in transcriptome and the occupancy 
of genome enhancer regions. Manipulating microbiome by fecal transplantation 
recapitulated the dietary impacts, suggesting gut microbiome is a key mediator of dietary 
reprogramming of host epigenomes leading to phenotypic consequences.  





Emerging interventions for CRC 
Preventive interventions for CRC can be generalized into primary prevention 
(reducing or eliminating risk factors), secondary (screening, early diagnosis, and 
treatment), and tertiary (disease management and improving survival)353–355. Lifestyle 
modification and medication for primary prevention can have benefits46,356. Nonsteroidal 
anti-inflammatory drugs (NSAIDs), such as aspirin, reduce the recurrence of human 
colorectal adenomas357,358 through modulating prostaglandin synthesis, Wnt pathway 
inhibition, and host immune responses359. However, long-term adverse event management 
and patient stratification are necessary.  A multi-target stool deoxyribonucleic Acid (MT-
sDNA, Cologuard™) screening test for CRC was developed by the  Mayo Clinic and 
Exact Sciences (Madison, WI)360 and was adopted by several national preventive and 
cancer communities361. The test detects quantitative KRAS mutations, aberrant NDRG4 
and BMP3 methylation, and hemoglobin with a weighted algorithm calculation. Although 
the benefits of MT-sDNA must be evaluated in the future, this work establishes that 
improved molecule profiling will likely add value to clinical biomarker discovery. 
With increasing assessments of host-diet-microbiota interactions, several 
intervention methods targeting gut microbial community were proposed. Probiotics and 
prebiotics are implicated for CRC prevention through modulating immune 
responses362,363. While probiotic means the live microorganism providing health benefits 
on the host, prebiotic is an ingredient allowing changes in gut microflora composition364. 
Through inducing the production of short chain fatty acids by food grade dairy 
Propionibacteria, Cousin et al. demonstrated a synergistic pro-apoptotic cytotoxicity with 
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co-treatment of TNF-related apoptosis-inducing ligand in human colon cell line365. A 
probiotic strain Lactobacillus casei BL23 was used against inflammation induced CRC in 
mouse model, and a Th17 response was identified as the mechenism366. Additionally, a 
mixture of oligofructose-maltodextrin-enriched bacteria strains were treated to an 
inflammation-induced rat model. Improved barrier function and reduced inflammation via 
TLR2 signaling were suggested as contributing to decreased tumor outcomes367. Beyond 
probiotics and prebiotics, fecal microbiota transplantation (FMT) has shown efficacy on 
C. difficile infection368–370 and may have beneficial potential towards IBD371,372 as well as 
CRC373,374. On the other hand, engineered non-pathogenic bacteria also has been proposed 
for bacteria-directed enzyme prodrug therapy375–377. Several bacteria showed selective 
tumor localization and proliferation in tumors after oral administration, supporting the 
delivery potential378–380. Hsieh et al. utilized engineered E. coli to produce b-glucuronidase 
to enhance the anticancer activity of a camptothecin analog by facilitating conversion to 
the therapeutic SN-38, a topoisomerase poison381. Murphy et al. demonstrated TNFa 
expressing E. coli produce therapeutic molecules inside tumors, and reduce tumor 
growth382.  Similarly, Zheng et al. reported a cancer immunotherapy using nonvirulent and 
flagellin secreting Salmonella to trigger immune response via TLR4 signaling and M1 
macrophage phenotype activation383. More recently, an engineered E. coli carrying 
myrosinase activity mixed with cruciferous vegetable showed anti-cancer activity by 





Conclusion and perspectives 
The colon is a major organ in contact with dietary exposures, and harbors up to 
1012 cfu/ml bacteria, leading to a complicated gut ecosystem385. Given that CRC is a 
complex disease involving gene-environment interactions68,386, comprehensive 
mechanistic insights are needed to develop improved prevention and treatment strategies. 
After the consensus molecular subtype described by transcriptome in 201537, several 
studies contributed to expand the molecular understanding in immune subtype and 
heterogeneity. With molecular profiling we are moving towards precision medicine. 
However, shifting the ‘one gene, one drug’ paradigm to ‘multi-genes, multi-drugs’ may 
offer novel perspectives and new strategies against multiple aberrant targets387. Dietary 
intervention could offer ‘multi-gene, multi-target’ potential208,209,233. Additionally, the 
recent literature reveals the capabilities of gut microbiota-mediated dietary benefits, drug 
activity and metabolism, towards host physiological modulation388–390. Together, diet-
microbe intervention could provide a novel angle for CRC intervention.  
From the literature reviewed, we noted that the majority of studies failed to 
integrate adequately multi-omic datasets, indicating a need for improved statistical 
methods, modeling, integration, and visualization313. Most omics involves constant de 
novo construction of the reference information, comparative analysis to separate signal 
and noise, and alignment/match to a database. Therefore, technologies and 
comprehensive, representative databases require constant advancements for better data 
interpretation307. As more high-throughput data from different technologies and tissue 
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sources are generated, improvements from sampling to measurements remain challenging 
and need to be further standardized.  
Multi-omic approaches in CRC can provide novel mechanistic leads and indicate 
the substantial role of diet-microbe on host physiology and pathology391–393. This review 
highlights the increasing use of multi-omic analyses in CRC research, with an urgent need 
for enhanced integration, as well as development of novel interventions based on advanced 
technologies and multi-omic approaches. Understanding the interplay among diet-
microbe-host with systematic interpretation will provide important future directions for 




Table III-1 Commonly used database and resources for genome, transcriptome, 


































Table III-2 Relevant multi-omic studies related to colorectal cancer. 
Abbreviations:  
CRC, human colorectal cancer; T/N, matched tumor and adjacent normal tissues from patients; UC, ulcerative colitis, FAP, 
familial adenomatous polyposis;  WGS, whole genome sequencing; WGBS, whole-genome bisulfite sequencing; CE-TOF/MS, 
capillary electrophoresis time of flight mass spectrometer; MaAsLin, multivariate analysis with linear modeling; LDA, linear 
discriminant analysis; EMMA, efficient mixed model association; REML, restricted maximum likelihood; GF, germ-free; Conv, 
conventional; NIST, National Institute for Technology Standards; GEM, Genome-scale Metabolic model. 
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Pearson correlation Tang et al.1
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Table III-2 Continued 
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RNA microarray 16S 
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CHAPTER IV  
A MIRNA SIGNATURE FOR AN ENVIRONMENTAL HETEROCYCLIC AMINE 
DEFINED BY A MULTI-ORGAN CARCINOGENESITY BIOASSAY IN THE RAT1   
 
Overview 
Heterocyclic amines (HCAs) produced during high-temperature cooking have 
been studied extensively in terms of their genotoxic/genetic effects, but recent work has 
implicated epigenetic mechanisms involving non-coding RNAs. Colon tumors induced in 
the rat by 2-amino-1- methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) have altered 
microRNA (miRNA) signatures linked to dysregulated pluripotency factors, such as c-
Myc and Krüppel-like factor 4 (KLF4). We tested the hypothesis that dysregulated 
miRNAs from PhIP-induced colon tumors would provide a “PhIP signature” for use in 
other target organs obtained from a 1-year carcinogenicity bioassay in the rat. Downstream 
targets that were corroborated in the rat were then investigated in human cancer datasets. 
The results confirmed that multiple let-7 family members were downregulated in PhIP-
induced skin, colon, lung, small intestine, and Zymbal’s gland tumors, and were associated 
with c-myc and Hmga2 upregulation. PhIP signature miRNAs with the profile miR-21high/ 
miR-126low/miR-29clow/miR-215low/miR-145low were linked to reduced Klf4 levels in rat 
tumors, and in human pan-cancer and colorectal cancer. It remains to be determined 
                                               
1 Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer Nature Archives 
of Toxicology (A miRNA signature for an environmental heterocyclic amine defined by a multi-organ 
carcinogenicity bioassay in the rat, Ying-Shiuan Chen, Rong Wang, Wan-Mohaiza Dashwood et al.), 
Springer Nature Archives of Toxicology (2017) 
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whether this PhIP signature has predictive value, given that more than 20 different 
genotoxic HCAs are present in the human diet, plus other agents that likely induce or 
repress many of the same miRNAs. Future studies should define more precisely the 
miRNA signatures of other HCAs, and their possible value for human risk assessment. 
 
Introduction 
Epidemiological evidence has linked the consumption of cooked and processed 
meat to increased risk for cardiovascular diseases394, and for malignancies of the digestive 
system395, breast396, and prostate397. Heterocyclic amines (HCAs) found in high-
temperature cooked meat can undergo metabolic activation to form bulky DNA adducts 
that are precursors to mutagenesis and carcinogenesis in various organs of the body 398–
400. For this reason, HCAs have been investigated historically in terms of their genetic 
aspects linked to genotoxicity and tumor initiation in target tissues401,402.  
One of the most abundant HCAs found in cooked protein-rich foods is 2-amino-1-
methyl-6- phenylimidazo[4,5-b]pyridine(PhIP)403–405. Metabolic intermediates of PhIP 
have been detected in various tissues, including serum, urine, and hair samples406–409, 
indicating wide systemic distribution in the human body. The US National Toxicology 
Program (NTP) classified PhIP as “reasonably anticipated to be a human carcinogen” 
(NTP 12th Report on Carcinogens)410, and the International Agency for Research on 
Cancer categorized PhIP as a Group 2B carcinogen (IARC 1993)411.  
In preclinical models, PhIP serves as a multi-organ carcinogen412–414, and can 
affect newborns through trans-placenta and neonatal exposure415. In PhIP-induced colon 
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tumors, genetic changes in Ctnnb1 constitutively activate β-catenin and β-catenin/T-cell 
factor (Tcf) signaling, dysregulating the β-catenin/c-Myc/E2F1/Bcl-2 axis and 
downstream apoptosis pathways416–418. In rat colon and prostate carcinogenesis models, 
PhIP exposure has been linked to chronic inflammation via changes in molecular 
endpoints such as NADPH oxidase, nuclear factor kappa-B (NFκB)419, 
cyclooxygenases420, and glutathione S-transferases421. PhIP-induced mammary 
carcinogenesis models identified changes in the expression of transcription factors, 
cyclins, annexins, matrix metalloproteinases, and extracellular signal regulated (ERK) 
kinases422.  
In addition to the genetic aspect mentioned above, research with PhIP and other 
HCAs has moved into the epigenetic realm. Non-coding RNAs have gained increasing 
attention for their roles in epigenetic regulation, and as signatures of environmental 
exposure 423–427. For example, in human-derived prostaspheres, bisphenol A silenced small 
nucleolar RNAs with C/D motif (SNORDs) through histone modifications428. Industrial 
exposure to metal-rich particulate matter altered microRNAs (miRNAs) linked to 
oxidative stress and inflammatory responses in blood429. It is well established that 
miRNAs are conserved, negative regulatory small RNAs comprising 21–23 nucleotides, 
which act via mRNA cleavage or translational inhibition to influence phenotypic 
outcomes such as cell proliferation, differentiation, autophagy, and apoptosis81,430.  
Dysregulation of miRNAs has been linked to various pathologies, including 
cancer, neurodegeneration, obesity, and chronic inflammation431. Consequently, altered 
miRNA signatures are regarded as possible biomarkers for disease diagnosis and 
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prognosis, due to their relative stability and accessibility in various tissues and biofluids127. 
For instance, miR-21 regulates phosphatase and tensin homolog (PTEN) and programmed 
cell death 4 (PDCD4) in tumors, leading to enhanced cell proliferation and stemness 
maintenance. In blood, miR-21 is viewed as a diagnostic and prognostic biomarker, 
whereas miR-141, a regulator of epithelial-to-mesenchymal transition, is a proposed 
circulating biomarker of late stage colorectal cancer432. Circulating and tissue miRNAs 
also respond to environmental exposures, such as air pollution433 and toxic chemicals129.  
In cultured human breast cancer cells, PhIP treatment was reported to alter 
miRNAs regulating the response to xeno-estrogen exposure434. In PhIP-induced rat colon 
tumors, dysregulated miRNAs were linked to the altered expression of cMyc and other 
pluripotency factors, such as Sox2, Nanog, Oct-3/4, and Krüppel-like factor 4 (KLF4)435. 
We were intrigued by the possibility that miRNAs altered in PhIP-induced rat colon 
tumors might serve as biomarkers of PhIP exposure in other target organs for 
tumorigenesis, and by extension, might represent a ‘HCA miRNA signature’ in the general 
population. The present investigation reports, for the first time, on miRNAs and their 
validated downstream targets that are dysregulated in PhIP-induced tumors of the colon, 
small intestine, skin, lung, spleen, and Zymbal’s gland, and correlates with the 
corresponding human datasets.  
 
Materials and methods 
Animal treatment. PhIP originally was defined as a prostate and colon carcinogen in 
male rats, and a mammary carcinogen in female rats, after continuous exposure in the diet 
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for a year413,436. Subsequently, a modified protocol was devised that reduced the overall 
carcinogen exposure markedly, starting with short-term administration of PhIP followed 
by a high-fat diet414,417,437. For the current investigation, PhIP was given by daily oral 
gavage (40 mg/kg body weight) for 2 weeks, alternating with a high fat diet for 4 weeks, 
and generated tumor incidence outcomes as follows: Zymbal’s gland 2%, liver 8%, spleen 
8%, lung 10%, small intestine 27%, skin 38%, and colon 58%156. The 1-year 
carcinogenicity bioassay involved male F344 rats, purchased at 3–4 weeks of age from the 
National Cancer Institute. At termination, each rat (n = 40) was euthanized by CO2 
inhalation, following a protocol that was approved by the Institutional Animal Care and 
Use Committee. After a thorough necropsy examination, tumor samples and other tissues 
were collected and flash-frozen before storage at −80 °C. Controls (n = 12 rat) that 
received vehicle by oral gavage for 2 weeks, alternating with a high-fat diet for 4 weeks, 
had no detectable tumors in any of the organs examined at the end of the study156. 
 
RNA extraction and profiling. The key methodologies were described in previous 
studies that defined the major miRNAs altered in PhIP-induced rat colon tumors156. In 
brief, vehicle controls, PhIP-induced tumors, and tumor-matched normal tissues from 
colon, small intestine, skin, Zymbal’s gland, spleen, and lung were homogenized on ice. 
Total RNA was extracted in Trizol reagent (Life Technologies), whereas, miRNA was 
extracted using the miRNeasy kit (Qiagen, Valencia, CA, USA). RNA quantity and purity 
were verified by Nanodrop ND-1000, from the absorbance at 260 and 280 nm (260/280 
ratio >1.9), as reported55,438,439. RNA (1 µg) from each rat tissue was reverse transcribed 
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using the Superscript III RT kit (Life Technologies) in 10- µl reaction buffer, and diluted 
10-fold before adding to a 10-µl reaction containing SYBR Green I Master mix (Roche 
Applied Science) and gene-specific primers. For miRNA analyses, 1-µg RNA from each 
rat tissue was reverse transcribed using the miScript II RT Kit (Qiagen) and diluted 
fivefold before adding to a 20-µl miScript Primer assay (Qiagen) containing primers 
specific for selected mature rat miRNAs. Real-time qPCR data were acquired on a Light-
Cycler 480 II (Roche Applied Science). Relative expression levels of miRNAs and 
mRNAs were calculated using U6B and Gapdh as internal references for normalization, 
respectively.  
 
Principal component analysis (PCA). PCA used the online tool MetaboAnalyst 3.0440, 
and clustering was performed using Pearson correlation and average linkage.  
 
Biological network analyses. MicroRNAs and their putative target mRNAs were 
examined via MetaCore pathway analysis (GeneGo Inc., St Joseph, MI, USA). For 
pathway enrichment analysis, p values were calculated using the formula for 
hypergeometric distribution, reflecting the probability for a pathway to arise by chance. 
Pathway maps were prioritized based on statistical significance, for tumors from animals 
given PhIP versus normal-looking tissue for each target organ. Interaction networks of 
miRNAs of interest were generated using Metacore (Thomson Reuters), as reported156. 




Surveying the cancer genome atlas (TCGA). Pan-cancer (PANCAN) miRNA (n = 
11,010) and gene-specific RNA-seq data (n = 9755) were downloaded on 8 April 2016 
from the UCSC Cancer Genomics Browser443. To be consistent with the rat preclinical 
model, only primary tumor and solid normal tissue data were analyzed, whereas 
metastatic, advanced metastatic, and recurrent cancers were not included. The miRNA 
database contained 364 primary colon adenocarcinomas and 8 solid normal colon tissues, 
plus 8402 primary tumors and 635 normal tissues from other origins. The gene expression 
database for colon and rectal cancers contained 380 primary tumors and 50 solid normal 
tissues, plus 8079 primary tumors and 626 solid normal tissues from other origins. A 
survival plot was generated by Graphpad6.07 (GraphPad Software Inc.) according to the 
relative expression level of miRNAs in PANCAN datasets for solid primary tumors. 
Proportion views of miRNA expression were captured from the Cancer Browser, and 
statistical analyses were performed using Student’s t test with Benjamin– Hochberg 
correction, designating significantly upregulated (red) or downregulated (green) targets.  
 
Statistical analyses. Unless indicated otherwise, results were presented as mean ± SEM 
with n = 3 per group. A paired two-tail Student’s t test was performed for tumor and tumor-
matched normal tissue. Unpaired two-tail Student’s t test was performed for TCGA data, 
comparing primary tumor and normal tissue. An asterisk in the figure designates 






Defining “PhIP signature” miRNAs in multiple target organs. The miRNAs most 
highly dysregulated in PhIP-induced colon tumors156 were examined in other target tissues 
of the rat, namely the small intestine, skin, spleen, lung, and Zymbal’s gland. Hierarchical 
clustering of miRNAs grouped the colon and small intestine as separate from the other 
tissues (Fig. IV-1A, upper blue panels). The miRNA pattern was similar for skin and 
Zymbal’s gland (Fig. IV-1A, bold red panels at center), and clustered spleen and lung 
separately, except for replicate Lung-PhIP-2 T (Fig. IV-1A, lower panels).  
Principal component analysis (PCA) was conducted on triplicate samples of each 
normal tissue, obtained from control rats that had received vehicle but no PhIP (Fig. IV-
1B). Colon and small intestine were clustered in one area, separate from spleen, and from 
skin, Zymbal’s gland and lung samples that were grouped together. When PCA was 
repeated for PhIP treated animals (Fig. IV-1C), analyzing both tumor and adjacent normal-
looking tissues, colon and small intestine continued to segregate from the other tissues 
examined. The results indicated that a panel comprising of miR-21, miR-126, miR-29c, 
miR-135, miR-215, plus eight members of the let-7 family could distinguish among the 






Figure IV-1 Target tissue miRNA profiling in the rat. 
A, Heatmap showing the relative expression level of miRNAs, with Pearson average 
clustering of “PhIP signature miRNAs” for the different subgroups indicated in the figure. 
For each tissue, n = 3 individual replicates, except for spleen and lung tumors, where n = 
2. T tumor; N normal-looking tissue adjacent to tumor. B, Principal component analysis 
(PCA) of miRNAs in normal tissues from control rats given vehicle but no PhIP. C, The 






The let-7 family is dysregulated in multiple target organs of PhIP tumorigenesis. The 
let-7 family is highly conserved across species and function444, and loss of let-7 expression 
























































transformation446. Using quantitative real-time RT-PCR, PhIP signature miRNAs that 
were examined in multiple target organs of the rat including let-7 family members let-7a, 
let-7b, let-7c, let-7d, let-7e, let-7f, let-7i, and miR-98. These miRNAs varied in expression 
among the various target tissues (Fig. IV-2A), with five members generally downregulated 
and two others marginally upregulated in PhIP-induced tumors (Fig. IV-2B).  
Targets of let-7 were validated in tissue samples from PhIP-treated animals. When 
all six target organs were assessed, collectively, both c-myc and Hmga2 mRNA levels, 
normalized to Gapdh, were increased significantly in PhIP-induced tumors compared with 
matched normal tissue (Fig. IV-2C, D, respectively). Notably, when peripheral blood 
mononuclear cells (PBMCs) were collected as negative controls from the same study, 
representing a site that did not develop tumors, no marked differences were detected 
between PhIP- and vehicle treated rats with respect to the relative expression levels of c-
myc, Hmga2, and the PhIP signature miRNAs (data not shown).  
In human colorectal cancers, and in “all other” cancers from the TCGA pan-cancer 
database, MYC and HMGA2 levels also were increased significantly compared with 
tissue-matched normal controls (Fig. IV-2E, F). The results are consistent with the tumor 
suppressor functions of let-7 family members, linked to upregulation of oncogenic targets 




Figure IV-2 Let-7 family is altered in multiple target organs of PhIP-induced 
tumorigenesis. 
A, Expression of let-7 members according to tissue of origin. Each point represents an 
individual let-7 member in PhIP-induced tumor (T), normalized to the corresponding 
expression in adjacent normal-looking tissue (N). B, Let-7 family members were 
downregulated in PhIP-induced tumors (all sites combined), with the exception of 
lowabundance members let-7i and miR-98. C, D, RT-PCR data for let-7 targets c-myc and 
Hmga2, normalized to Gapdh, in PhIP-induced tumors and adjacent normal tissue in the 
rat. E, F, The corresponding human MYC and HMGA2 expression data from The Cancer 




PhIP signature miRNAs predict worse prognosis. A second group of highly 
dysregulated PhIP signature miRNAs included miR-21, a well-known oncomiR447, and 
reported tumor suppressors miR-145, miR-126, miR-29c, and miR-215156,448. When 
miRNAs were compared in PhIP-induced tumors (n = 16) versus adjacent normal-looking 
tissue (n = 16), there was a trend towards upregulation of miR-21 and downregulation of 
miR-126, miR-29c, miR-145, and miR-215 (Fig. IV-3A). Statistically significant 
differences were noted for miR-21 (p < 0.01), miR-29c (p < 0.001), and miR-145 (p < 
0.01).  
This miRNA signature was used to profile the human pan-cancer database in 
TCGA, and predicted a significantly worse overall survival in cancer patients (Fig. IV-
3B, red line). Metacore analysis for the corresponding miRNAs revealed a network of 
interactions centered on KLF4 (Fig. IV-3C, red square). Subsequent investigation 
confirmed that the predicted target was significantly lower in the majority of PhIP-induced 
rat tumors (Fig. IV-3D), and in human primary colorectal and “other” cancers (Fig. IV-
3E). Thus, tumors harboring a PhIP signature miRNA profile predicted worse overall 






Figure IV-3 PhIP signature miRNAs predict poor prognosis. 
A, Expression profile of five major PhIP signature miRNAs in tumors compared with the 
corresponding adjacent normal tissue; n = 16, **p < 0.01, ***p < 0.001. B, Survival curves 
of patients listed with primary tumors in the Pan-Cancer TCGA database, grouped 
according to the relative expression of PhIP signature miRNAs indicated in the figure. C, 
Metacore pathway analysis of five PhIP signature miRNAs defined a central node 
involving KLF4 (red square). D, In RT-PCR analyses, Klf4 was downregulated in PhIP-
induced tumors compared with adjacent normal tissue in the rat, except for skin tumor 
samples, where the reverse trend was observed (gray dotted lines). E, TCGA data showing 
downregulation of KLF4 in human colorectal cancer and pan-cancer primary tumors (T), 









Overlapping PhIP signature miRNAs in human primary tumors. When TCGA data 
were examined in more detail, among the 13 most highly dysregulated miRNAs in PhIP-
induced rat tumors, 9 were similarly changed in human colon adenocarcinomas (Fig. IV-
4A), and 10 were correspondingly altered in human pan-cancer datasets (Fig. IV-4B). 
Functional annotation identified key pathways for these miRNAs, including MAPK 




Figure IV-4 PhIP miRNA signature from rats recapitulated in human primary 
tumors. 
A, TCGA data were mined for PhIP signature miRNA levels in human colon primary 
adenocarcinomas (COAD) compared with normal tissue. The heatmap is color-coded to 
indicate the relative gene expression level within each dataset. The expression profile of 
each miRNA that recapitulated the corresponding outcome in rat is shown in bold. B, 
Corresponding data for pan-cancer, excluding the colon adenocarcinoma (COAD) data 
already analyzed in A. C, Functional annotation of gene targets of PhIP signature miRNAs. 
miR-21, miR-145, and let-7 family members were entered into TargetScan 
(http://www.targetscan.org), which identified 180 predicted target genes. These predicted 
targets were uploaded into DAVID, and the functional annotation results for the top five 














































































































Environmental factors can impact epigenetic mechanisms that regulate the 
crosstalk between DNA methylation, histone modifications, and non-coding 
RNAs72,156,449–452. Historically, HCAs have been investigated in terms of their 
genotoxic/genetic influences and various prevention strategies401,453–456, but few studies to 
date have explored the possible epigenetic aspects linked to human intake of PhIP and 
structurally related compounds in the diet.  
Starting with the colon tumors, we performed an unbiased screen and validated the 
most highly dysregulated miRNAs and their downstream targets in the rat156. The current 
investigation builds upon those initial observations, testing the hypothesis that PhIP 
signature miRNAs in colon tumors might be applicable to other target organs of the rat. 
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Indeed, a relatively small and focused 13-panel miRNA profile clustered colon and small 
intestine separately from skin, Zymbal’s gland, spleen, and lung. Similar groupings were 
reported following genome-wide miRNA profiling of 55 different organs and tissues in 
the rat457. 
Dysregulated miRNAs in tumors trigger upregulation or downregulation of mRNA 
targets, depending on the circumstances. Overexpression of miR-21, for example, causes 
loss of tumor suppressors PDCD4 and PTEN to promote cell survival458, epithelial-to-
mesenchymal transition459, and chemoresistance460. In addition to targeting PDCD4, 
PTEN, and FASL to inhibit apoptosis 447, miR-21 can coordinate with miR-145 in 
regulating colon cancer stemness and chemoresistance through CD44, SOX-2, and β-
catenin 461. Interestingly, both miR-21 and miR-145 were among the PhIP signature 
miRNAs dysregulated in multiple target organs of the rat.  
Mir-21 is one of a cadre of miRNAs altered by environmental exposures such as 
cigarette smoking, air pollution, diesel exhaust, nanoparticles, particulate matter, toxic 
metals, and diverse chemicals81. Environmental pollutants such as bisphenol A, 
polychlorinated biphenyls, arsenic, mercury, lead, and cadmium also downregulate 
members of the let-7 family of suppressor miRNAs 163, which can impact IL6-STAT3 
signaling and epigenetic transformation446.  
Multiple let-7 family members were among the PhIP signature miRNAs, with let-
7a, let-7b, let-7c, let-7d, led-7e, and let-7f being downregulated in the different target 
organs of PhIP tumorigenesis. In accordance with the tumor suppressor functions ascribed 
to let-7 members462, we confirmed upregulation of their oncogenic targets, c-myc and 
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Hmga2, in the corresponding rat tumors. Interestingly, human breast cancer cells treated 
with bisphenol A or dichlorodiphenyltrichloroethane (DDT) also had attenuated let-7 
levels463, highlighting a potential broader impact of environmental influences on these 
suppressor miRNAs. 
Four additional suppressor miRNAs were downregulated at multiple tumor sites 
in PhIP treated rats, namely miR-126, miR-29c, miR-145, and miR-215. In human stage 
II and III colon cancers, miR-215 is decreased and is associated with poor prognosis464, 
but miR-215 also plays a role in chemoresistance465. As discussed above, miR-215 can 
coordinate with miR-21 to regulate CD44, SOX2, and β-catenin in colon cancer cells461. 
Mir-126 inhibits pancreatic466 and breast cancer progression and metastasis467 by targeting 
ADAM9 and PI3K, whereas downregulation of miR-126 is associated with poor prognosis 
in non-small cell lung cancer, due to dysregulated EGFL7468. The miR-29 family regulates 
DNA methylation and metastasis in lung cancer and nasopharyngeal carcinoma by 
targeting DNA methyltransferases469,470.  
We postulated that the miRNA profile prioritized in PhIP-induced rat tumors might 
serve as a “fingerprint” of environmental HCA exposure in the human population. 
Insufficient miRNA data were available in TCGA to interrogate the entire panel of 13 
PhIP signatures miRNAs, collectively. However, a focused panel comprising of miR-
21high/ miR-126low/ miR-29clow/miR-215low/miR-145low predicted significantly worse 
overall patient survival (Fig. VI-3b). Interestingly, this subgroup consisted of 153/9723 
available cases, giving an estimated frequency of 1.57% of pan-cancers in the human 
population. However, we are cautious not to over-interpret these findings as being directly 
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associated with PhIP exposure. There are more than 20 different genotoxic HCAs present 
in the diet398,405. Also, polycyclic aromatic hydrocarbons, N-nitroso compounds, lipid 
peroxides, and reactive oxygen species are thought to contribute to meat-associated DNA 
damage and cancer etiology471,472, and might induce or repress the same miRNAs as PhIP.  
Nonetheless, we were interested in the fact that PhIP signature miRNAs defined 
KLF4 as a central player (Fig. VI-3c), a transcription factor with known links to cell 
proliferation, autophagy, transformation, metastasis, and pluripotency473. Expression of 
KLF4 was reduced significantly in human primary colorectal and human pan-cancer, and 
Klf4 also was decreased in the majority of PhIP-induced rat tumors. In PhIP-induced skin 
tumors, however, Klf4 was overexpressed rather than downregulated. It is known that 
KLF4 can serve as a bivalent transcription factor, with activating or repressive functions 
on gene expression according to the circumstances474. In the skin, nuclear KLF4 was 
linked to squamous epithelial dysplasia475, but KLF4 deficiency also correlated with 
increased cell proliferation and enhanced tumor outcomes in a classical mouse skin 
carcinogenesis model476. Cross-talk with other transcription factors, such as the 
glucocorticoid receptor477, likely contributes to the divergent actions of KLF4 in the skin.  
Finally, when PhIP signature miRNAs were compared, as a group, with TCGA 
data for colon adenocarcinoma and pan-cancer, most of the miRNAs in human subjects 
were upregulated or downregulated in the same direction as in the rat tumors. 
Bioinformatics analyses implicated gene ontology pathways linked to endocytosis, 
apoptosis, MAPK signaling, Wnt signaling, and colorectal cancer. We did observe a 
relatively modest change in c-myc and Hmga2 expression in PhIP-induced tumors, 
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compared with adjacent normal tissue, whereas the expression range of these proteins was 
larger in human tumors from the same organs. The wide range of expression in humans 
probably reflects different types of environmental exposure. Thus, it is difficult to make 
firm conclusions about the relative abundance of these proteins and attribute them 
specifically to PhIP, or other HCAs, in humans. Nonetheless, the current investigation has 
laid the groundwork for follow-up studies on other environmental HCAs, their miRNA 
signatures, and the downstream targets implicated in cancer development. 
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CHAPTER V  
GUT MICROBIOME AND HOST TRANSCRIPTOME CHANGES IN A 
PRECLINICAL MODEL OF COLORECTAL CANCER GENETIC VERSUS 
DIETARY DRIVERS OF DISEASE OUTCOMES 
 
Overview 
There is great interest in delineating the role of gut microbes, the host, and their 
responses to specific dietary exposures that regulate physiological and pathophysiological 
development.  We employed a multi-omics approach to examine these interrelationships 
in an Apc-mutant model of colorectal cancer following tumor suppression by dietary 
spinach. For the intervention groups, increasing diversity coincided with reversal of 
microbiome taxonomic composition in both wild type rats and in the polyposis in rat colon 
(Pirc) model of human familial adenomatous polyposis (FAP). Metagenomic prediction 
implicated pathways in cancer and the TCA cycle, as well as butanoate and a-linoleic acid 
metabolism. Transcriptomic analyses of mRNA and miRNA profiles prioritized, among 
other targets, inflammatory responses and TNFa signaling via NF-kB in normal-looking 
Pirc colon, which were further dysregulated in Pirc colon polyps, along with E2F targets, 
G2M checkpoint, and oncogenic signaling networks. Tumor suppression was associated 
with altered TNFa signaling, hypoxia, epithelial mesenchymal transition, and KRAS 
signaling, along with decreased Serpine1 and increased miR-143/145 levels. Microbiome 
diversity was negatively associated with colon tumor outcome, and several 




Serpine1, Plcd1, Tcf7l1 and Slc30a10. We conclude that dietary spinach reshapes the gut 
microbiota and impacts host transcriptome changes, contributing to tumor suppression 
outcomes in the colon. 
 
Introduction 
The mammalian gut microbiome is strongly implicated in host physiological and 
pathophysiological development478–480. Studies in germ-free models of colorectal cancer 
(CRC) revealed decreased bowel inflammation and carcinogenesis481,482. Fecal microbiota 
transplantation has been used successfully to treat recurrent Clostridium difficile 
infection483, and provides benefit to patients with inflammatory bowel diseases, functional 
gastrointestinal (GI) disorders, and obesity484.  There is increasing interest in defining 
specific dietary interventions that might alter the gut microbiota in a beneficial manner for 
disease prevention and treatment.  Epidemiological studies show that low consumption of 
green vegetables and fiber is associated with increased CRC risk, whereas intake of dark 
leafy vegetables is linked to decreased risk485.  Little is known, however, about how these 
dietary intake patterns influence the crosstalk between gut microbiota, host transcriptomic 
profiles, and disease outcomes. Spinach is a dark leafy vegetable with a high chlorophyll 
content and appreciable levels of bioactive phytochemicals such as carotenoids, betaine, 
flavonoids, and polyunsaturated fatty acids486–488.  While evaluating anticancer strategies 
in the Apc-mutant polyposis in rat colon (Pirc) model55,489,490, we observed that dietary 
spinach was associated with significant suppression of adenomatous polyps in the 




adenomatous polyposis (FAP) patients, involving spontaneous tumor development both 
in the colon and in the small intestine53,491. This genetic model circumvents the need for 
carcinogen treatment, which in prior studies revealed anticancer effects of dietary spinach 
in the colon156.  We report here, for the first time, a multi-omics approach that examined 
gut microbiome and host transcriptomic changes in the Pirc model, and the implications 
for genetic versus dietary drivers of colon tumorigenesis.   
   
Materials and methods 
Preclinical studies. Experiments were approved by the Institutional Animal Care and Use 
Committee.  After weaning, Pirc (F344/NTac-Apcam1137, Taconic Farms, Inc. USA) and 
wild-type F344 male rats were assigned randomly to basal AIN93 control diet (Ctrl) or 
AIN93 diet containing 10% freeze dried spinach by weight (SPI). Diets were replenished 
every 2 to 3 days, and animal body weights were monitored weekly.  Monthly endoscopy 
was employed for temporal tracking of polyp development in the colon, as described in 
prior studies55. Each polyp was assigned a unique ‘address’ in the colon, based on a 
reported methodology.54 Prior to termination, 3-4 rats in each group were injected with 
bromodeoxyuridine (BrdU, 100 mg/kg body weight), and animals were euthanized 1 h 
later by CO2 inhalation. A thorough necropsy examination was performed, and tissue 
samples were taken for histopathology and molecular analysis, as reported55. 
 
Histology, immunostaining and immunoblotting. Tissue sections (5 µm) were stained 




Biosciences # 610153), cleaved caspase-3 (Cell signaling #9661), and BrdU (BD 
Biosciences # 347580) was conducted at the Research Histology, Pathology and Imaging 
Core, The University of Texas MD Anderson Cancer Center. A BrdU labeling index was 
determined, as described417, and cleaved caspase-3 was quantified as percent positive-
stained crypts in a given field. Two to three biological replicates were employed for WT-
Ctrl, WT-SPI, Pirc-Ctrl, and Pirc-SPI groups. For each tissue section, at least 15 
independent fields were quantified in the proximal, middle, and distal regions of the colon.  
Other proteins were immunoblotted as reported492, using Cell Signaling primary 
antibodies for PARP (#9542), b-catenin (#9581), p53 (#9282), and cyclin D1 (#2926), 
with b-actin as loading control (Sigma, A1978). 
 
Microbiome analysis. Frozen cecum content from rats in each group was submitted for 
bacterial genomic DNA extraction at the Alkek Center for Metagenomics and Microbiome 
Research (CMMR), Baylor College of Medicine. The 16S rDNA V4 region was amplified 
and barcoded through PCR and sequenced using the MiSeq platform (Illumina) with the 
2x250 bp paired-end protocol. Operational Taxonomic Units (OTUs) at a similarity cutoff 
value of 97% were generated by the UPARSE algorithm and mapped to SILVA database. 
OTU tables and Agile Toolkit for Incisive Microbial Analyses (ATIMA) were provided 
by CMMR for primary data visualization. ATIMA microbiome data were subjected to the 
Kruskal-Wallis test, with the adjusted P-values indicated in the figures. LDA Effect Size 
(LEfSe) used rarefied OTU data from CMMR, and results were generated with LDA>2 




Reconstruction of Unobserved States (PICRUSt) used raw BIOM files to map Greengenes 
for metagenome prediction494, coupled to Statistical Analysis of Metagenomic Profiles 
(STAMP)495. Results were replotted using Prism or Excel. To associate microbiome and 
disease outcome, we calculated the corresponding diversity and OTUs with matched 
tumor multiplicity and tumor volume datasets. At the family and genus level, tumor 
outcomes were plotted by linear regression analysis, coupled to Pearson correlation 
coefficient. To integrate microbiome OTUs with host gene predisposition and anticancer 
outcomes, we calculated the Pearson correlation by group for enriched microbiome OTUs 
from LEfSe (genus level) and the reads per kilo base per million mapped reads (RPKM) 
of the host transcriptome.  
 
RNA analyses. Flash-frozen rat tissues (n=3 replicates per group) were subjected to total 
RNA extraction using a Qiagen miRNeasy mini kit, according to the manufacturer’s 
instructions.  After DNase digestion and purity/integrity confirmation, as reported55, RNA 
samples were run on a 1% denaturing agarose gel prior to library preparation for RNA and 
small RNA sequencing. For RNA library preparation, NEBNext® Poly(A) mRNA 
Magnetic Isolation Module (NEB, E7490) and NEBNext® Ultra™ Directional RNA 
Library Prep Kit (NEB, E7420) were performed with 3µg RNA input as the starting 
material. For small RNA library preparation, NEBNext® Small RNA Library Prep Set for 
Illumina® (NEB, E7300) were performed with 1µg RNA input as the starting material. 
The RNA went through 3’ ligation, primer hybridization, 5’ ligation, 1st strand synthesis, 




library construction, each sample was tagged with a specific index during at the PCR 
amplification step. The library concentration was measured by Qubit dsDNA HS Assay 
Kit (Thermo Fisher Scientific) and the size of the library was accessed by 2% agarose gel 
with 2ng library. The samples were diluted to 1pmol for further library pooling. Before 
loading the pooled library into the NextSeq 550/500 system (Illumina), 1nM library was 
denatured and diluted according to NextSeq System Denature and Dilute Libraries Guide 
(Illumina). Stranded RNA sequencing was conducted by paired-end sequencing with 75 
bp read length and small RNA sequencing was conducted by single-end sequencing with 
50 bp read length. Fastq files were generated on BaseSpace for further bioinformatics 
processing and analysis. 
 
Bioinformatics and differentially expressed genes (DEGs). RNA-seq data were 
mapped to rn6 genome assembly using bowtie2.2.5496 with default parameters. The count 
table for each gene were calculated by using HTseq-count497. The DEGs were called using 
DESeq2 with an adjusted p value less than 0.05. miRNA-seq raw fastq data were first 
trimmed the adaptor sequence using cutadaptor498. Reads with exactly the same sequence 
were collapsed and counted. Mature and hairpin microRNA sequence data for rat were 
downloaded from miRbase (http://www.mirbase.org/ftp.shtml) on June 23rd,2016. 
Collapsed reads were mapped to rat mature microRNA sequences using blastn. The counts 
table was input to DESeq2 to call differential expressed miRNAs (DEmiRs) with adjust p 
value <0.05. Principal Component Analysis (PCA) was performed using DESeq2 for both 




application v3.0 Beta 2. The cutoff for significance was using FDR<25%. 6 miRNAs were 
prioritized for further target RNA analysis. Target prediction was conducted by Targetscan 
7.2 algorithm442 for rat specific analysis, and only the miRNA-mRNA pairs with 
correlation value less than -0.5 were retained in the Cytoscape view499.   
 
Quantitative RT-PCR. The basic methodology for RNA extraction and purification was 
as reported, using three replicates per group201,490,500–502.  After SuperScript III (Thermo 
Fisher Scientific) or miScript RT II (Qiagen) kits, quantitative PCR (qPCR) reactions were 
performed by LightCycler® FastStart DNA Master SYBR Green (Roche Applied 
Science) on a LightCycler96 instrument. Primers listed in Table V-1 for mRNA qPCR 
were designed by NCBI-BLAST, whereas primers for miRNA qPCR were purchased from 
Qiagen miScript Primer Assays.  Internal controls were Gapdh and U6B small nuclear 
RNA, for mRNA and miRNA analyses, respectively. Selected RNAs and miRNAs were 
based on prior validation and ranking in GSEA data. Original gene lists for tight junction 
and anti-microbial function were obtained from KEGG and GO, respectively, and further 
sorted by the sequencing data to generate genes of interest for RT-PCR. We focused on 
six miRNAs consistently altered during tumor formation in Pirc, and filtered miRNA-
mRNA pairs by conserved UTR target site in human and rat, with a linear correlation <-
0.7 in sequencing data. We verified miRNAs and mRNAs by qPCR (Pearson’s test, with 





Statistical analyses. Statistical analysis of two-group comparisons was performed using 
an unpaired two-tailed t-test. Correlation analysis was performed by linear and Pearson’s 
correlation, for miRNA-RNA target and microbiome-host correlations (tumor and diet 
groups). For matched tumor outcome-microbiome correlation, seven biological replicates 
of Pirc/Ctrl or Pirc/SPI were considered, whereas for spinach responsive genes-
microbiome correlations, average levels of the three groups were considered. 
 
 Results 
Dietary spinach exerts anti-tumor activity in a genetic model of FAP. Pirc and wild 
type (WT) male rats were fed basal AIN93M diet (Ctrl), or basal diet containing 10% 
freeze-dried spinach (SPI), starting at 4 weeks of age (Fig. V-1A). No significant 
treatment-related effects were observed with respects to food consumption and body 
weight throughout the study (Fig. V-1B).  Applying an established endoscopy 
methodology in the Pirc model,54,55 SPI was found to suppress colon polyps as early as 
12-weeks into the experiment (Fig. V-1C), i.e., after 8-weeks of SPI treatment.  During 
this period and at later times, endoscopy revealed significant inhibition of small colon 
polyps, and of large colon polyps after week 20 (Fig. V-1D). When the experiment was 
terminated at 30 weeks, tumor multiplicity was decreased significantly both in the colon 
and in the small intestine, and tumor volume also was reduced significantly in the colon 
by SPI treatment (Fig. V-1E). No marked changes were observed in the histology of 
normal-looking colon or colon polyps in the treatment groups (data not shown), and the 




(data not shown). In Pirc and WT controls, BrdU labeling suggested reduced cell 
proliferation rates by SPI, although this was not consistent for all regions of the colonic 
crypt (data not shown). Immunohistochemical analyses confirmed the anticipated 
overexpression of b-catenin in colon polyps and adjacent normal-looking colon and, 
notably, this was unaffected by SPI treatment (Fig. V-1F). We concluded that although 
the Wnt/b-catenin signaling pathway is deregulated in the Apc-mutant Pirc model, other 









Figure V-1 Dietary spinach suppresses polyp formation in a preclinical model of 
FAP. 
A, Study design in Pirc and WT male rats; n=10 for WT-Ctrl and WT-SPI, n=8 for Pirc-
Ctrl, and n=17 for Pirc-SPI. B, Food consumption and animal body weight gain were 
plotted for monthly changes among the 4 groups. C, Monthly endoscopic tracking of colon 
polyps. Topography images reflect progressive changes observed in polyp size and 
location, whereas the bar graph represents average multiplicity via endoscopy. D, Number 
of small (size grade 1-3) and large polyps (size grade 4-5) by monthly endoscopy, based 
on a reported grading system54. E, Final tumor outcomes for colon and small intestine (SI) 
polyps at the 30-wk necropsy. F, Immunohistochemistry staining of b-catenin in Pirc 
males given Ctrl or SPI diets. Scale bar indicates 100 µm in 20X images, or 500 µm in 4X 
images. Numerical data are presented as mean ±SEM; *p<0.05, **p<0.01, ***p<0.001, 
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The gut microbiota is profoundly altered by dietary spinach. We performed 16S rRNA 
sequencing of the cecum/gut microbial community in Pirc and WT rats. The observed 
Operational Taxonomic Units (OTUs) and Shannon index revealed that a-diversity was 
not altered by host genotype, but was significantly increased by SPI in Pirc and WT rats 
(Fig. V-2A). There was no clustering separation between Pirc and WT rats for weighted 
UniFrac principal coordinates analysis (PCoA) (Fig. V-2B), but a significant separation 
was observed in unweighted UniFrac PCoA (Fig. V-2C). The gut microbiome in both host 
genotypes clustered separately in weighted UniFrac PCoA between Ctrl and SPI groups 
(Fig. V-2B), with a marked shift in unweighted UniFrac PCoA (Fig. V-2C). The results 
were consistent with previous studies that used a diverse range of inbred and outbred 
mouse strains338, and concluded that diet plays a dominant role over genetic background 
in shaping interindividual variations in host-associated microbial communities245. Pirc had 
a higher abundance of Bacteroidetes and Proteobacteria than WT rats, while Firmicutes 
and other phyla were lower (Fig. V-2D), which is consistent with prior findings from the 
proximal colonic mucosa microbiome in ApcMin/+ mice503. Interestingly, these abundances 
were reversed by SPI intake in Pirc, such that Pirc and WT rats responded similarly to SPI 
intake, independent of host genotypes (Fig. V-2E). On Ctrl diet, Pirc had a reduced 
abundance of Lachnospiraceae and increased abundances of Ruminococcaceae, 
Bacteroidaceae, Desulfovibrionaceae and Erysipelptrichaceae compared to WT, and these 
patterns were reversed by SPI (Fig. V-2F). As with the phylum- and family- level 
observations (Fig. V-2E-F), at the genus level, abundances were also reversed by SPI in 




that SPI re-shapes the microbiome composition, reversing the effects of host genetic 




Figure V-2 Microbial composition in relation to host genetics and dietary 
intervention. 
A, a-diversity measured by observed OTUs and Shannon index; n=7 replicates for 16S 
sequencing in each group.  Weighted UniFrac (B) and unweighted UniFrac (C) Principal 
coordinate analysis (PCoA) plots displaying b-diversity of host genetics and dietary 
intervention. D, Taxonomic composition in Pirc and WT rats at the phylum level. E, 
Relative abundance changes by dietary spinach in Pirc and WT rats at the phylum level. 
F, Left, top five most abundant family members. Right, abundance changes by SPI in Pirc 
and WT rats. G, Left, top five most abundant genera. Right, abundance changes by SPI in 




We used linear discriminant analysis (LDA) effect size (LEfSe) to analyze the 
OTU microbiome data. Twenty-three, sixty-nine, and seventy-two differentially abundant 
genera were identified, respectively, between Pirc and WT rats on Ctrl diet, WT-Ctrl vs. 
WT-SPI, and Pirc-Ctrl vs. Pirc-SPI. From the corresponding cladograms (Figs. V-3A-C), 
host genotype and dietary SPI intake both influenced Ruminococcaceae and 
Lachnospiraceae family members. In response to SPI, LEfSe analyses revealed that Pirc 
and WT rats shared ~50% common changes at the genus level (Fig. V-3D). We next 
applied Phylogenetic Investigation of Communities by Reconstruction of Unobserved 
State (PICRUSt) and categorized 328 terms following Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway analysis. Two terms, ether lipid metabolism and alpha-
linolenic acid metabolism were altered significantly in Pirc vs. WT rats. Notably, 
PICRUSt analysis revealed a marked effect of SPI intake. In response to SPI, 85 terms (57 
decreased and 28 increased) and 112 terms (71 decreased and 41 increased) were changed 
significantly in Pirc and WT rats, respectively, and seventy-five terms overlapped between 
the two genotypes, i.e., 54 decreased and 21 increased (Fig. V-3E). We identified 
increased membrane transporters, cell motility, signal transduction, transcription, 
carbohydrate metabolism, and kinases among the top 10 terms prioritized by KEGG 
analysis in Pirc and WT rats given SPI (Fig. V-3F). The corresponding decreased terms 
were related to translation, replication/repair, and energy/nucleotide metabolism. 
Porphyrin and chlorophyll metabolism, identified after PICRUSt/KEGG, likely reflects 
the chloroplast DNA detected during 16S sequencing, excluded in the microbiome 




butanoate (butyrate) metabolism, and a decrease in TCA cycle and Pathways in cancer 




Figure V-3 Dietary spinach shapes the microbiome and its predicted metagenome. 
Cladograms and LDA scores showed enriched clades between two-group comparisons 
from LEfSe: WT vs Pirc (A), WT responding to SPI (B), and Pirc responding to SPI (C). 
Cladograms illustrate all significant changes in taxonomy, whereas bar graphs below show 
representative enriched bacteria taxonomy. D, Venn diagrams of enriched clades in Pirc 
and WT rats responding to SPI. E, Venn diagrams of metagenome prediction from 
PICRUSt in Pirc and WT rats responding to SPI. F. Top ten functional predictions of 
metagenome in Pirc and WT rats given SPI. G, Alpha-linolenic acid (p=2.19e-5) and 
butanoate metabolism (p=1.44e-9) were significantly increased, and TCA cycle (p=9.86e-
4) and Pathways in Cancer (p=2.85e-3) were decreased by SPI Pirc and WT rats. Statistical 
analysis was performed in STAMP with ANOVA. 
 
  









Spinach impacts key genes associated with tumorigenesis in the Pirc model. We 
utilized RNA-seq to map 17378 transcripts in colonic tissues from Pirc and WT rats. 
Principal component analysis (PCA) segregated tumor tissues from normal tissues (Fig. 
V-4A). Host genetics (Pirc vs. WT rats) and SPI consumption had less effect on overall 
transcriptome levels than tumor development in the colon. There were 261 differentially 
expressed genes (DEGs) identified between Pirc and WT normal-looking tissues, half of 
which (138 genes) overlapped with the 2180 DEGs associated with tumorigenesis (Fig. 
V-4B). Heatmaps of DEGs showed a distinct tumor feature compared to the expression 
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profiles from Pirc and WT normal-looking tissues (Fig. V-4C). Gene Set Enrichment 
Analysis (GSEA) overlapping with HALLMARK identified nine significantly altered 
pathways in Pirc adjacent normal-looking colon (PCN) compared to WT normal colonic 
tissue (WCN) (Fig. V-4D, upper panel), indicating differences in host genetics for Pirc vs. 
WT, and five of these pathways were further altered during tumorigenesis (Fig. V-4D, 
PCN → PCT, lower panel, underlined). The five pathways included Inflammatory 
Response, Allograft Rejection, TNFa signaling through NF-kB, Adipogenesis, and 
Myogenesis. As expected in the Apc-mutant Pirc model, Wnt/b-catenin signaling was 
upregulated significantly in Pirc tumors (Fig. V-4D, PCN → PCT, lower panel, red font). 
Other pathways of note were related to cell cycle changes, immune response, oxidative 
stress, and metabolism. Immunoblotting corroborated changes at the protein level for 
PARP cleavage, b-catenin overexpression, decreased p53, and increased cyclin D1 in Pirc 
tumors compared to adjacent matched normal and WT normal colonic tissue (data not 
shown). After further validation by real-time PCR (RT-PCR), genes upregulated 
significantly in Pirc colon tumors vs. Pirc adjacent normal-looking colon included Cxcl6, 
Serpine1, and Il-1b, whereas Hspb8, Tpm2 and Fhl1 were downregulated significantly 
(Fig. V-4E). Compared to adjacent normal colon, upregulation of Defa6 and Bcl3 and 
downregulation of App, Myh11, and Myl9 in Pirc tumors indicated changes in tight 
junctions and anti-microbial activity in Pirc tumorigenesis (Fig. V-4F). We also mapped 
559 miRNAs with small RNA-seq and revealed the separation of tumor profiles from 
normal-looking profiles (Fig. V-4G). Similar to RNA profiles, the heatmap indicated that 




marked changes occurred during tumorigenesis (Fig. V-4H). Among the 115 differentially 
expressed miRNAs (DEmiRs) associated with tumorigenesis in Pirc (Fig. V-4H), we used 
TargetScan and both RNA and small RNA sequencing datasets to identify miRNA-RNA 
pairs of the most altered miRNAs during Pirc tumorigenesis (Fig. V-4I), and validated 
significant changes in miR-215, miR-143, and miR-145 in Pirc normal colon compared to 
colon tumors (Fig. V-4J). Other candidates, such as miR-146b, miR-34a, and miR-21 did 





Figure V-4 Transcriptomics of colonic tissues from Pirc and WT rats. 
Transcriptome analyses were performed at the 30-wk timepoint (Fig V-1A). WCN, WT-
control diet-normal colon mucosa; WSN, WT-SPI diet-normal colon mucosa; PCN, Pirc-
control diet-normal looking colonic mucosa; PCT, Pirc-control diet-colon tumor; PSN, 
Pirc-SPI diet-normal looking colonic mucosa; PST, Pirc-SPI diet-colon tumor. Each group 
contain 3 biological replicates, and Pirc normal-looking colon was matched to Pirc tumor. 
A, PCA highlighted the distribution of RNA-seq. B, Venn diagrams of DEGs. C, Heatmap 
of overall DEGs of RNA-seq data from WCN, PCN and PCT. D, Enriched GSEA 
HALLMARK analysis of DEGs between WCN and PCN (upper panel), and between PCN 
and PCT (lower panel). Underlined terms indicate incrementally altered pathways for 
WCN → PCN to and PCN → PCT group comparisons. Normalized enrichment score 
(NES) is indicated by color scale; -4 (blue) to +4 (red). Wnt pathway (in red font) was 
enriched, as expected in the Apc-mutant Pirc model. E, Validation by qPCR of genes in 
the five incrementally altered pathways (underlined in d). F, Validation by qPCR of genes 
related to tight junctions and antimicrobial function. G, PCA highlighted the distribution 
of small RNA-seq. H, Heatmap of overall DEmiRs. I, Cytoscape view of conserved 
miRNA-RNA targets and the negative associations in the rat RNA-seq and small-RNA 
seq data. J, Validation of selected miRNAs in Pirc colon tumors. *p<0.05, **p<0.005, 
***p<0.001. Two-tailed t-test was performed for qPCR results in two-group comparisons. 
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The prior analyses did not consider spinach effects on predicted targets, and the 
corresponding data are summarized in Fig. V-5. Compared to the control diet group, 
dietary spinach altered 4 genes in common among the 101 DEGs in WT rats and 80 DEGs 
in Pirc normal colon (Fig. V-5A). GSEA indicated significant downregulation of cell 
cycle-related pathways and upregulation of immune-related pathways in Pirc and WT rats 
fed SPI, with five pathways in common among the genotypes (Fig. V-5B). The latter 
pathways included TNFa Signaling through NFkB, Hypoxia, Epithelial Mesenchymal 
Transition, Apoptosis, and KRAS Signaling Up. After SPI consumption, 2945 DEGs were 
identified in Pirc colon tumors compared to adjacent normal colon, and 1754 of the DEGs 









































































































































































































(Fig. V-5C). Among the pathways most strongly implicated were IFN-a and IFN-g for 
tumors from SPI-fed rats compared to rats given control diet.  
While evaluating the preventive actions of SPI, we considered two scenarios: (i) 
genes that were up- or downregulated in Pirc colon tumors, relative to adjacent normal 
colon, and were reversed by SPI in Pirc normal colon, and (ii) genes that were 
‘normalized’ in colon tumors from Pirc rats given SPI compared with colon tumors from 
Pirc rats given control diet. The first scenario involves putative gene targets altered by SPI 
in normal colon, representing ‘primary prevention’ of early lesions (e.g., aberrant crypt 
foci and microadenomas), before they advance to frank adenoma or carcinoma stages. 
Gene candidates related to scenarios (i) and (ii), above, were validated by RT-PCR (Figs. 
V-5D and V-5E, respectively). Tumor-associated genes that were reversed in Pirc normal 
colon by SPI consumption included Serpine1, Itga6 and Duoxa2, whereas Tcf7l1, Plcd1 
and Slc30a10 were upregulated (Fig. V-5D). Comparing tumor to tumor, Ccl21 and Klf7 
were partially normalized by SPI ingestion relative to basal diet controls (Fig. V-5E). On 
the other hand, 66 DEmiRs were found in tumors from SPI-fed rats, with 41 DEmiRs also 
detected in tumors from animals on Ctrl diet (Fig. V-5F).  
After investigating the miRNA-RNA pairs conserved in humans and with negative 
associations in the rat (Fig. V-4J), loss of miR-145 was associated with increased 
Serpine1, whereas gain of miR-34a was associated with reduced Klf4 (Fig. V-5G) in Pirc 
tumors. The negative correlation for miR-145/Serpine1 was further enhanced by SPI 
consumption, whereas the trend for miR-34a/Klf4 was reversed by SPI in Pirc colon 





Figure V-5 Transcriptome changes due to SPI treatment in Pirc and WT rats. 
A, Venn diagram of DEGs for RNAs altered by SPI in normal mucosa of Pirc and WT 
rats. B, Statistically significant pathways from GSEA HALLMARK analysis, highlighting 
SPI effects on WT normal colon. Underlined terms indicate affected pathways in Pirc 
normal-looking colon. C, Venn diagram of tumor DEGs in Pirc tumors under Ctrl or SPI 
diet consumption, and GSEA enrichment in Pirc tumors arising despite SPI treatment (i.e., 
putative ‘SPI-resistant’ lesions). D, Validation by qPCR of genes reversed in PCT vs. PSN 
groups. E, Partially normalized targets associated with oncogenic effects in tumors. F, 
Venn diagram of tumor DEmiRs in Pirc tumors from rats given Ctrl or SPI diet. G, 
Correlation of miRNA-mRNA target relationships, validated by RT-PCR in Pirc tissues 
from Ctrl and SPI groups. See Table V-2 for further miRNA-mRNA prediction data. 
*p<0.05, **p<0.005, ***p<0.001. Numerical data are presented as the mean±SEM, n=3. 
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Association between microbiome and host responses. We integrated the data on tumor 
outcomes (Fig. V-1) with a-diversity calculated by observed OTUs (Fig. V-2), and 
observed a significant negative association for tumor multiplicity but not tumor volume 
(Fig. V-6A). Tumor multiplicity was inversely correlated with three unclassified 
Bacteroidales families (Fig. V-6B). At the genus level, one unclassified Lachnospiraceae 
and one unclassified Ruminococcaceae genus were negatively correlated to tumor 
multiplicity, while one unclassified Ruminococcaceae genus was positively correlated, 
based on 16S sequencing (Fig. V-6C). Metagenome predictions in relation to tumor 
multiplicity outcomes found significant inverse correlations for butanoate metabolism and 
calcium signaling, and positive associations for peptidases and pathways in cancer (Fig. 
V-6D). In addition to the altered patterns in the bacteria populations correlated to tumor 
outcomes (Figs. V-6A-6D), we also compared microbiome to host gene expression 
changes (Fig. V-6E). A significant positive correlation was observed for (i) 
Lachnospiraceae (Unc0396i) and Slc30a10, a manganese efflux transporter; (ii) 
Bacteroidales (Unc00krl) and Plcd1, a tumor suppressor; (iii) Ruminococcaceae 
(Unc01k4o) and Plcd1; (iv) Ruminococcaceae (Unide781) and Serpine1, a serine protease 
inhibitor and (v) Ruminococcaceae (Unc00vst) and Serpine1. Negative correlations were 
detected for (i) Ruminococcaceae (Unide781) and Tcf7l1, a transcription factor; and (ii) 
Ruminococcaceae (Unc00vst) and Tcf7l1. We concluded that the microbiome contributes 






Figure V-6 Integrating gut microbiome, gene expression, and tumor outcomes in 
response to SPI intervention. 
A, Associations between a-diversity of gut microbiome and host disease outcomes for 
tumor multiplicity and tumor volume. Associations also were probed between tumor 
multiplicity and the relative abundance of bacterial OTUs at the family level (B) and genus 
level (C). d, Correlations of tumor multiplicity and metagenome prediction. E, 
Associations between relative abundance of bacterial OTUs and preventive genes 
identified in Pirc normal-looking colon. Pearson’s correlation coefficient was indicated on 
the right (red, positive correlation, blue, negative correlation; asterisk indicates statistical 
significance). For Pearson’s correlation in A-D, degree of freedom(N-2) =12 and the 
critical value=0.533 (p=0.05), and 0.661 (p=0.01). For Pearson’s correlation in E, degree 




























































































































-1          +1
A





































Ruminococcaceae (Unide781) * *


































































Calcium signaling pathwayButanoate metabolism
Pathways in cancer









There continues to be much interest in modulating the human microbiome as an 
approach to prevention and treatment of cancer504,505. We report here on the 
interrelationships between gut microbial composition, host genetics, dietary exposure, and 
disease pathogenesis in a preclinical model of FAP.  The Apc-mutant genetic background 
of the Pirc rat predisposed to a lower a-diversity in the cecum microbiome, and this was 
circumvented by feeding dietary spinach under conditions in which significant 
suppression of adenomatous polyps occurred in the GI tract.  This work extends prior 
observations on the decreased microbial diversity and loss of Firmicutes, Clostridia, and 
Lachnospiraceae in the ApcMin/+ mouse503 and in human colorectal cancers303. In a short-
term clinical study, Firmicutes was decreased by consumption of an animal-based diet, 
whereas Bacteroidetes was decreased by a plant-based diet245. Ruminococcaceae 
phylotypes were increased by resistant starch in obese men, whereas Lachnospiraceae 
phylotypes were increased by non-starch polysaccharides506. These trends were 
recapitulated in the current investigation, with decreasing Bacteroidetes and increasing 
Firmicutes and Lachnospiraceae after intervention with dietary spinach. Spinach 
consumption also reduced Desulfovibrio sulfur-reducing bacteria, implicating 
inflammatory and barrier functions507,508.  
In contrast to the marked effect on the gut microbiome, prolonged spinach 
consumption had a relatively mild effect on host transcriptomics, based on mRNA and 
miRNA profiling. We prioritized genes associated with adenomatous polyp suppression 




plasminogen activator inhibitor type 1 (PAI-1), a protein that plays an essential role in 
extracellular matrix proteolysis and matrix metalloproteinase activity509, and PAI-1 
elevation was observed in sporadic CRC510 and FAP tumors511. Mucosal gene expression 
profiling of SERPINE1, along with other inflammatory regulators such as CXCL1, STAT3 
and ILs, were negatively correlated with decreased abundance of Firmicutes and 
Bacteroidetes subsets in human CRC512. DUOXA2 is a maturation factor for the epithelial 
antimicrobial dual oxidase DUOX2, which is among several NADPH oxidase/dual-
oxidase family members dysregulated in Crohn’s disease and CRC, acting via NFkB331,502. 
DUOX2 expression was negatively correlated with Bacteroides, Lachnospiraceae, and 
Blautia, but positively correlated with Pasteurellaceae, Enterobacteriaceae, and 
Gammaproteobacteria331.  
We also report here on the negative associations between miRNAs and their 
mRNA targets in the Pirc genetic model, extending prior work in a carcinogen-induced rat 
model that also exhibited significant colon tumor suppression by dietary spinach156.  The 
latter investigation and the current study both prioritized multiple miRNAs, including 
miR-215 downregulation in colon tumors. Mir-145 was among the most highly 
downregulated miRNAs in Pirc colon tumors, consistent with its proposed tumor 
suppressor role in human CRC. This “suppressor miR” was unexpectedly upregulated in 
a prior report, possibly related the mechanisms associated with the carcinogen 
treatment156.  Previous studies prioritized SERPINE1 as a target of miR-143/145 in bladder 
cancer513, as well as miR-34a in liver cancer regulating KLF4514.  KLF4 can be regulated 




in the Pirc model the miR-34a/Klf4 axis was disrupted by spinach treatment. KLF4 is an 
important zinc-finger transcription factor involved in cell cycle regulation, somatic cell 
reprogramming, and tumorigenesis.  Reduction of KLF4 is well documented in rat157,435 
and human colon tumors515,516, providing a potential mechanistic target for spinach, in the 
context of CRC prevention or treatment517. In a mouse colitis model225, fecal miRNAs also 
were implicated in dysbiosis and altered disease outcomes, revealing a complex crosstalk 
between host cells, intestinal content, and gut microbiota. Collectively, the present 
investigation and published reports provide support for the interplay of microbiome and 
host factors in the protection afforded by anticancer agents against CRC.  This warrants 
further investigation using both carcinogen-induced and genetic models, where spinach 
and other dietary interventions have proven highly effective.  Interestingly, polyethylene 
glycol, an osmotic laxative that reduces GI transit time and increases bowel frequency, 
reduced colon tumor multiplicity significantly in the Pirc model518. Although the 
mechanism was unclear, colon transit time modulating microbiome and bacterial 
metabolism519 could be a possible explanation.   
Limitations of the current investigation will be overcome in future studies that 
advance 16S sequencing towards meta-genomic or meta-transcriptomic analyses, and 
extend the statistical associations to cause-and-effect determination in the context of host-
microbiota-diet interactions. Chen et al. suggested that lumen- and mucosa-associated 
microbiota might play different roles in CRC progression through indirect co-metabolism 
and direct interaction, respectively520. Gut microbes can affect, in a site specific manner, 




the complex interactions that affect normal homeostasis and pathology in the gut will 
require integration of multi-omics data, beyond what has been reported here,522,523  
including optimized sample acquisition, data generation and interpretation, and network 
integration262,263.  
In conclusion, we report here on the efficacy of dietary spinach in a murine model 
of FAP, linked to marked changes in the gut microbiome, and associated changes in host 
transcriptomics. Taken together, the data reaffirm the importance of the complex 
interactions between host genetics, immune response, and microbiota during malignancy. 
Future studies should seek to enhance the integration of multi-omics datasets, for both 
natural dietary interventions and standard of care therapeutic agents, with a view to 





Table V-1 Primers for rat mRNA qPCR. 
Rat gene Forward primer Reverse Primer 
Fhl1 TCTCAAAGACACTCAGGTCCC CTTATGGGCTTGCGGCATTC 
Tpm2 CAGGCTCTCAAGTCGCTGAT GCACTAGCCAAAGTCTCTTCCA 
Hspb8 TGGAACCCTAAGGTCTGGCA CTCTTCGTGCTTCCCTGACAC 
Il1b CTGTGACTCGTGGGATGATG GGGATTTTGTCGTTGCTTGT 
Serpine1 AGTCTTTCCGACCAAGAGCAG GTTGGATTGTGCCGAACCAC 
Cxcl6 GGTGGAAGTCATAGCTAAGTTGA GCAAGTGCATTCCGCTTTGT 
Myl9 GAGCGCTACGTCCAATGTCT GGGCCTCGTTCATCATACCC 
Myh11 ATCACGGGGGAGCTGGAAAA AATGAACTTGCCAAAGCGGG 
App CAACCGTGGCATCCTTTTGG CGTCGACAGGCTCAACTTCA 
Myh9 AGGCTCAAGAACCTGATCTGC TGACTTATGGCCAGGACCTGAA 
Bcl3 CCGCAGGGTCATTGATATCCTAA AAGCTTGGAGCATCCTTCGG 
Defa6 GATTTTGAGATAGGAAGGCCAGT CAGAACGCAGTGGCATATTCTT 
Itga6 GGCACTCAGGTTCGAGTGA GACGGCTGAGTGTGGATCTC 
Duoxa2 CACTCAGAGGAACACCAATGC GGTGGTACAATCCGCAAGGA 
Tcf7l1 TCCAGCACACTTGTCCAACA GGAGAAGTGGTCGTTGCTGTA 
Plcd1 CGTGTCCGGATCATCTCTGG CACCGTGGGTTGAAACCATT 
Slc30a10 GTAGCAGGTGATTCCCTGAACA TGCCAGTTACACGGGTCTTC 
Ccl21 CACCCCGGAAGCAATCTCAG GTCTGTTCAGTCCCCTTGCAG 
Il22Ra2 CACTGGAGAAGGAACAAAAAGCC CTCCCGGTTTCAGACCAGTT 
Pecam1 GGTAATAGCCCCGGTGGATG TTCTTCGTGGAAGGGTCTGC 
Rrm2B CAGCAGAGGAGGTTGACTTGT CTGGAACCTGCACCTCTTGA 
Ptprj CCAAGCAGGCTCAGGACTAC AGTTGATGAGCAGGTCGGTG 
Klf4 TACCCTCCTTTCCTGCCAGA TTTGCCACAGCCTGCATAGT 



















































CHAPTER VI  




The adenomatous polyposis coli (APC) gene is a tumor suppressor gene which is 
mutated inactively in the majority of colorectal cancer patients. Polyposis in rat colon 
(Pirc) model is a heterozygous APC mutation rodent model, and develops predominantly 
colon polyps, which are similar to the symptom observed in human familial adenomatous 
polyposis (FAP). Freeze-dried spinach has demonstrated chemoprevention effects in 
dietary intervention trials with Pirc and carcinogen-induced colorectal cancer rat models. 
The aim of the study is to use untargeted metabolomics to characterize metabolic changes 
of tumorigenesis, as well as impacts from dietary spinach, in the Pirc model. Multivariate 
analysis indicated metabolic differences between genetic backgrounds, tissue types, and 
dietary spinach exposures. We found decreased lipids and fatty acids, and increased 
nucleic acids and vitamins and cofactors in Pirc tumors compared to adjacent normal and 
wild-type normal colonic tissue. Preliminary mummichog analysis revealed linoleate, 
arachidonic acid and purine metabolism were most affected metabolic changes in Pirc 
tumors. Dietary intervention had mild influences on metabolomics. Although the 
responses to spinach were different in wild-type and Pirc rats, fatty acid related pathways 
were commonly affected. We sought to explore the metabolome of scraping samples 




preliminary data suggestion purine, lipid, and bile acid metabolism were altered. 
Additionally, purine metabolism was also enriched in tumors growing under spinach 
intervention indicating a central role in Pirc tumorigenesis. After long-term exposure to 
dietary spinach, amino acids and vitamins and cofactors were downregulated, and lipids 
and fatty acids were upregulated. We conclude that lipid and fatty acid and purine 
metabolism were important in Pirc tumorigenesis, and dietary spinach could reverse the 
tumor metabolic signatures to achieve chemoprevention of colorectal cancer. 
 
Introduction 
Colorectal cancer is one of the most commonly diagnosed cancers with the third 
leading incidence rate and the forth mortality rate in the world524. In 2015, Colorectal 
cancer accounted for more than 0.14 million new cases and 52,396 deaths in the United 
States234. To reduce the prevalence of colorectal cancer, several screening methods for 
early diagnosis and treatment options for primary and recurrent diseases have been 
developed. There are more than 1,200 ongoing clinical trials for therapy and 139 trials for 
prevention in primary and advanced colorectal cancers across the world 
(Clinicaltrials.gov, database accessed in September, 2018) indicating the vigorous effort 
to against colorectal cancer. The causes of colorectal cancer can be categorized by 
sporadic (>65%), familial (<30%), and hereditary (<5%) factors. Genetic and epigenetic 
alternations are important features of colorectal carcinogenesis, including chromosomal 
instability (CIN), microsatellite instability (MSI), CpG island methylation (CIMP) and 




related to oncogenic activation. Tumor suppressors, such as APC, TP53 and TGFBR2, are 
found inactivated mutated in colorectal cancer patients525. Adenomatous Polyposis Coli 
(APC) gene is a key tumor suppressor gene, and APC mutation is  believed to be one of 
the early events during the multi-step sporadic colorectal carcinogenesis19. APC protein is 
a negative regulator of Wnt signaling by modulating protein interaction, subcellular 
localization and turnover of b-catenin, and plays important role in cell adhesion and 
motility. Germline gene predisposition in APC causes Familial adenomatous polyposis 
(FAP) while more than 80% of sporadic colorectal cancer tumors carry somatic APC 
mutations526 indicating the essential role of APC in colorectal cancer. Currently, there are 
two well-established rodent models utilizing mutant APC for facilitating colorectal cancer 
research. They are ApcMin/+ (multiple intestinal neoplasia) mouse model and Pirc 
(polyposis in rat colon) rat model. Pirc model has several advantages over ApcMin/+ model 
to be closer mimicking human conditions. Pirc rats have closer genome structure to human 
than mouse and spontaneously develop predominant colonic tumor53,527. Also, Pirc rats 
have longer lifespan that longitudinal intervention study can be conducted during different 
stages of the multi-step colorectal carcinogenesis.  
Mass-spectrometry based metabolomics has enabled the small molecular profiling 
in various specimens to advance research in cancer metabolism and novel biomarker 
identification528,529. The metabolites represent the functional products of gene expression, 
protein enzymatic processes, environmental exposure and microbial co-metabolism. Thus, 
Metabolome is a sum of the critical biological processes connecting genome to phenome. 




additional insights for mechanistic studies for human diseases530,531. A study including 
almost 3000 participants from German KORA F4 and British TwinsUK cohorts revealed 
37 genetic loci associated with serum metabolites using ultrahigh-performance(UHP)- 
liquid-phase chromatography (LC) and gas-chromatography (GC), coupled with tandem 
mass spectrometry532. Many of the metabolites were found correlated with chronic 
diseases, novel biological functions, and pharmacotoxicity suggesting new leads for 
researches. In colorectal cancer patients, metabolomic profiles were found to distinguish 
normal and cancerous tissue304 and to predict the prognosis after treatments533,534. Short 
chain fatty acid, amino acids, nucleotide and energy metabolism were implicated in 
colorectal cancer tumors comparing to adjacent mucosa306. MYC-activated global 
metabolic reprogramming was identified by capillary electrophoresis time-of-flight mass 
spectrometry (CE-MS) in adenoma stage patients, and knockdown MYC lead to reset of 
metabolic gene expression related to transporter, purine and pyrimidine metabolisms325. 
In ApcMin/+ mouse model, choline phospholipid metabolism was altered in non-tumor 
gastrointestinal tissues535, and increasing TCA cycle metabolites was reported in APC min/+  
polyp tissues536.  
Accordingly to the epidemiology studies, western lifestyle and environmental 
exposures were significantly associated with colorectal carcinogenesis, changing lifestyle 
such as diet habits, avoiding known risk factors such as carcinogenic chemicals, and 
managing precancerous conditions also provide the prevention approaches lowering the 
risks of getting colorectal cancer46. Several metabolomic based study focusing on dietary 




antimicrobial activity by reducing uremic toxin level and further decreased IL-6 level and 
normalized the dysregulated lipid metabolism in ApcMin/+ colon tumor537. In serum 
samples, American ginseng attenuated the impaired amino acids, carbohydrates and lipid 
metabolism to extend the lifespan of the ApcMin/+ mouse538.  Freeze-dried blackberries 
have been demonstrated in a clinical phase 1 pilot trial on demethylation of SFRP2 and 
WIF1 and downregulation of β-catenin and E-cadherin protein539 that a follow-up study 
using ApcMin/+ mouse identified the prevention associated metabolites in colon, liver and 
fecal samples were involved in amino acids, glutathione, lipid and nucleotide 
metabolism540. Collectively, lipid metabolism played important role in tumorigenesis in 
ApcMin/+ mouse and could be a potential chemoprevention target.  
We have not seen report on metabolomic study using rat model, and our previous 
studies indicated dietary spinach can reduce 50% tumor outcome in carcinogen-induced156 
and genetic driven colorectal tumorigenesis(CHAPTER V). In this study, we hypothesized 
that the untargeted analysis of metabolites in Pirc colonic tissues would provide novel 
metabolic fingerprints reflecting the APC mutation driven colorectal tumorigenesis and 
prevention effects from dietary spinach which shown drastic modification of the cecum 
microbiome in rats.  Here we applied the UHPLC- Quadrupole-Orbitrap™ Mass 
Spectrometer to profile the metabolome from rat colonic samples, and reveal the 
contributions of multiple factors, including genotype, phenotype and diet intervention, in 






Materials and methods 
Rats and sample collections. In brief, Pirc (F344/NTac-Apcam1137, Taconic Farms, Inc. 
USA) and wild-type F344 male rats were assigned randomly to basal AIN93 control diet 
or AIN93 diet containing 10% freeze dried spinach by weight (SPI) for a 30-week 
colorectal cancer prevention study as previously described (CHAPTER V). The 3-day 
exposure arms were added to both wild type and Pirc rats to obtain the acute responses in 
for dynamic metabolomic and transcriptome evaluation. All samples were collected under 
normoxia during rat necropsy. The samples were flash-frozen and stored at -80°C till 
sample preparation for further analysis. Experiments were approved by the Institutional 
Animal Care and Use Committee. 
 
Sample preparation for aqueous phase extraction. The tissue samples, including 
normal snip (N, mucosa biopsy), mucosa scraping (S), and polyps (T, tumors), were 
weighed and homogenized in 0.5 ml of cold methanol and 0.2 ml chloroform in pre-cooled 
garnet bead tubes using Precellys®24 beadbeater. The samples were centrifuged at 3000 
rpm for 10 minutes at 4 ° C and 0.7 ml of cold water was added to the supernatant. The 
aqueous phase was collected by centrifugation at 3000 rpm for 1 minute, and the extraction 
procedure was repeated again. The pooled aqueous (upper) phase was passed through a 
sterile nylon cell strainer and. and lyophilized (Labconco). The lyophilized sample was 
re-constituted in 50ul of methanol/water (1:1, v/v). The samples were stored at −80°C until 





Untargeted metabolomic data acquisition. The untargeted liquid chromatography high 
resolution accurate mass spectrometry (LC-HRAM) profiling was conducted on a Q 
Exactive™ Plus Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (Thermo Scientific) 
coupled to a Dionex UltiMate 3000 HPLC system (Thermo Scientific). Synergi Fusion-
RP C-18 column was used with a gradient of methanol/acetonitrile solvent system, and 
the mass scanning was range from 50 to 750. The data was collected in positive mode. 
MS1 and MS1-dependent MS2 spectra were collected at a m/z resolution of 70,000 and 
17,500, respectively. Autosampler was maintained at 4 °C.  Blank (methanol and water at 
1:1 v/v) samples were injected between each sample to prevent any sample carryover. The 
raw data acquisition was performed by Chromeleon™ (Thermo Scientific). 
 
Metabolomic data analysis. Data was imported to Progenesis QI software (Waters) for 
alignment, peak picking, compound identification and data processing. There were 17243 
features detected, and many were identified using Human Metabolome Database (HMDB) 
and Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Raw abundance data 
were normalized to each sample weights. All features were taking consideration for Partial 
least squares Discriminant Analysis (PLSDA) analysis. Features were further filtered by 
1) at least appeared in 3 groups, 2) at least 3 biological replicates, and 3) significant by 
ANOVA test resulting in 5946 differential features. The significant features were 
subjected to clustering and correlation by MetaboAnalyst 4.0541. p-values (two-tailed T-
test) and t-scores (standardized test statistic) were generated for multiple two-group 




functional metabolites by mummichog version 2 in R542. Mummichog processed multiple 
two-group comparisons with various significant features list. The feature p-value cutoff 
and feature numbers were included in the figure legend. Empirical compounds were 
collected from multiple mummichog predictions to form a consensus predicted compound 
identification of 883 features. The primary prediction of the 883 compound names were 
mapped to KEGG Compound collections of Compounds with biological roles, Lipids, and 
Phytochemical compound with total 5575 small molecules. The three categories were 
furfure breakdown to eight sub-categories for the compound characterization evaluation. 
Pathway analyses by mummichog were ranked according to the p-value and using p=0.05 
cutoff.  
 
RNA sequencing and bioinformatics. RNA sequencing data was acquired previously 
with additional normal and tumor samples under 3-day spinach exposure (N=2 for each 
group). RNA analyses and bioinformatics were previously described (CHAPTER V). 
 
Visualization of metabolites and gene interaction. The metabolite feature information 
was extracted according to the empirical compound predictions corresponding to the 
enriched pathway. The gene expression profile was extracted from the previous study in 
transcriptome (CHAPTER V) according to the KEGG defined genes, associated to the rat 
metabolic pathway. The metabolites and gene associated with the enriched pathways were 
displayed in heatmaps. For the assumption that the scraping samples contain a mixture of 




we used KEGG Search&Color Pathway tool to map the predicted metabolites from 
scraping samples without defining the species-specific information.  
 
Results 
Untargeted metabolomic profiles can distinguish genotypes, tissue types and dietary 
exposure. The study included wild-type (WT) and polyposis in rat colon (Pirc) rat in three 
dietary conditions: AIN control diet, AIN control diet containing 10% freeze dried spinach 
for 3-day intervention (short-term, 3d), and AIN control diet containing 10% freeze dried 
spinach for 26 weeks (long-term, SPI). The sampling tissue types were normal snip(N), 
mucosa scraping(S), and polyps(T) (Fig. VI-1A). LC-MS/MS was indicated a robust 
metabolomic platform for identification and quantification of small molecules543. We 
applied untargeted liquid chromatography-quadrupole-orbitrap mass spectrometry (LC-
MS/MS) to determine the metabolites in the total 84 rat colonic samples, and the 
instrumental detections resulted in over 17,000 metabolite features. Partial least squares 
discriminant analysis (PLSDA) of WT Normal, WT scraping, Pirc Normal, Pirc scraping, 
and Pirc Tumor revealed intra-group variations and mild clustering effects of short- and 
long-term exposure of dietary spinach (Fig. VI-1B). For each diet comparisons, long-term 
spinach groups were more different from AIN control groups than 3-day spinach groups. 
For the five groups in control diet, tumors were the most different group clustered away 
from other four groups. We further calculated the 5946 significant features for overall 
statistical analyses. The one-way hierarchical clustering revealed distinct small molecular 




indicated tumor profiles were the most different tissue type among the three tissue types 
from both WT and Pirc rats indicating the distinct metabolic profiles of tumorigenesis 
(Fig. VI-1D). Interestingly, the Normal snip profiles and scraping profiles from WT and 
Pirc were more similar in the same tissue types than source genotypes suggesting the tissue 
collecting methods harvested different metabolites in the gut surface, potentially carrying 




Figure VI-1 Study design and an overview of the untargeted metabolomic analyses 
of all sample collections. 
A, Study design included two rat genotypes: WT and Pirc, three diet conditions: AIN 
(control diet), 3d (3-day spinach diet), and SPI (26-week spinach diet), and three sample 
types: colonic normal snip(N), mucosa scraping(S), and polyps(T) leading to total 15 
groups. Numbers in the circle indicated the biological replicates of LC-MS/MS data 
included in the study for each group. B, Partial least squares Discriminant Analysis of 
17243 LC-MS/MS features. The comparisons included the diet effects on the five major 
tissue types and a comparison of the five tissue types on AIN diet. C, Heat map of 
hierarchically clustered 5946 significant features among the 15 groups of rat samples. Data 
represented the average of each group and were auto-scaled by features. D, Correlation 
analyses across all individual samples in five major tissue types: WT Normal, WT 










Lipid, nucleic acid and vitamin metabolism were altered during Pirc colon 
tumorigenesis. To evaluate the metabolic molecules and pathways of the untargeted 
metabolomics during Pirc tumorigenesis, we primarily used mummichog to reduce the 
burden of compound identification and confirmation in a high throughput dataset. The 
consensus empirical compounds were mapped to KEGG Compound database leading to 
eight categories of small molecule. The categories included lipid and fatty acids, amino 
acid derivatives, phytochemicals, carbohydrates, nucleic acids, vitamins and cofactors, 




each category in WT Normal, Pirc Normal and Pirc Tumor samples, and the lipid and fatty 
acids, amino acid derivatives, and phytochemicals were the most abundant molecules in 
the consensus predictions across all samples (Figs, VI-2A-2C). There was no significant 
difference between Pirc Normal and WT Normal metabolic profiles. However, Lipid and 
fatty acid level was decreased while nucleic acids and vitamins and cofactors were 
increased during Pirc tumorigenesis (Fig. VI-2D). Two group analyses by mummichog542 
provided step-wise metabolic changes for Apc mutant driven tumorigenesis in Pirc model. 
Comparing to WT Normal, significant features in Pirc Normal were enriched for pathways 
involved in fatty acid metabolism (i.e. arachidonic acid, omega-3 fatty acid and 
Leukotriene metabolism), nucleotide metabolism (i.e. pentose phosphate pathway), and 
vitamin metabolism (i.e. retinol, biotin, and CoA metabolism) (Fig. VI-2E). Comparing 
to Pirc Normal, significant features in Pirc Tumors were enriched for pathways related to 
fatty acid metabolism (i.e. Linoleate, Arachidonic acid, omega-3 metabolism), purine 
metabolism, carnitine shuttle and glutathione metabolism (Fig. VI-2F). Our findings in 
lipid metabolism dysregulation in step-wise Pirc tumorigenesis recapitulated the human306 
and APC min/+  studies540. In order to understand the directional changes of the enriched 
pathways during Pirc tumorigenesis, we retrieved the metabolites for further investigation. 
The majority of metabolites associated with linoleate metabolism, arachidonic acid 
metabolism purine metabolism, and metabolites from eicosapentaenoic acid were 
decreased in Pirc tumors while metabolites related to omega-3 fatty acid metabolism, beta-
alanine metabolism, carnitine shuttle, and glutathione metabolism were increased (Fig. 




the enriched pathways in Pirc tumors (Fig. VI-2H). Notably, gene expression profile of 
the Pirc tumor metabolic pathways was different from WT and Pirc Normal, and the 
changes seemed to have a balance of the up and down dysregulation, unlike the same 





Figure VI-2 Predicted metabolites and pathways altered by Apc mutation in Pirc 
and tumorigenesis in Pirc colon. 
A-C, Features were annotated according to KEGG Compounds and further divided to 
eight biological compound categories. D, Statistical increases were observed in nucleic 
acids and vitamins and cofactors in tumor samples. E, Enriched metabolic pathways by 
significant metabolites features between Pirc and WT normal snip samples (654 features, 
mummichog feature cutoff at 0.05). F, Enriched metabolic pathways by significant 
metabolites features between Pirc tumor and adjacent normal snip samples (807 features, 
mummichog feature cutoff at 0.005). G, Heat map of the associated LC-MS/MS features 
contributing to the enriched pathways in Figure V-2F. H, Heat map of the gene expression 
profile according to the genes associated with the enriched pathways in Figure V-2F. 
Individual column represented individual samples. FA, fatty acid; AA, arachidonic acid; 










Dietary spinach exposure altered fatty acid metabolism in Pirc and WT rats. To 
investigate the dietary spinach effects on Pirc and WT rats, we compared the short- and 
long-term spinach effects on WT (Fig. VI-3A-C) and Pirc (Fig. VI-3D-E) respectively. 
Short-term spinach had a greater influence than long-term exposure on metabolomic 
changes in both Pirc and WT rats (Fig. VI-3A and 3D). However, more detected 




upregulated in Pirc rats. In the categorical view, there was no statistical differences in both 
Pirc and WT Normal samples when subjected to dietary spinach exposure (Fig. VI-3B and 
3E). Only hormone and steroids and nucleic acids had similar decreasing trends in Pirc 
and WT rats by dietary spinach. Other metabolites were affected differently in Pirc and 
WT rats. In WT rat colon, mummichog pathway enrichments indicated that omega-3 fatty 
acids were the most changed metabolic pathway by short-term spinach along with other 
alanine and vitamin related metabolisms, and linoleate metabolism was the most altered 
pathway by long term spinach (Fig. VI-3C). For Pirc, linoleate metabolism was more 
affected by short-term spinach, and C21-steroid biosynthesis and metabolism was the most 
altered pathway by long term spinach along with other fatty acids related metabolisms 
(Fig. VI-3F). Taken together, lipid and fatty acid metabolism seemed critically involving 







Figure VI-3 Spinach effects on WT and Pirc normal snip tissues. 
A, The significant (p<0.05) up and downregulated features of all detected features in short- 
and long-term dietary spinach exposure. B, Features in WT normal snip tissues were 
categorized according to the eight biological compound categories. C, Enriched metabolic 
pathways by significant metabolites features between short- or long-term dietary spinach 
exposure compared to AIN control diet. (3dSPI: 461 features, mummichog feature cutoff 
at 0.01; SPI: 1036 features, mummichog feature cutoff at 0.2) D, The significant (p<0.05) 
up and downregulated features of all detected features in short- and long-term dietary 
spinach exposure. E, Features in Pirc normal snip tissues were categorized according to 
the eight biological compound categories. F, Enriched metabolic pathways by significant 
metabolites features between short- or long-term dietary spinach exposure compared to 
AIN control diet. (3dSPI: 1010 features, mummichog feature cutoff at 0.05; SPI: 894 
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Pirc and WT Scraping samples exhibit distinct metabolic changes by dietary spinach. 
Brown et al. observed low conserved metabolites overlapped between colonic mucosa and 
stool samples indicating microbial or other mechanism contributing to the complexity of 
colorectal cancer biology306. It also has been shown the host-microbiota interactions are 
niche specific339,521. Therefore, we included mucosa scraping samples in the study. In the 
Scraping samples of Pirc and WT rats, dietary spinach affected the metabolites very 
differently and few metabolites were changed by dietary intervention in the current LC-
MS/MS analysis. Among the detected features, 669 features were upregulated and 56 were 
downregulated in WT Scraping samples under short-term spinach, and 818 features were 
upregulated and 63 were downregulated in the long-term spinach exposure. However, very 
few were affected in Pirc Scraping samples. 8 upregulation and 22 downregulation in 
short-term group while 54 upregulation and 11 upregulation in long-term group were 
observed. Using KEGG reference metabolic pathway, we were able to reveal the effects 
of dietary spinach in Pirc and WT Scraping samples. The significant metabolites did not 
cluster to a specific metabolic pathway but rather affecting several functional biosynthesis 
and degradation pathways, including bile acid and steroid hormone biosynthesis, 
phosphatidyl-ethanolamine biosynthesis, sphingosine degradation, lysin and valine 






Figure VI-4 Spinach effects on WT and Pirc normal scraping tissues. 
Predicted metabolites were mapped to KEGG Reference pathway-metabolic pathway. Light green, metabolites affected by short-
term spinach; green, metabolites affected by long-term spinach; circle, WT scraping sample; triangle, Pirc scraping sample. 
Black boxes indicated the primary category title from KEGG, and the yellow boxes indicated the modules associated with the 
compounds in the sub-area of the Reference pathway map.  
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Purine metabolism was essential for tumorigenesis in Pirc model while fatty acid 
metabolism may be the long-term benefit of dietary spinach. In the previous reports, 
dietary spinach showed about 50% efficacy to reduce tumor outcomes in the male Pirc 
model (CHAPTER V). Here we thought to assess the effects of spinach on tumor tissue 
and to explore the metabolic signature of the tumors resisted to dietary spinach. 
Comparing to the adjacent normal snip tissue, the tumors growing under long-term 
spinach exposure exhibited enrichments of four metabolic pathways (Fig. VI-5A). Among 
the four, purine metabolism was the one persisted altered in tumors both in AIN control 
(Fig. VI-2F) and SPI diet. Other lipid regulated pathways, such as linoleate, arachidonic 
acid, and omega-3 fatty acid metabolisms, were not enriched in the tumors under dietary 
spinach intervention. From a tumor to tumor comparison, nucleic acids were 
downregulated by short-term spinach exposure while lipid and fatty acids were increased, 
amino acid derivatives and vitamins and cofactors were decreased by long-term spinach 
exposure (Fig. VI-5B). In the mummichog pathway analysis, steroid hormones, fatty acid 
metabolites, and TCA cycle were most affected by short-term spinach exposure in Pirc 
tumor tissues (Fig. VI-5C) while long-term spinach affected omega-3 fatty acids and 
butanoate metabolisms (Fig VI-5D). After retrieved the individual metabolites, steroid 
hormone related metabolites were decreased in Pirc tumor by short-term spinach, and 
omega-3 fatty acids and butanoate related metabolites were increased by long-term 
spinach (Figs. VI-5E, light green and green colored, respectively). When looking into the 
tumor metabolites under spinach diet, pyrimidine and purine metabolites were further 




obvious trends on gene expression associated with the spinach effects (Fig. VI-5F, light 
green and green colored), but there were differences in the tumor-normal comparisons 





 Figure VI-5 Spinach effects on Pirc tumor tissues. 
A, Enriched metabolic pathways by significant metabolites features between Pirc tumor 
and adjacent normal snip samples under long term spinach exposure. (318 features, 
mummichog feature cutoff at 0.001) B, Features in Pirc tumor tissues were categorized 
according to the eight biological compound categories. C, Enriched metabolic pathways 
by significant metabolites features between short-term dietary spinach exposure compared 
to AIN control diet. (3dSPI: 363 features, mummichog feature cutoff at 0.05) D, Enriched 
metabolic pathways by significant metabolites features between long-term dietary spinach 
exposure compared to AIN control diet. (SPI: 822 features, mummichog feature cutoff at 
0.001) E, Heat map of the associated LC-MS/MS features contributing to the enriched 
pathways in Figs. V-5A, 5C and 5D. Individual column represented individual samples. 
F, Heat map of the gene expression profile according to the genes associated with the 
enriched pathways in Figs. 5 V-A, 5C and 5D. D-E, light green: short-term spinach effect 
on tumors, green: long-term spinach effect on tumors, yellow: tumor effect to adjacent 










Colorectal carcinogenesis is a multi-step process and usually takes years to 
develop without any symptoms. Therefore, early diagnosis of molecular events and 
effective intervention could provide significant benefits to reduce the burden of tumor 
initiation and formation. According to Satoch et al., significant metabolic changes occur 
at the adenoma stage, and not necessarily directly associated with genomic mutation 




acid (TCA) cycle, and fatty acid metabolism were significantly altered in colorectal 
clinical samples. Similarly, Tian et al. identified significantly increased glycolysis and 
decreased lipids in colorectal cancer (CRC) samples across stages I to IV, and most 
differences were found between low-grade tumors and adjacent normal tissues544. 
Dysregulation of glycolysis implicated the Warburg effect, via a high rate of glycolysis 
followed by lactate accumulation, and enhanced cell division with biomass 
incorporation545,546.  The PPP interconnects with glycolysis, fatty acid metabolism, and 
mitochondrial oxidative phosphorylation, and was indicated as a potential target for cancer 
therapy547,548. Lipid and fatty acid metabolism contributes to energy, signaling, oxidative 
stress, and inflammation in cancer biology549,550.  From the current dissertation project, 
arachidonic acid metabolism and PPP were the most highly altered metabolic pathways in 
Pirc normal looking colonic tissues as compared to normal colon from control WT rats, 
indicating that the mutant Apc status can cause deregulated metabolic phenotypes before 
morphological changes that result in tumor formation.  Extending these observations from 
normal looking colon to Pirc tumors, several fatty acid pathways were implicated, 
including linoleate, arachidonic acid, and omega-3 metabolism. Additionally, beta-alanine 
metabolism was enriched. Alanine is implicated in glycolysis and glutamate oxidation551, 
and previous a report in prostate cancer identified significant increases of lactate and 
alanine in tumor tissue by metabolic imaging552. 
Notably, while spinach reduced polyp burden significantly in the Pirc model, the 
anticancer outcomes reset (‘normalized’) certain aspects of the tumor metabolomic 




acids, and increased metabolites related to amino acid derivatives, nucleic acids and 
vitamin and cofactors (Fig. V-2B), dietary spinach reversed these metabolites changes 
(Fig. V-5B), i.e., lipid and fatty acids were increased and amino acid derivatives, nucleic 
acids and vitamin and cofactors were decreased by the dietary intervention. Surprisingly, 
tumor grown under long-term spinach treatment showed significant increases of 
pyrimidine and purine metabolism and their metabolites (Fig. V-5A. and Fig. V-5F). In 
the context of tumor grown under the basal control diet (Fig. V-2F), purine metabolism 
was a central metabolic feature, while pyrimidine metabolism featured as a resistance 
pathway in Pirc.  Purine and pyrimidine metabolism were both implicated in MYC-
regulated global metabolic reprogramming in human CRC325 and were reversed by 
knockdown of MYC expression. Purine metabolism also has been implicated in gut 
inflammation and gut microbiota interactions553–556. Among inflammatory bowel diseases, 
Crohn’s and ulcerative colitis had disease-specific purine gene dysregulation, and 
correlated with inflammation scores in biopsy samples557. Colonization of certain 
microbes, such as S. cerevisiae, promoted purine metabolism and inflammation in mice558.  
In Pirc rats given dietary spinach, several metabolic pathways were implicated in 
colonic mucosa scrapings of normal looking tissues, which likely capture microbiota-
derived metabolites in close proximity to the host, as opposed to gut contents.  However, 
without further careful separation of rat cells and mucus layer, conclusions cannot be made 
regarding microbiome versus host aspects of the scraping samples. To dissect the 
interactions of the host-microbe-environment, various techniques and additional models 




with metabolic oligosaccharide engineering (MOE) and bio-orthogonal click-chemistry 
(BCC), proved useful to study bacteria-derived polysaccharides and glycoproteins in 
bacterial-host communication559,560. Indole-3- acetate and tryptamine were identified as 
key microbiota-dependent gut metabolites, which reduced liver inflammation through 
macrophage chemotaxis and hepatocyte fatty acid metabolism, by comparative study 
using germ-free animals344. Isotopic glucose labeling also determined the metabolic 
incorporation of 13C in metabolic products, such as lactate, formate, acetate and butyrate, 
during human intestinal fermentation modeling in vitro561. In addition to purine 
metabolism, glycerophospholipid and sphingosine degradation, bile acid and steroid 
hormone biogenesis were implicated in Pirc scrapings after dietary spinach intake (Fig. 
V-5). Both bile acids and cellular lipids, such as glycerophospholipid, steroids, and 
sphingolipids, play important roles in gut mucosal interactions and cellular membrane 
function562. Intestinal bacteria can transform primary bile acids to unconjugated 
hydrophobic secondary bile acids, contributing to microbiota maintenance563. There are 
known inter-species differences for human and murine bile acid synthesis and metabolism, 
and diet-microbiota interactions were reported critical for cross talk with host FXR 
signaling564.  The dynamics of secondary bile acids and FXR signaling determined glucose 
and lipid regulation, and bile acid synthesis, between intestinal and hepatic feedback 
regulation565,566. Phosphatidylethanolamine participates in membrane constitution, 
membrane function, mitochondrial integrity, and protein folding567, and the metabolite 
ethanolamine provided nutrient advantages for pathogenic Salmonella growing in 




yeast, fungi, and mammalian cells, and dysregulation of sphingolipid homeostasis has 
been linked to neurodegeneration, cancer, and inflammatory diseases569.  Upregulation of 
mammalian sphingosine kinase 1 (Sphk1) regulated NF-κB-induced IL-6 and STAT3 
signaling in colitis-associated cancer570, and Sphk1 also was found overexpressed in CRC, 
contributing to cetuximab resistance571.  
Molecular signatures of CRC in The Cancer Genome Atlas (TCGA) define 
MSI/CIMP and CIN categories33.  However, mass-spectrometry-based proteomic 
characterization identified five subtypes of cohort with various clinical outcomes in 
TCGA34.  Importantly, the study also indicated poor prediction from mRNA information 
to protein abundance.  This infers the need to profile different metabolic aspects to better 
understand complex biological events in CRC development. In 2015, consensus molecular 
subtypes (CMS) aggregated several transcriptomic analyses into four classifiers, namely, 
CMS1: MSI-immune; CMS2: Canonical; CMS3: Metabolic; and CMS4: 
Mesenchymal37,387.  The Apc-mutant Pirc model is related to CMS2 signature in WNT 
activation, MYC target activation, and epithelial markers with poor immunogenic 
property. CMS2 also contributes to 37% of human CRC, which have better prognosis 
compared to other CMS categories.  However, it is unclear how environmental 
exposures337,572 and microbiota interactions affect these CRC subgroups573–575. Purcell et 
al. recently examined colon tumor microbiome and CMS categories,576 noting that the 
abundance of Selenomonas sp., Porphyromonas gingivalis, and other bacteria were 
correlated with CMS1, CMS2, and CMS3.  This provided further support for microbiota-




The current dissertation project extended previous work by the Dashwood lab 
which focused on host gene expression changes in FAP patient samples and Pirc colon 
polyps (ref IJC) by examining microbiome changes in the rat during tumorigenesis and 
chemoprevention by spinach. Integrating host transcriptome, microbiome and 
metabolomics may offer novel insights to mechanistic processes.  For instance, Gardinassi 
et al. identified innate cell immunity and platelet activation by integrated metabolomics 
and transcriptomes in parasite infection578. The study also found different blood 
metabolites, such as tryptophan, kynurenine, and glutamate, and gene dysregulation in 
Type 1 interferon, neutrophil and coagulation in partial tolerance patients (semi-immune). 
Another study utilized blood transcriptome, plasma metabolomics, plasma cytokines and 
cell populations to understand the vaccination response in humans579. With detailed 
clinical measurements, Li et al. identified that IFN-g+ T cells are the most significant 
predictor of IgG response, and the transcription factor SREBP1 was critical to determine 
intracellular sterol metabolism and extracellular humoral responses.  
The current dissertation project revealed several limitations and challenges in the 
study design. 1) High intragroup variability in the Pirc model leads to less statistical power 
among the sample size. Compared to the tumor efficacy outcome study, metabolomics 
acquires many more variables, with high degree of diversity due to high sensitivity of the 
instrument detection. To achieve better statistical analysis, larger sample size and 
additional internal controls, such as isotope labeling or internal control of extraction, may 
improve ‘Big Data’ approaches towards precision medicine. 2) Compound identification 




collected from preclinical studies in Pirc, with and without dietary spinach intervention, 
makes this one of the most detailed and comprehensive studies of its kind.  Indeed, 
untargeted LC-MS/MS metabolomics detected more than 17,000 features in these 
experiments. However, annotation remains challenging to match the MS/MS spectra to 
the reference database with high confidence. Moreover, the microbial metabolites and co-
metabolites with host metabolism are still incomplete. In the current dissertation project, 
mummichog was used to primarily analyze the data focusing on rat metabolism, and 
generated 883 consensus predictions, mapping to KEGG Compound collections.  Current 
work is focused on annotation and identification of putative compounds agreed by two or 
more databases. Positive mode LC-MS/MS was applied to the aqueous phase of 
MeOH/chloroform extracts, which could miss negative mode metabolites, or volatile and 
low polarity metabolites frequently monitored by GC-MS detection, or certain metabolites 
requiring specific organic extraction (e.g., chlorophyll-derived metabolites580,581 and 
polyphenol phase-II metabolites582)  
To our knowledge, this is the first investigation of global, non-targeted 
metabolomics in the Pirc model.  The study identified critical metabolic pathway networks 
associated with Apc mutation in normal looking rat colon, and further dysregulated during 
tumorigenesis events.  In addition, dietary spinach intervention led to diverse responses in 
rat colon according to genotype, as well as in colonic surface niches (within mucosal 
scrapings), highlighting the complexity of host-microbe-environment interactions in the 
gut. Findings from the study reiterate the variability of individual animals, and the 




intervention.  To confirm the individual metabolites and to understand their interplay with 
the enzymatic proteins will provide powerful insights for further cancer prevention and 
treatment through precision medicine approaches.  The large datasets generated from this 
project can be mined in the future for important and valuable new leads – thus, the 
dissertation project might represent the ‘tip of the iceberg’ rather than a complete and final 








CHAPTER VII  
SUMMARY  
 
Discussion and future directions 
A previous study of carcinogen-induced tumors in the rat and prevention by dietary 
spinach implicated dysregulation of the Let-7/c-Myc/Lin28 pathway156. In the beginning 
of this dissertation research, I sought to identify component(s) or fraction(s) of spinach 
extract that had anti-cancer properties in human CRC lines. Chlorophyll dissolved in 
DMSO, water extracts, and isopropanol extracts of spinach were shown to decrease 
LIN28A and LIN28B protein levels along with b-catenin level in Caco2 cells, but the let-
7 family was not altered significantly after 48 hours of treatment. Dr. William Bisson at 
Oregon State University performed in silico modeling of chlorophylls binding to murine 
Lin28A Arg50 cold shock domain, which implicated inhibitory effects on pre-let-7 
miRNA interaction. Dr. Arthur Laganowsky and Dr. Wen Liu assisted in purifying human 
and mouse full-length Lin28A and the cold shock domain for further biochemical testing. 
A crystallography trial in 96x6 conditions produced no crystal formation when combined 
with specific chlorophyll derivatives. The LIN28A proteins complexed with chlorophyll 
derivatives in classic spectrophotometry titration experiments, indicating an affinity of 
200 µM (equilibrium dissociation constant).  Taken together, these experiments did not 
provide a clear answer to the focused mechanistic question at the outset; that chlorophylls 
in spinach might interact directly with components of the Lin/Let pathway, upregulating 




However, these studies were discontinued and omitted from the dissertation for the 
simple reason that in silico, in vitro, and cell-based assays were misleading, and did not 
predict the situation in the Pirc model with respect to the let-7/ Lin28 axis. Unlike the 
carcinogen-induced model, the Pirc model showed relatively mild downregulation of let-
7 family after spinach treatment, and colon polyps had almost undetectable Lin28 proteins, 
despite the excellent preventive efficacy of spinach in both genetic and carcinogen models. 
Subsequent detailed molecular profiling of Pirc the model sought to identify the 
‘true’ targets of spinach for further mechanistic study. Interestingly, Lin28 levels were 
associated with invasive tumor growth in human CRC, but the authors were unable to 
detect Lin28 proteins in ApcMin/+ and DSS/AOM-induced gastrointestinal tumors583. The 
study indicated independent roles of Wnt pathway and Lin28/let-7 axis in colorectal tumor 
development. We did not observe b-catenin downregulation in the colon polyps from Pirc 
rats fed with spinach, despite evidence to the contrary from cell-based assays (data not 
presented in the dissertation).  This suggested the following: 1) spinach solvent extracts 
functioned differently from the digesta of spinach diet in rodent digestive system, along 
with the presence of microbiome; 2) rat colonic cells with heterozygous Apc mutation 
behaved differently from immortalized human CRC cell lines growing a in petri dish; 3) 
re-focus the goals and overall scope of the dissertation to findings in vivo, from the Pirc 
model.  
The first molecular candidate considered was Krüppel-like factor 4 (KLF4), one 
of four pluripotency factors and an important transcription factor regulating cell 




hypermethylation585,586 and  miRNA regulation315,587. Together with OCT4, and SOX2, 
KLF4 was identified as a direct target of miR-145 and can determine self-renewal and 
differentiation in human embryonic stem cells587. KLF4 is a downstream mediator of Wnt 
signaling in human gastrointestinal cancer, and has crosstalk with oncogenic pathways 
and epithelial to mesenchymal transition588. KLF4 was reduced in colorectal cancer patient 
samples as well as colorectal cell lines, and Zhao et al. found evidence for loss of 
heterozygosity, hypermethylation of 5’-untranslated region, and point mutations of Klf4 
leading to p21 induction, indicating a tumor suppressive role515,589,590. Klf4 was 
downregulated in all PhIP-induced tumors in the rat (except skin tumors), and divergent 
functions of Klf4 in skin was discussed in Chapter IV. Klf4 also was implicated as a miR-
34a target in Pirc colon tumors, and reversed by dietary spinach.  However, unambiguous 
confirmation of miRNA-mRNA pairing would require additional crosslinking and 
immunoprecipitation (CLIP) methods to verify the targeting events591.  Although Klf4 has 
not been widely proposed as a therapeutic target, an inhibitor strategy is in development 
involving arginine protein methyltransferase-mediated KLF4 protein turnover592. 
Additional work on the response of Klf4 to environmental exposures and epigenetic 
regulation might corroborate Klf4 as a valuable target for cancer intervention473.  
Dietary spinach is among the most potent and effective anti-cancer regimens tested 
thus far in the Pirc model, and reaffirmed the potential of dietary intervention for disease 
prevention83,593,594.  It was important to persist with experiments that might provide further 
clues; thus, the dissertation project switched from hypothesis-testing to hypothesis-




microbiome and metagenome prediction affected by dietary spinach were shared between 
Pirc and WT rats, implying that diet indeed has profound effects on the microbiome245,595. 
However, there are still differences between the responses in host transcriptome and a 
subset of microbiome, indicating that host genetic influences on microbiome cannot be 
ignored. Technically, whether filtering out low abundant OUT read can provide a more 
critical insights would be worth tested in the current dataset and how different locations 
(cecum versus colon and content versus mucus) would affect the microbiome profiling 
can be tested in the future.  
 Spinach effects were marked and compelling in terms of reversing Pirc 
microbiome deregulation (dysbiosis) and metabolomics, despite the incomplete nature of 
the latter. The results raise fundamental questions as to how exactly microbiota and 
metabolites contribute to spinach cancer prevention. Is one or the other the driving force? 
What is cause and what is effect? These questions should be addressed in future studies. 
Recently, fecal material transplantation (FMT) emerged as a strategy for disease 
management and therapeutics369,596. Carefully assessing host genetics, microbiome 
intervention, and dietary patterns in long-term FMT studies might assure the desirable 
outcome and improve future intervention designs. To validate whether microbiome is 
required for prevention by dietary spinach, one can perform experiments in germ-free or 
gnotobiotic animals to evaluate tumor outcomes.  Alternatively, these questions might be 
answered by FMT from rats consuming dietary spinach to Pirc rats with control diet, or 




insights into the roles of microbiota and metabolites for designed dietary interventions 
against human CRC.  
 This thesis project also challenged the definition of “prevention” among the many 
groups evaluated.  Dietary spinach reduced the tumor outcomes ~50% in the Pirc model, 
but there were still polyps detected in all the rats. Chapter V described two scenarios for 
prevention by spinach: 1) against polyp formation at the outset, such that normal looking 
colon in Pirc rats remained ‘normal’ and with an opposite molecular profile of polyps, and 
2) polyps that still formed in the present of spinach treatment, under the strong Wnt 
pathway driving force, had ‘partially-normalized’ molecular signatures, leading to delayed 
onset and/or smaller lesion size.  In fact, the Apc-mutant Pirc model is a genetically driven 
counterpart of human FAP,  which makes all interventions technically secondary or 
tertiary prevention 353,597,598, and the latter scenario is closely aligned to cancer ‘therapy’. 
Therefore, ambiguity exists regarding prevention versus therapeutic outcomes for spinach. 
 There are limitations of the carcinogen and genetic rat models used in this 
dissertation. For the cooked meat heterocyclic amine project, unbiased analysis of tumors 
from different organs was not undertaken, and it is highly likely that there are tissue 
specific deregulation of miRNAs, and other epigenetic players.  The original PhIP study156 
did not have enough tissue samples for further analysis, so assessing the prevention effects 
of dietary spinach became more dependent on the Pirc model.  In the latter case, sample 
size was calculated according to published tumor outcomes, but there was high polyp-to-
polyp variability of some molecular read-outs, inferring the need for a larger sample size 




to the tissue requirements of each technology, samples were subdivided into two main 
groups in order to have matched data for the most sought-after correlated measurements. 
Thus, one group was taken for RNA and miRNA, and another group for microbiome and 
metabolomics. Using group average data limited the analysis power and lost the 
information from individuality. There were relatively fewer features changed by dietary 
spinach exposure, compared to tumor-normal comparison, in the current LC/MS-MS work 
using aqueous phase extracts. Additional insights might come from organic phase extracts 
and more time points, especially for early time points, for example, during weaning, and 
right when the dietary intervention started, etc.) and sample numbers, to obtain a 
comprehensive picture of the dynamic changes of metabolites by dietary spinach exposure 
leading to tumor inhibition. 
Sample collection is another aspect that can be improved in the future, and there 
are several factors worth considering. 1) Tumor heterogeneity plays an important role in 
most human malignancies, and immune cells or stem cells are minor but important sub-
populations599–601. Transcriptome analysis after cell sorting or utilizing single cell 
sequencing technology602,603 can provide population structure and cell-specific regulation 
information. 2) There is a proposed driver-passenger model of microbial agents in human 
CRC520,575,604,605, and the region of colon also contributes to noticeable differences in 
microbiome profiles606,607. 3) Gut environment is an ecological complex system with host 
cells, microbiota, and digestive content or stool. Separating host cells from extracellular 
content (surface mucus layer or lumen content/stool) may be helpful to concentrate on 




Metabolomic imaging is another powerful technology to detect biodistribution and 
metabolism in tissue sections608–610. In this dissertation work, there were nine groups for 
transcriptomics, four groups for cecum microbiomics, and 15 groups for metabolomics in 
the Pirc model, which lead to a high complexity of analysis and interpretation. Acquiring 
new insights from additional data mining is recommended, for follow-up hypothesis 
driven studies with targeted groups in vivo.  
Moreover, since there are emerging interests in monitoring miRNAs for 
environmental exposure and disease78,81,142,611, detection methods might involve cell-free 
circulating miRNAs or cell-based (PBMC or platelet) miRNA in blood samples of PhIP 
and Pirc models214,216,612,613.  A longitudinal study on miRNA changes by environmental 
exposure or disease progression could provide valuable insights for disease management. 
There also is the concept of detecting circulating cancer cells by digital PCR614–617, but it 
may not be suitable due to the fact that both rat models mimic early CRC stages before 
invasion and metastasis.  However, if additional rodent models of metastasis are tested 
with spinach intervention, circulating cancer cells might be of interest618.    
Among the various omic data acquired, untargeted metabolomics is the most 
difficult to analyze and extract information. This is mainly because identification and 
validation of compounds is a critical bottleneck291,543, despite the fact that LC/MS-MS is 
a robust approach. Unlike sequencing technology and sequence information, 
metabolomics has higher resolution/dynamics to detect subtle differences, but lacks a 
well-established and finite ‘reference map’619,620. This thesis project focused, to the 




statistical analysis and associated enrichment metabolic pathway evaluations. For 
instance, a recurring theme was the identification of linolenic acid, stearidonic acid, 
leukotriene A4, and glutamate in fatty acid related pathways. This suggests the need to 
pursue lipid metabolism and purine metabolism, and to spike in standards to provide 
sufficient evidence for final identification confirmation. On the other hand, hit validation 
also can be performed on nuclear magnetic resonance spectroscopy (NMR)621,622 as a gold 
standard. With data in the form of ‘features’, ‘putative identification’ and ‘confirmed 
identification’, the study can be reported according to the Metabolomics Standards 
Initiative619,623, and provide leads for future mechanistic studies in cell-based assays of 
spinach inhibition. 
Despite the limitations of the preclinical models, and insufficient matched 
molecular profiling across all biological individuals, there are opportunities to integrate 
multivariate data to provide insights from multi-omic measurements.  Bioinformatics is in 
demand for Big Data analysis, and there are several potential methods utilizing dimension 
reduction techniques and correlation structure to integrate multi-omic data624,625.  
Buescher and Driggers emphasized the importance of statistical behavior, relationship 
between layers, and timing differences of the layers313 in integration of omics, or in most 
cases, “co-analysis”, and suggested the condition-dependent unbiased co-clustering on the 
same timescale to offer valuable insight from the literature. Beyond correlation analysis, 
more sophisticated methods exists, including identifying the scaffold, decomposing the 
scaffold, cellular modeling, and trans-omics312,314. However, the current data include 




information, so unbiased co-clustering with reduction techniques may be a practical 
method to explore for further understand the overall measurements. 
Summary and conclusion 
The dissertation project focused on utilizing various molecular profiling 
techniques to understand fundamental aspects cancer etiology in preclinical models of 
colorectal carcinogenesis. Both genetic and carcinogen-induced rat models have pros and 
cons, and intrinsic value for the kind of work pursued here. The carcinogen-induced model 
reflects aspects of environmental exposure, which results in multiple genetic mutations 
and epigenetic dysregulation, capable of driving carcinogenesis in a ‘moderate’ fashion, 
akin to sporadic cancer in humans.  The genetic model exemplifies the single penetrant 
gene-driver concept, via inactivation of murine Apc, leading to extensive polyposis in the 
intestine and colon, mimicking human FAP.  
An initial focus was on whether miRNA profiles of colon tumors, the primary 
target organ of foodborne carcinogen PhIP, had predictive value for other PhIP-induced 
tumors (small intestine, skin, liver), and to validate miRNA and mRNA targets implicated 
in a subset of human cancers (Chapter IV). Downregulation of the let-7 family and 
upregulation of their targets, c-myc and Hmga2, were consistent in rat tumors and human 
primary tumors. A five-miRNA ‘PhIP signature’ was identified in the carcinogen-induced 
rat tumorigenesis model, and revealed the signature correlated to poor prognosis of a 
subgroup human cancer patients. The ‘PhIP signature’ also was linked to downregulation 
of the pluripotency gene Klf4, and pathway predictions associated with MAPK, 




epigenetic regulation.  This extends the traditional ‘genotoxin’ perspective of PhIP and 
other environmental heterocyclic amines. 
In order to broaden this work towards genetic predisposition syndromes, the Pirc 
model was chosen to recapitulate aspects of human FAP, including a colon tumor burden 
and lifespan suitable for intervention and disease monitoring.  Sequencing technologies 
and mass spectrometry facilitated comprehensive analysis of biological datasets, and 
enabled extensive molecular profiling in Pirc tumors and normal tissues, including RNA, 
miRNA, metabolomics, and microbiomics (Chapters V-VI).  
The dissertation project prioritized inflammatory pathways, lipid metabolism, and 
purine metabolism in Pirc colon polyps, which recapitulated human CRC features. 
Microbiomics in Pirc rats indicated a reduced relative abundance of Firmicutes and 
increased Bacteroidetes, without a significant change in a-diversity, and small RNA 
sequencing indicated significant downregulation of suppressor miRNAs.  Dietary spinach 
started after weaning, followed by 6.5-month intervention, lead to ~50% reduction of 
tumor outcome in Pirc rats. Spinach is among the most effective prevention strategies 
tested thus far in the Pirc model, and given that the Apc-mutant background is considered 
a ‘strong’ oncogenic driver, has potentially important clinical implications for FAP 
patients. It is unlikely that a person with a family history of FAP will put off standard-of-
care, indefinitely, but consumption of dietary spinach might help to ‘buy time’ before total 
colectomy and anticancer drug treatments.   
Transcriptomics suggested immune related pathways, extracellular matrix 




consumption. Spinach was shown to reshape the metabolome against changes in the Pirc 
microbiome changes, and the metabolome also conferred reversing effects in lipid and 
steroid metabolism.  This investigation provided the fundamental molecular profiling of 
the Pirc model for further intervention design, and revealed potential targets of genes, 
metabolic pathways, and microbiota for further validation.  
This thesis project identified step-wise, temporal molecular signatures associated 
with colorectal carcinogenesis, and provided support for PhIP and Pirc preclinical models, 
that were complementary, which each offering useful insights. The complex interactions 
within host biological system and the interactions between host genetics, microbiota and 
environmental exposure require further integration to clarify the multi-dimensional 
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